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ABSTRACT 
Celiac disease (CD) is a lifelong T cell-mediated enteropathy occurring in genetically 
susceptible individuals and triggered by the ingestion of gluten and related prolamins, plant 
storage proteins found in wheat, barley and rye which results in small intestinal mucosal 
injury, including villous atrophy with crypt hyperplasia and intraepithelial lymphocytosis and 
subsequent nutrient malabsorption. CD is characterised by a wide, and often unsuspected 
range of clinical presentations, including “classic” gastrointestinal symptoms (characterized 
by a malabsorption syndrome, ie, chronic diarrhea, abdominal pain and distention, weight 
loss) which are less common of the atypical CD, with few or no gastrointestinal 
manifestations and of the silent and latent forms. 
Although the small intestinal mucosa represents the main site of the gut involved in CD, 
other mucosal surfaces belonging to the gastrointestinal tract and to the gut-associated 
lymphoid tissue can also be involved. In fact, modifications have also been found in the 
gastric, rectal and esophageal mucosa. Furthermore, several studies have described the 
determination of anti-endomysial and anti-transiglutaminase autoantibodies in media of 
cultured intestinal mucosa biopsies from affected patients. 
A site which could be studied less invasively is the mouth, as it is the first part of the 
gastrointestinal system and a part of gut-associated lymphoid tissue. In fact, some oral 
ailments have been reported as possible atypical aspects of CD, mainly dental enamel 
defects and aphthous-like ulcers. Furthermore, it has been shown that inflammatory 
changes occur after oral supramucosal application and submucosal injection of gliadin in 
the oral mucosa of CD patients. 
However, only few studies have focused on the histomorphological features of the oral 
mucosa in CD patients and until this research project was not known whether the oral 
mucosa of patients with CD was able to produce anti-endomysial and anti-transiglutaminase 
autoantibodies or not. The aims of the PhD study were: a) to examine the frequency of 
oral lesions in adults and children with CD and to assess their usefulness in making CD 
diagnosis; b) to perform a screening for CD in patients with oral lesions potentially 
associated with CD, and sharing a common immune-mediate pathogenesis with CD, such 
as oral lichen planus and recurrent apthous stomatitis; c) to study the histomorphology of 
clinically healthy oral mucosa of untreated CD patients: (i) to assess the presence, quality 
(B⁄T lymphocytes) and intensity of lymphocytic infiltration and its relation to the severity of 
the intestinal histological damage; and (ii) to detect any other histological aspect which 
could be linked to CD; d) to evaluate the ability of the oral mucosa of patients with CD to 
produce antibodies in an in vitro culture system.  
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a) To examine the frequency of oral lesions in adults and children with CD and to 
assess their usefulness in making CD diagnosis. To achieve this objective two case- 
control studies were performed. The primary aim of the first study was to assess the 
frequency of oral diseases, including soft and hard tissue lesions and dental delayed 
eruption in CD patients, in comparison with otherwise healthy controls; the secondary 
objective was to consider what contribution an oral clinical examination could give to help 
suspect a CD diagnosis. Patients and methods. One hundred and ninety-seven CD patients 
(90 adults and 107 children) and 413 controls (180 adults and 233 children) were recruited 
and underwent oral examination. Results. Forty-six out of 197 CD patients (23%) were 
found to have enamel defects vs. 9% in controls (p<0.0001). Clinical delayed eruption was 
observed in 26% of the pediatric CD patients vs 7% of the controls (p<0.0001). The 
prevalence of oral soft tissues lesions was 42% in the CD patients and 2% in controls 
(p<0.0001). Aphthous-like ulcers were found in 37⁄197 (19%) CD patients vs 3⁄413 (1%) 
controls [p< 0.0001; OR=18.9505 (95% CI=9.552:37.595)].  The other soft tissue lesions 
detected were aspecific atrophic glossitis and geographic tongue. The first was found in 
31⁄197 (16%) CD patients vs 1⁄413 (0.2%) controls [p< 0.0001; OR=22.464 (95% 
CI=10.500:48.063)], while geographic tongue was noted in 14 ⁄197 (7%) CD patients vs 5 
out of 413 (1%) controls [p< 0.0001; OR=7.0326 (95% CI = 2.650:18.666)]. Aphthous-like 
ulcers disappeared in 89% of the patients after 1 year of gluten-free diet. Multi-logistic 
analysis selected the following variables as the most meaningful in coeliac disease patients: 
dental enamel defects (OR =2.652; CI =1.427–4.926) and soft tissue lesions (OR = 41.667, 
CI=18.868–90.909). Artificial Neural Networks methodology showed that oral soft tissue 
lesions have sensitivity= 42%, specificity=98% and test accuracy =83% in CD diagnosis. 
Conclusions. The overall prevalence of oral soft tissue lesions was higher in CD patients 
(42%) than in controls. However, the positive-predictive value of these lesions for CD 
diagnosis was low. 
The objectives of a second case-control study were to assess the prevalence of aphthous-
like ulcers in CD patients living in the Mediterranean area, and to evaluate the impact of a 
gluten-free diet. Patients and methods. A test group of 269 patients (age range 3–17 years) 
with CD was compared with a control group of 575 otherwise clinically healthy subjects for 
the presence, or a positive history of aphthous-like ulcers. CD patients with aphthous-like 
ulcers were re-evaluated 1-year after starting a gluten-free diet. Results. Aphthous-like 
ulcers were found significantly more frequently in CD, in 22.7% (61/269) of patients with CD 
vs 7.1% (41/575) of controls (p = < 0.0001; chi-square = 41.687; odds ratio = 4.3123; 95% 
confidence interval = 2.7664:6.722). Most CD patients with aphthous-like ulcers and 
adhering strictly to gluten-free diet (71.7%; 33/46) reported significant improvement on 
gluten-free diet, with no or reduced episodes of aphthous-like ulcers (p = 0.0003; chi-square 
= 13.101; odds ratio = 24.67; 95% confidence interval = 2.63:231.441).  
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Conclusions. The epidemiological association found between CD and aphthous-like ulcers 
suggests that recurrent aphthous-like ulcers should be considered a risk indicator for CD, 
and that gluten-free diet leads to ulcer amelioration. 
b) To perform a screening for CD in patients with oral lesions potentially associated 
with CD and sharing a common immune-mediate pathogenesis with CD. In a first study 
the assessment of the prevalence of CD in patients with oral lichen planus and the effects of 
the gluten-free diet on this oral disease was performed. Patients and methods. Twenty-three  
patients with oral lichen planus confirmed both clinically and histologically were tested for 
serum coeliac autoantibodies. All patients with positivity to anti-endomysial and/or anti-
transiglutaminase autoantibodies underwent small intestinal biopsy to confirm CD, and in 
case of confirmed diagnosis were re-evaluated after 3 months of gluten-free diet. Results. 
Only 2/23 (8.7%) female patients with atrophic/erosive oral lichen planus localized on buccal 
mucosa, associated to burning sensation, despite topical corticosteroid therapy, showed 
positive values of celiac antibodies associated to low serum levels of folate, vitamin B12 and 
iron. The small intestinal biopsy confirmed the diagnosis of CD. A gluten-free diet was 
started and the oral soreness and anaemia gradually improved over the next 3 month. 
Conclusions. It is uncertain whether the oral lesions are a direct manifestation of gluten 
enteropathy or due to the effect of malabsorption and of the consequently haematinic 
deficiencies on the rapidly dividing mucosal cells already predisposed to soreness by pre-
existing lichen planus. However, the resolution of the burning sensation after gluten-free 
diet, in patients with oral lichen planus and refractory to local therapy could be justify the 
second hypothesis. Furthermore, a search for underlying nutritional deficiencies in patients 
with atrophic/erosive oral lesions should be important in relieving oral soreness. 
In a second study the assessment of the prevalence of CD in patients with recurrent 
aphthous stomatitis was performed. Patients and methods. Twenty-five patients with 
recurrent aphthous stomatitis were included. The patients had at least three ulcerative 
episodes per years. Patients were screened by IgA anti-endomysial antibody, IgA anti-
tissue transglutaminase and serum IgA level. Those with a positive serology underwent 
endoscopic biopsies of the duodenal mucosa. Results. Two out of 25 recurrent aphthous 
stomatitis patients had a positive CD serology and the histological findings were compatible 
with gluten-sensitive enteropathy. Conclusions. Although our study concerned a limited 
sample population of patients with recurrent aphthosis, it showed that a good percentage 
(8%) of patients with recurrent aphthous stomatitis had CD. If this results is compared with 
the 1% prevalence of CD in general population of Italy this study suggest that evaluation of 
CD could be appropriate in patients with recurrent aphthous stomatitis.   
c) To study the histomorphology of clinically healthy oral mucosa of untreated CD 
patients in order: (i) to assess the presence, quality (B⁄T lymphocytes) and intensity 
ABSTRACT 
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of lymphocytic infiltration and its relation to the severity of the intestinal histological 
damage; and (ii) to detect any other histological aspect which could be linked to CD. 
Patients and methods. Twenty-one untreated CD patients (age range 13–68 years) with 
clinically healthy oral mucosa were enrolled and compared with 14 controls. Intestinal and 
oral biopsies were carried out and specimens were evaluated after staining with 
hematoxylin and eosin. Results. Intra-epithelial lymphocyte B and T infiltrates of the oral 
mucosa were found to be similar in both groups; likewise, intensity of the lymphocytic 
infiltrate in the lamina propria was similar in both groups and was not related to intestinal 
damage; important signs of spongiosis of the oral mucosa epithelium were found to be more 
significantly present in CD patients (90%) compared with controls (p=0.0002). This 
spongiotic reaction was characterized by the presence of intraepidermal and intercellular 
oedema; intercellular spaces were widened with an elongation of the intercellular bridges. 
The foci of spongiosis were also characterized by a mild lymphocytic infiltrate, but not by the 
presence of eosinophils or neutrophils. These lesions were exclusively microscopic without 
any corresponding identifiable vesicles on the oral mucosal surface. Conclusions. This 
study showed that the healthy oral mucosa of untreated patients does not reflect the 
intestinal damage by CD, but it is unexpectedly affected by spongiosis, as being detected 
for the first time in the literature. This latter feature could be related to gliadin ingestion and 
could contribute to explain the higher susceptibility of CD patients to suffering from oral 
mucosa lesions.  
d) to evaluate the ability of the oral mucosa of patients with CD to produce antibodies 
in an in vitro culture system. Patients and methods. Twenty-eight patients with new 
diagnosis of CD (15 adults and 13 children) and 14 adult subjects with other diseases 
(controls) were studied. All underwent oral mucosa biopsy and subsequent anti-endomysial 
and anti-tissue transglutaminase assays on the mucosa culture medium. Results. Sensitivity 
and specificity of anti-endomysial and anti-tissue transglutaminase assayed in the oral 
mucosa culture medium for CD diagnosis were 54% and 100% and 57% and 100%, 
respectively. The diagnostic accuracy of anti-endomysial and anti-tissue transglutaminase 
assayed in the oral mucosa culture medium for CD diagnosis was 79%.  The CD clinical 
presentation, such as the presence of oral mucosa lesions, did not influence the results of 
the anti-endomysial and anti-tissue tranglutaminase assays in the oral mucosa culture 
medium. There was an association between positivity of antibodies and greater severity of 
the oral mucosa lymphocyte infiltration. Conclusion. This study demonstrates for the first 
time that the oral mucosa contributes to anti-endomysial and anti-tissue transglutaminase 
production in untreated patients with CD. 
 
In summary, the researches conducted in the context of this project, have yielded important 
results not only in terms of prevalence of oral lesions potentially associated with CD, but 
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above all, thanks to the highly innovative research lines has led to consider the oral cavity, 
for the possibility to perform easily oral biopsies to be processed with appropriate methods 
of immunofluorescence and conventional histological examination, as a potential diagnostic 
gate minimally invasive and easily accessible in comparison with the endoscopic approach. 
However, clinical trials conducted on largest sample size and on CD patients before and 
after the gluten-free diet, will need to see if the mouth can really be helpful to duodenal 
endoscopy for the first diagnosis of CD, but also in the follow-up of the disease. 
Furthermore, the demonstration that the oral mucosa is a new site involved in the release of 
pathognomonic autoantibodies of CD and which may show some histological peculiarities 
offers us a site to obtaine bioptic samples to be underwent cDNA microarrays studies and 
cell and tissue cultures, in order to depth the pathogenesis of CD and to test less toxic 
compounds in the treatment of this condition. 
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EMA anti-endomysial antibody 
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INTRODUCTION 
It was until 1987 that attention was drawn to celiac disease (CD), when Dr. Samuel Gee 
described the classical features of the disease in children1 as diarrhoea, lassitude, and 
failure to thrive. At that time he realised that the diet was important in the treatment and 
noted that the diet was not age-specific1,2. In 1953, the Dutch paediatrician Dicke presented 
his thesis on the role of gluten in CD patients3. He demonstrated in a controlled study, that 
wheat, rye and barley triggered CD, and that the condition could be reversed after their 
exclusion from the diet3.   
Today it is known that CD, also known as celiac sprue and gluten sensitive enteropathy 
(GSE) is an immune-mediated enteropathy triggered by the ingestion of gluten, the storage 
protein of wheat, in genetically susceptible individuals4. In this context, the term “gluten” is 
used to refer to prolamins of wheat, rye (secalins) and barley (hordeins)5. There is scientific 
evidence that avenins of oats are less harmful than glutens6,7. The major predisposing 
genes are the histocompatibility leukocyte antigen (HLA)-DQ2 and DQ8 genotypes found in 
at least 95% of patients5, although non-HLA genes have been recently reported to be 
involved in CD pathogenesis8.  
CD, originally through to occur only rarely in childhood, is now recognised as a common 
condition that could be diagnosed at any age5.  
Until recently considered a rare condition, CD is now well-known to be relatively common; 
its estimated prevalence in the general population of North America and Western Europe 
appears to be close to 1%, with a reasonable range of 0.71% to 1.25%9. CD prevalence is 
increased in at-risk conditions such as family history of CD, autoimmune diseases, 
especially type 1 diabetes and thyroiditis, IgA deficiency, and some genetic syndromes 
(Down, Turner, and William syndromes)10.  
CD affects primarily the small intestine; in fact, in individual with CD, gluten induces typical 
small intestinal histological damage with villous atrophy or flat duodenal and jejunal mucosa, 
crypt hyperplasia, intraepithelial lymphocyte (IEL) accumulation, and numerical increase of 
plasma cells in the lamina propria. These histopathological changes lead to subsequent 
nutrient malabsorption and clinical manifestations11. 
The development of GSE is paralleled by the appearance of serum antibodies, especially 
the IgA class anti-tissue transglutaminase (anti-tTG), anti-endomysial antibody (EMA) and 
antigliadin antibodies (AGA), and eventually clinical manifestations.  
The dramatic advances made during the last decade in the understanding of CD have 
revealed the disease to have a heterogeneous, wide, and often unsuspected range of 
clinical presentations. In fact, today it is apparent that the ‘‘classic’’ clinical form 
(characterized by a malabsorption syndrome, i.e., chronic diarrhea, abdominal pain and 
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distention, weight loss) is less common, and most patients have atypical CD, with few or no 
gastrointestinal symptoms and predominance of extraintestinal manifestations, such as 
short stature, iron-deficient anemia, abnormalities in liver function test12. Furthermore, silent 
and latent forms have also been described5. CD patients are prone to develop long-term 
complications (eg, osteoporosis, infertility, autoimmune diseases, malignancies)13, and 
some studies report an increased all-cause mortality compared with the general 
population14,15. The wide range of the CD clinical manifestations reluts in patients presenting 
to many different specialists: gasteoenterologists, endocrinologists, rheumatologists, 
haematologists, cardiologists, neurologists, as well as paediatricians, dermatologists and 
dentists to consider this disorder when a patient presents with those extraintestinal signs 
and symptoms that might be related to CD5. In this regard, also some oral ailments have 
been reported as possible atypical aspects of CD, mainly dental enamel defects (DEDs) and 
recurrent aphthous stomatitis (RAS) or better aphthous-like ulcers (ALU)16,17.  
In active CD, the serum of patients contains autoantibodies against self-antigens including 
endomysium and tTG18,19. In many cases the presence of EMA and anti-tTG antibodies, and 
their disappearance after a gluten-free diet (GFD), confirms the diagnosis20. Despite the 
high sensitivity and sensibility of the today available CD serological tests, in many cases the 
diagnosis should not be based on symptoms of the patients or findings in the serological 
testing alone7 and small intestinal biopsy sampling is the gold standard. Furthermore, recent 
avidence shows that the diagnostic accuracy of an intestinal biopsy can be greatly 
increased by measung ant-tTG and EMA produced in loco by duodenal mucosa 21-24. 
Although novel therapies have been proposed8, the strict and lifelong adherence to a GFD 
is the only treatment currently available, and usually results in remission. Compelling 
evidence suggests that GFD may prevent or reduce the risk of long-term complications.  
Although the small intestinal mucosa represents the main site of the gut involved in CD, 
other mucosal surfaces belonging to the gastrointestinal tract (GT) and to the gut-
associated lymphoid tissue (GALT) can also be involved. In fact, modifications have also 
been found in the gastric 25,26, terminal ileal27 and rectal mucosa28-33. Rectal mucosa, 
furthermore, has also been used for gluten challenges32,34-38. Finally, esophageal 
involvement has also been shown in patients with untreated CD25,39. All this demonstrates 
that gluten-driven T-cell activation is not restricted to the proximal part of the intestine but is 
present in the whole intestine.  
A site which could be studied less invasively is the mouth; in fact the oral cavity mirrors well 
our general being. The oral cavity is closely bound to the immunogenic defence systems. 
The lymphoepithelial structures of Waldeyer’s pharyngeal ring in the posterior part of the 
oral cavity, including oral mucosal and nasal-associated lymphoid tissues (NALT) constitute 
an important part of GALT. GALT is the major part of mucosal-associated lymphoid tissue 
(MALT)40. After antigen-activation, proliferation and partial differentiation in MALT, memory 
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B and T cells migrate to regional lymph nodes and secretory glands, including salivary 
glands where they can begin to produce secretory immunoglobulin class-A (sIgA). 
As the first part of GT, the oral cavity is the route for all materials ingested, including 
products made from cereals. It might be suspected that oral cavity would react to ingested 
gluten in the same way as the mucosa of the gut, showing oral changes when the disease is 
untreated and improvement in these changes when CD is treated with GFD. 
In this context, Lahteenoja et al. showed that local challenge of the oral mucosa in treated 
CD patients provoked a gluten-dependent mucosal immune response, displayed by the 
increase of intraepithelial CD4+ T cells, as well as of CD4+ and CD8+ T cells in the lamina 
propria41. This feature suggest that, in CD patients, the mucosal surface of the mouth could 
respond to gluten in a similar way to the mucosa of the small intestine. Nevertheless, the 
same group later failed to find significant immunological differences in oral mucosa between 
untreated CD and control patients42. In some recent studies, detection of salivary anti-tTG in 
CD patients re-opened the possibility that the mouth might be actively involved and used as 
a new site for detection of CD43-45. 
However, only few studies have focused on the histomorphological features of the oral 
mucosa in CD patients and until this research project was not known whether the oral 
mucosa of patients with CD was able to produce EMA and anti-tTg autoantibodies or not. 
In this light, the aims of this PhD study were: a) to examine the frequency of oral lesions 
in adults and children with CD and to assess their usefulness in making CD diagnosis; b) to 
perform a screening for CD in patients with oral lesions potentially associated with CD, and 
sharing a common immune-mediate pathogenesis with CD, such as oral lichen planus 
(OLP) and recurrent apthous stomatitis (RAS); c) to study the histomorphology of clinically 
healthy oral mucosa of untreated CD patients: (i) to assess the presence, quality (B⁄T 
lymphocytes) and intensity of lymphocytic infiltration and its relation to the severity of the 
intestinal histological damage; and (ii) to detect any other histological aspect which could be 
linked to CD; d) to evaluate the ability of the oral mucosa of patients with CD to produce 
antibodies in an in vitro culture system.  
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CHAPTER I 
 
Review of the literature 
 
1. Celiac disease 
 
1.1. Historical background 
CD was first described in the second century AD by Aretaeus of Cappadocia1, a 
contemporary of the Roman physician Galen, who used the Greek word “koeliakos”, which 
means “suffering of the bowels”. He described the characteristic stools and chronicity of the 
disease, noting it to be present also in children. Vincent Ketelaer, a Duch physician, for the 
first time described the oral aphthous ulceration associated with sprue as early as 16692. 
However, only in 1888 AD did Samuel Gee of St. Bartholomew’s Hospital give the classical 
clinical description of CD in his classical paper: On the Coeliac Affection. He described the 
disease in children. Dr. Gee’s description of the features of the disease was remarkably 
accurate and he even suggested that the disease might be treated by means of a diet3: 
“There is a kind of chronic indigestion which is met in persons of all age, yet is especially 
observed in children between one and five years.” 
Gee supposed that the diet is important: 
“The causes of the disease are obscure. Children who suffer from it are not all weak in 
constitution. Errors in diet may perhaps be a cause, but what error? Why, out of a family 
of children all brought up in much the same way, shoul on alone suffer? This often 
happens…To regulate the food is the main part of the treatment…..Malted food is better, 
also rusks or bread cut thin and well toasted on both sides….The disease being a failure 
to digestion, nothing seems more reasonable, at first sign, than to digest the patient food 
artificially before it is given….But if the patient can be cured at alla, it must be by means 
of diet.” 
The natural course of CD was very often very miserable before the understanding of the 
importance of gluten in diet: 
“Naked-eye examination of dead bodies throws no light upon the nature of the coeliac 
affection: nothing unnatural can be seen in the stomach, intestines, or other digestive 
organs. Whether atrophy of the glandular crypts of the intestines be ever or always 
present, I cannot tell”. 
Many theories on CD have been introduced since Gee’s paper. 
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In the 1920s, Haas introduced a banana diet excluding bread, potatoes and cereals from 
the diet as treatment of CD4. This might account for part of the success of this banana diet. 
Blumgart, in 1923, on post-mortem histological examination of a small bowel wall, detected 
a thin atrophic mucosa with shortened villi and lymphoid cell infiltration5. However, the 
investigators attributed generally morbid anatomical findings in the small intestine of CD 
patients to post-mortem changes6. These views dominated the thinking on the subject until 
1950s. Still more observations were made on atrophy of the small intestinal mucosa with 
morphological changes in the villi and chronic inflammatory cell infiltration in the lamina 
propria7-9. 
No real progress in treating the disease was made until the 1930s-1950s, when WK Dicke, 
a Dutch pediatrician, showed that the health of celiac children dramatically improved when 
wheat, rye and barley, which were unavailable during the 2nd World War, were removed 
from their staple diet, only to relapse at the end of the war when the consumption of wheat 
flour started afresh in the Netherlands10. 
The dietary treatment of CD has remained unchanged until today, but its discovery 
stimulated an enormous amount of research to find out the mechanisms by which gluten 
brings about malabsorption. 
Finally, the stage was set for the introduction of another important advance in the 
understanding of CD – the technique of jejunal biopsy. At the same time, Shiner in England 
and Royer and co-workers in Argentine were independently able to obtain biopsy 
specimens of the jejum as well as the stomach11,12. Since the introduction of per-oral 
intestinal biopsy instruments, the autopsy findings and per-oral biopsy findings could be 
correlated, and it was detected that the major site of CD lesion is the small intestine9. This 
procedure has become the diagnostic standard in the avaluation of patients with suspected 
CD13. 
CD is the result of both environmental (gluten) and genetic factors (HLA and non-HLA 
genes), and the distribution of these two components can probably be used to identify the 
areas of the world at risk for gluten intolerance. In this respect, the world geographical 
distribution of CD seems to have followed the spread of wheat consumption and the 
migratory flows of mankind. Indeed, man was not originally a gluten eater, but led a 
nomadic life obtaining food by hunting, fishing and collecting fruit as well as vegetables, and 
for hundreds of thousands of years never had any contact with gluten-containing cereals. 
Only about 10000 years ago in a small region of South Western Asia, called the “Fertile 
Crescent” including Anatolia (Southern Turkey), Lebanon, Syria, Palestine and Iraq, were 
wild grains (wheat or Triticum Dicoccoides and barley or Hordeum Spontaneum) cultivated, 
due to the special environmental conditions created by the flooding of the Tigris and 
Euphrates. In the Fertile Crescent some tribes changed from a nomadic lifestyle to one of 
stable settlement because land cultivation permitted food storage, and they later migrated 
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westwards because new lands for cultivation were needed. They spread through the 
Mediterranean area (Northern Africa, Southern Europe) and the Danube valley (Central 
Europe) and their expansion continued from 9000 to 4000 BC by which time the cultivation 
of wheat and barley had spread all over the Old Continent, also reaching Northern Europe 
(Ireland, Denmark and the Scandinavian countries). However, this expansion in farming was 
not limited to the diffusion of agricultural practices, but was also a “demic” expansion, 
because the peoples coming from South West Asia replaced the local inhabitants. Hence, 
the European and North-African populations share a genetic background with the peoples of 
South West Asian origin (Middle-East), including also DR3-DQ2 and DR4-DQ8, the CD-
predisposing haplotypes14. 
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1.2. Epidemiology 
CD is more common in female than in male with a female to male ratio generally accepted 
to be 2-2.1:1, although some have suggested it my be more equal15. 
CD, originally through to occur only rarely in childhood, is now recognised as a common 
condition that could be diagnosed at any age. 
On the basis of the clinical frequency, CD was previously regarde as rare, occurring in 1 in 
3345 people worldwide16. However, serologic screening studies have shown the worldwide 
prevalence to be 1 in 26617. Such a rate established CD as one of the most common 
genetically based disease18. 
The epidemiological changes of CD are efficiently conceptualized by the “iceberg model”, 
originally introduced by Richard Logan in 199119. In fact, until the introduction of the more 
accurate serological diagnostic CD test, the atipycal, silent or latent forms remained 
clinically undetected. The prevalence of CD can be conceived as the overall size of the 
iceberg, which is primarily influenced by the frequency of the predisposing genotypes in the 
population. 
In fact, the most important determinants of prevalence in any population are the frequency 
of major histocompatibility complex (MHC) class II alleles that encode for HLA-DQ and 
exposure to dietary products that contain gluten. HLA-DQ is a cell surface dimer, largely 
restricted to antigen-presenting cells, that presents foreign peptides to T lymphocytes. The 
DQ dimer is composed of non-covalently associated alpha and beta chains encoded by 
HLADQA1 and HLA-DQB1 genes, respectively. As DQA1 and DQB1 genes are inherited 
from each parent, each individual has two DQA1 and two DQB1 genes20. These can be 
identified serologically as DQ types 1–9 or genetically as over 100 separate alleles. Genetic 
characterization is now widely used, although some laboratories continue to use both 
genetic and serological typing. The contribution of HLA type to the genetic risk for CD has 
been variously estimated at 36–53%21,22. Approximately 90% of patients are serotyped as 
DQ2, whereas most of the remainder have DQ8. With genetic testing, DQ2 is almost 
synonymous with DQB1*02, a gene with two common alleles designated DQB1*0201 and 
DQB1*0202. Another consideration is strong linkage disequilibrium between DQB1*0201, 
DQA1*0501 and DRB1*03 creating the serologically defined haplotype, DR3-DQ2.5. The 
frequency of DQ2 in Caucasian populations in western Europe has been estimated at 20–
30% and relatively high frequencies also occur in northern and western Africa, the Middle 
East and central Asia. Thereafter, the frequency of DQ2 declines from west to east with low 
frequencies in populations in South-East Asia and the virtual absence of DQ2 in Japan. 
Overall, only one of approximately 30 people with DQ2 will develop CD, although much 
more complex analyses of risk have been associated with HLA antigens that have been 
defined by genotyping22. 
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The second important determinant of CD is exposure to gluten-containing cereals, 
representing also the primary environmental factor. So it is logical to assume that the 
geographical distribution of CD reproduces, at least in part, that of gluten-containing cereals 
consumption. Domestication of ancient grasses began in the “Fertile Crescent” of western 
Asia approximately 8000 years ago and subsequently spread to Africa, India and western 
Europe. Globally, wheat is the most consumed cereals in the human diet (according to FAO, 
availability per capita in 1998 amounted to 71.5 kg per year compared to 58.1 kg/year of 
rice). 
In Developing Countries, the availability of wheat (63.4 kg/year) is second to that of rice 
(71.4 kg/year), but is increasing more rapidly than the latter (in 1961s was 54, 4 kg/year of 
rice and 29.3 kg/ year of wheat). This trend could lead to celiac “pandemy”, related, 
probably, on the progressive “Westernization of food worldwide”.  
 
 
 
Figure 1. Wheat consumption (Kg) per person per year for countries in the Asia-Pacific region20. 
 
In fact, although wheat is the staple cereal of most Caucasian populations, the diet of many 
populations in Asia and South-East Asia is based on rice. In some countries such as India, 
diets vary in different regions with wheat cereal as the staple diet in north-western states 
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and rice as the staple diet in most of the southern states. An additional issue is the 
increasing use of wheat-based products associated with urbanization and rising incomes in 
areas of Asia that were once considered traditional rice-eating regions. The current wheat 
consumption per capita per year in countries in the Asia–Pacific region is shown in Figure 1.  
Until a few years ago, gluten intolerance was thought to be a disorder almost exclusively 
affecting Europeans or people of European origin (North Americans and Caucasian 
Australians) and the phenotype blue eyes and blond hair was described as typical of CD 
patients14,23. In this respect, serological screening in the general, unselected populations of 
the Western world, North America and Australia clearly demonstrated that the prevalence of 
gluten intolerance in these areas of the world likely ranges from 0.5%-1%, that is from 1:200 
to 1:100 (Table I). 
 
Table I. Prevalence of CD in Europeans and people of European ancestry based on unselected 
population serological screening. 
 
Europe 
 
Czechoslovakia 1:218 
Estonia 1:88 
Finland 1:99 
Hungary 1:85 
Ireland 1:122 
Italy 1:106 
Norway 1:262 
Portugal 1:134 
Spain  1:118 
Sweden 1:190 
Switzerland 1:132 
Netherlands 1:198 
United Kingdom 1: 100 
United States 1:133 
Australia 1:251 
 
On the other hand, until recent years CD had been observed only in sporadic cases among 
native African immigrants in Europe14,24-26, in a few African-Americans serologically 
screened for CD in the United States14,16,27, and in one black patient of South Africa28. 
Similarly, until a few years ago, there were only limited case studies and occasional 
observations of CD in Latin America14,29-32, in North Africa33,34; and in the Middle East35-37, 
where gluten intolerance was believed to be rare. In addition, CD has been historically17 
considered absent in the Far East (China, Japan, Korea, Malaysia, etc.). 
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In contrast, recent large screening studies performed by means of simple, sensitive and 
specific tests (AGA, EMA and anti-tTG antibodies assays) on the general population and at-
risk groups in those developing areas of the world where there is a large consumption of 
wheat, such as North Africa, India and Middle East, showed that the prevalence of gluten 
intolerance had been underestimated and that it is, instead, similar to that of the so-called 
Western countries. 
In African populations, specifically in the Maghreb area (the Northern Region of Africa 
including Morocco, Algeria, Tunisia, Libya and Egypt) very high incidences of CD have 
recently been reported both in the general population38,39 and in at risk-groups. 
Serological screening in 2500 Tunisian healthy blood donors showed that the prevalence of 
EMA in the general population is 1:355, which is close to that of Europeans40. These high 
frequencies are not surprising because wheat and barley are the major staple foods in the 
Maghreb countries40, and because there is a high frequency of the DR3-DQ2 CD 
predisposing haplotypes in these populations41,42. 
Another population in North Africa with an elevated prevalence of CD (5.6%), which is the 
highest known in the world today42, is the Saharawi people, who are of Arab and Berber 
origin, who have a high degree of consanguinity, and who live as refugees in Algeria 
(Sahara Desert). This elevated prevalence may be explained both by genetic factors, as the 
Saharawi population has a very high frequency of the DR3-DQ2 haplotype, and by 
environmental factors, because in the last few decades they have changed their dietary 
habits. For example, the rates and duration of breast-feeding have been reduced and large 
amounts of gluten are now being consumed in early life as part of the staple diet, due to the 
humanitarian aids supplied by Western countries43. However, other genetic and 
environmental factors probably play an important role in explaining such a high frequency of 
CD in the Saharawi people, because gluten-containing foods are also the staple diet in 
Sardinia and similar frequencies of DR3-DQ2 have been observed in the Sardinian 
population, but here there is a much lower prevalence of CD44. 
CD is a relatively common cause of chronic diarrhea in Iran, Iraq and Kuwait and has been 
diagnosed in 2–8% of patients with type 1 diabetes in Iran, Israel and Saudi Arabia45. Many 
of these countries have a per capita wheat consumption that ranks among the highest in the 
world. Although only a limited number of genetic studies have been carried out, the 
population of countries such as Iran, Saudi Arabia and Turkey have a high frequency of 
HLA-DQB1*02 . Using adult blood donors, prevalence rates for celiac disease in Iran, Israel, 
Syria and Turkey were 1:166 (0.6%)46, 1:157 (0.6%)47, 1:62 (1.6%)14 and 1:87 (1.2%)48, 
respectively. Similar prevalence rates were determined in surveys of Iranian children (1:165, 
0.6%)49 and Turkish children (1:115, 0.9%). These prevalence rates are almost identical to 
those of a variety of countries in Europe23. 
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These data on the new epidemiology of CD among Middle Eastern people do not appear 
surprising because these populations live in countries included in the “Fertile Crescent”, the 
region where CD originated and where there is both a large consumption of wheat 45,50 and 
a high frequency of the HLA CD predisposing genes51,52. 
In Southern Asia there are still no data available on CD prevalence in the general and 
unselected populations. Therefore, because in past decades reports of gluten intolerance 
were sporadic, CD was believed to be very rare in this area of the world53-55. In contrast, 
several recent studies suggest that gluten intolerance is also common in South Asia. For 
example, CD has been diagnosed in 26% to 49% of Indian children presenting with chronic 
diarrhea at tertiary care hospitals56,57, and during the last few years a large number of CD 
patients have been observed in many case studies in the Indian Sub-continent, especially in 
Northern India58-61. In addition, during these years some studies62 reported CD in South 
Asian patients who had immigrated to Europe or North America. In this respect, a recent 
Italian multi-center study on immigrant children with CD showed that 3 were native to 
Pakistan and 1 to Sri-Lanka (formerly Ceylon, to the south of India), while in previous 
studies63,64 respectively 10 and 13 CD children of Punjabi descent were reported in the UK. 
Interestingly, in the Punjab (Northern India), gluten intolerance is called “summer diarrhea” 
and in summer the “chapattis”, which are the typical staple food, are made of wheat while in 
the winter maize flour is used. However, the people living in South Asia have the CD-
predisposing HLA genes because they are Aryan in origin65-67 and their staple diet is rich in 
wheat-derived foodstuffs. These data clearly support the hypothesis that CD is widespread 
in South Asia, but likely under-diagnosed. Therefore, both greater attention and awareness 
among physicians as well as mass serological screenings in the general populations are 
needed to establish the real prevalence of CD in these countries68.  
CD has been historically17,69 considered absent in the Far East (China, Japan, Korea, 
Malaysia, etc.). On the contrary, recently three cases of gluten intolerance have been 
observed in Canada among adult descendents of Japanese (two patients) and Chinese 
(one patient) immigrants63. This finding, even when limited suggests that genetic 
susceptibility to CD exists also among these populations. It might be related to genes 
different from DR3-DQ2 and DR4-DQ8 haplotypes, as these are rare or absent in these 
areas of the world17,70. Furthermore, HLA-DQB1*02 is virtually absent from the Japanese 
population but is present at low frequency in the Chinese population. However, other 
questions arise in this regard.  
CD is likely to be rare in Indonesia, Korea, the Philippines and many smaller Pacific islands 
because of low wheat consumption and a low frequency of HLA-DQB1*02. In South-East 
Asia, HLA-DQB1*02 is often present in more than 5% of the population but CD is predicted 
to be rare, as staple diets are based on rice. In contrast, prevalence rates that are similar to 
those in Europe are likely to apply to most of the Middle East and may also apply to 
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countries that extend from Pakistan in the south to Kazakhstan in the north. Ancient 
migration patterns that determine the frequency of DQB1*02 would also predict more 
patients with CD in western China than in eastern China. Figure 2 shows the prevalence of 
CD in Asia-Pacific Region20. 
 
 
Figure 2. Prevalence of celiac disease in countries in the Asia–Pacific region. For the majority of 
countries, the prevalence is unknown20. 
 
 
CD is a common disorder in Latin America, both in the more developed (e.g. Brazil and 
Argentina) and in the less developed (e.g. Cuba, Chile, Uruguay) countries. This 
phenomenon is noteworthy because a large proportion of Latin American people share 
common European ancestry and because wheat is commonly present in their staple diet. A 
high prevalence (1:167; 0.60%) of undiagnosed CD cases has been recently observed 
following serological screening among the general population in Argentina71, in Uruguayan 
children (1:51; 1.96%) and in 2 studieson healthy Brazilian blood donors, 1:276 (0.36%) and 
1:292 (0.34%) respectively14. These rates are higher than those of the first serological 
screening performed on a general population in Latin America (i.e. Brazil), where the 
observed prevalence of undiagnosed subclinical CD patients was 1:681 (0.15%). However, 
this lower prevalence might be due to the fact that most of the studied subjects were men 
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(while CD is more frequent in women), that anemic subjects were excluded from the 
screening in the study design (iron-deficiency anemia is a very common atypical form of 
CD), and that a single serological test (IgG AGA assay) was used as a first-level screening 
test14. 
In Latin America there is also a high prevalence of gluten intolerance among the groups at 
risk. In Cuba, undiagnosed CD prevalence among children with type-1 diabetes mellitus, 
with Down’s syndromeand among undernourished children was respectively 2.5%, 2.3% 
and 2%. Similarly, in Brazilian children and adolescents with type-1 diabetes mellitus or with 
Down’s syndrome, the prevalence of undiagnosed and subclinical forms of CD was 4.8% 
and 5.6%, while the rate of silent cases of gluten intolerance among first degree relatives of 
celiac patients was 13.66%. Overall, these data on the general population and on groups at 
risk clearly indicate that the epidemiology of gluten intolerance in Latin America is 
comparable to that of European and North American Caucasian populations14. 
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1.3. Pathology 
CD affects the mucosa of the prossimal small intestine with damage gradually decreasing in 
severity towards the distal small intestine, although in severe cases, the lesion extend to the 
ileum. The degree of proximal damage varies greatly depending on the severity of the 
disease. The proximal damage may be very mild in “silent” form with little or no abnormality 
detectable histologically in the mid jejum. Abnormalities of the gastric and rectal mucosa 
may be observed in some cases. 
The introduction of per-oral endoscopy to take biopsy specimens of the proximal small 
intestinal mucosa allowed to distinguish between normal villous mucosa and flat biopsy 
specimens that are present in CD with degrees of abnormalities falling between these two 
categories.  
Normal small intestinal mucosa exhibits digitate villi, leaf forms, and ridges (Appendix I, 
Figure 1A). The villi vary in size, shape, and height but are usually 3 times taller than they 
are wide. Convolutions, which are normal, are long ridges that can be regarded as villi that 
have fused and buckled. There are different appearances of the small intestinal mucosa, 
depending on whether subjects reside in temperature or tropical climate. Fully convoluted 
appearances occur in more than 5% of normal subjects in tropical areas. Infants exhibit 
broad leaves and villi, with finger-shaped villi rarely present. 
The small intestinal mucosa in CD may be flat and featureless and may present a flat 
mucosal pattern caused by interaction of deep depressions leaving elevated mounds. Each 
mound has 8-10 crypt openings. 
The characteristic histologic appearance of small intestine mucosa from a patient with 
untreated CD classically ehibits a flat mucosa with reduction in the normal villous height to 
crypt depth ration from between 5:1 and 3:1 (Appendix I, Figure B-D). The appearance of 
villous atrophy signals the most severe lesion in CD. The nomenclature describing the 
various stage or grades is confusing. It includes partial villous atrophy (shortening of the 
villi), subtotal villous atrophy (i.e. sever villous atrophy or a flat mucosa), and total villous 
atrophy (i.e. abstent villi) (Appendix I, Figures B-D). In this context Oberhuber et al.72 
proposed the following terms: mild atrophy (villous atrophy indicates minor or moderate 
degrees of shortening and blunting of the villi), marked atrophy (villous atrophy indicates 
that only short tent-like remainders of the villi are to be seen, flat mucosa or total villous 
atrophy (it indicates that no more villi are to be recognised and that the surface is flat). The 
term subtotal villous atrophy was used in the original classification in cases whit a flat 
mucosa72. Today, the term subtotal villous atrophy is often used to describe a marked 
villous atrophy.  
The characteristic patchy lesions may occour especially in relapses and DH. Patchy lesion 
denotes that parts of the mucosa may appear mormal and others severely diseased. The 
latter may be missed when only single biopsies are taken. 
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The total thickness of the mucosa may be increased because of crypt hyperplasia and 
infiltration of the lamina propria by plasma cells and lymphocytes. Crypt hyperplasia 
represent the first architectural change which could be found in the dynamic process of the 
development of the CD. Initially, the elongated crypts are covered by normal appearing villi; 
later on, when the lesion is more advanced, by shortened villi, which may be absent in the 
most severe stage. Crypt hyperplasia can only be appreciated on sections cut perpendicular 
to the plane. Crypt mitotic activity is normally confined to the lower third of the crypt, but in 
CD this activity my be increased, although the histologic appearance of the crypt seems 
normal. 
Surface enterocytes height is reduced. Especially, in a flat mucosa, the surface epithelium is 
often cuboidal and basophilic, and the cytoplasm may contain vacuoles.  
The histologic differential diagnosis will be between CD, tropical sprue, eosinophilic enteritis 
and Chron’s disease. Confirmation of the diagnosis will include improvement in the 
histologic abnormalities on the small intestinal biopsy specimen as well as symptomatic 
improvement with GFD. 
There is a generalized lymphocytic infiltration of the epithelium that may extend into the 
crypts. 
The time taken for the cells to migrate from the crypt to the surface is reduced from between 
3 and 5 to between 1 and 2 days. The number of IELs in relation to the number of surface 
cell enterocytes is increased in patients with active disease. Chronic inflammatory cells 
infiltrate the small intestinal mucosa in untreated CD. There are increased numbers of 
plasma cells in the lamina propria and lymphocytes in the surface epithelium. Most IELs 
express the common leukocyte antigen CD3, 70% express the suppressor/cytotoxic 
phenotype, and 20% of the cells are CD3+, CD4-, and CD8-. There is also an increase in 
the number of IELs expressing the more primitive λ/δ T-cell receptor in the untreated 
condition. 
According to Marsh73 the mucosal lesion has been classed into 5 types. 
 Type 0 preinfiltration lesion. The duodenal histology is histological indistinguishable 
from the normal mucosa, but pathological intestinal specimens are able to secrete AGA 
(IgA and IgM). However it is not true if the duodenal mucosa of these patients remains 
static or progresses to a more severe injury. This lesion has been described in 5% of 
patients with gluten-associated dermatitis herpetiformis (DH) (distinguished from linear 
IgA disease thanks to granula deposits of IgA in dermal papillae). 
 Type 1 infiltrative lesion. There is a normal mucosal architecture but with an increased 
number of IELs This lesion occurs in 40% of patients with DH and in 10% of first degree 
relatives of patients with CD. This lesion is not associated with any symptoms or signs of 
malabsorption and intestinal permeability are normal. 
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 Type 2 hyperplastic lesion. In addition to the increased IELs, there is an increase in 
crypt depth without a reduction in villous height. Gluten-challenge can induce these 
changes, which are seen in 20% of untreated DH patients and celiac patients. 
 Type 3 destructive lesion. This is the classic CD lesion. It is found in 10% of DH 
patients, and, 10%-20% of first degree relatives of celiac patients, and, despite marked 
mucosal changes, many individuals are asymptomatic and therefore classified as 
subclinical. This lesion is characteristic of, but not diagnostic for, CD and can also be 
seen with severe giardiasis, infantile food sensitives, graft versus host disease (GVHD), 
chronic ischemia of the small intestine, tropical sprue, Ig deficiencies, and other immune 
deficiencies and allograft rejection. This lesion includes entirely the criteria established 
by intestinal immuno-mediated cell immunity (Table II). 
 Type 4 hypoplastic lesion. This can be considered the end-stage lesion in a very small 
group of patients who are unresponsive to GFD and may develop malignant 
complications. There is deposition of collagen in the mucosa and submucosa 
(collagenous sprue), which is usually unresponsive to treatment with steroids, 
immunosuppressive agents, or chemotherapy. 
 
 
Table II. Features of the cell-mediated immunological of the small intestina mucosa73. 
 Disappearance of intestinal villi 
 Crypt hypertrophy  
Increased rate of cell mitosis 
Increased rate of cell migration 
 Lymphoid infiltration of the epithelium 
Surface 
Crypts 
 Oedema of the lamina propria 
Increased microvascular hyperpermeability 
Increased cell population 
     Plasma cells 
     Neutrophils 
     Eosinophils 
     Basophils 
     Mast cells 
Secretion of cytokines and inflammatory mediators 
 Altered profile of differentiation of the membrane hydrolase of the superficial enterocytes  
 Upregulation of the expression of class 2 MCH  
 Increased fluid secretion 
 Increased permeability 
     
Oberhuber et al.72 slightly have modified the classification of Marsh73. 
In Marsh’s classification, cases with mild, marked as well as total villous atrophy were 
embraced by one specification (destructive lesions, type 3), which does not allow one to 
read these differences when only a code is used. Oberhuber et al., in 1999, have 
subdivided type-3 lesions into subgroups a-c (Table III). 
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Tabella III. Marsh classification modified by Oberhuber et al72. 
 Type 0 Type 1 Type 2 Type 3a Type 3b Type 3c 
IEL∗ < 40 > 40 > 40 > 40 > 40 > 40 
Crypts Normal Normal  Hypertrophic Hypertrophic Hypertrophic Hypertrophic 
Villi Normal Normal  Normal Mild atrophy Marked atrophy Absent 
* Numbers as given as IELs/100 epithelial cell 
 
The severity of CD is distinguished as follow: 
Type 0. This is a normal mucosa with less than 40 IELs/100 enterocytes.  
Type 1. This is the infiltrative type, which is characterised by a normal villous architecture, a 
normal height of the crypts and an increase in IELs, number up to more than 40 IEL/100 
enterocytes. This type of lesion may be observed in CD patients on a GFD and indicates 
that minimal amounts of gliadin are still ingested or that the patient is not yet in full 
remission.  More importantly, it is also found in some family members of CD patients 
(potential CD, see later). This stage is not diagnostic for CD and, currently, these patients 
do not have to undergo a GFD, even if they produce EMA. However, they will have to be 
followed up for years, because the changes from type-1 to flat mucosa may occur at any 
time within several years. IELs counts may fall with gluten exclusion and rise on its re-
introduction. 
Type 2. This is the hyperplastic type, which is characterised by a normal villous architcture, 
an increase in IELs up to more than 40 IELs/100 enterocytes and crypt hyperplasia. This 
stage is only rarely encountered; it could be observed in patient on a GFD having a patchy 
lesion or in individuals who have not yet developed full blown disease.  
Type 3. This stage signals the so called “destructive” type of the CD lesion. It is divided into 
three different subgroups depending on the digree of villous atrophy. Type 3 lesions 
represent diagnostic lesions. 
3a. Characterised by a mild villous atrophy, crypt hyperplasia and an increase in 
IELs up to more than 40 IELs/100 enterocytes.  
3b. Characterised by a marked villous atrophy, crypt hyperplasia and an increase in 
IELs up to more than 40 IELs/100 enterocytes. 
3c. Characterised by a flat mucosa, crypt hyperplasia and an increase in IELs up to 
more than 40 IELs/100 enterocytes. 
Type 4. This is the very rare hypoplastic lesion, which is characterised by a flat mucosa with 
normal crypt height and normal IELs counts.  
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1.4. Etiology 
1.4.a. Gluten and peptides 
CD could may be defined as a condition in which there is an abnormal proximal small 
intestinal mucosa that improves morphologically on treatment with a GFD and relapses 
when glutan is reintroduced. 
Gluten is the protein fraction of most cereals, including wheat, rye, and barley. 
In this context, gluten collectively refers to prolamine of wheat, rye, barley and oats, the 
latter still being a matter of controversy, since recent studies seem to exclude its 
pathogenetic role69,74-77. 
The precise structure of the part of gluten, which cause damage in CD, remains unclear.  
Wheat grains have 3 major constituents that are separated by milling: the outer husk or 
bran, the germ, and the endosperm or white flour, which constitutes 70%-72% of the whole 
grain by weight and contains the toxic components (Figure 3). 
The storage proteins of cereals fall into 2 major groups: the ethanol-soluble fraction termed 
prolamins and the glutenins (alcohol-insoluble)69. Prolamins from the different cereals are 
termed gliadins from wheat, secalins from rye, hordeins from barley, avenins from oats, and 
zeins celiac non-toxic maize. 
Wheat proteins are divided into classes according to their solubility characteristics: gliadins 
are soluble in 40-90% ethanol, and glutenins are insoluble in neutral aqueous solution, 
saline, or ethanol. The gliadins may be further subdivided into alpha, beta, gamma and 
omega subfractions either according to their relative electrophoretic mobility, or alpha, beta, 
and omega according to their N-terminal amino acid sequences.  
Although there is recent evidence that even glutenins could be involved in the pathogenic 
mechanisms of CD78,79, prolamins (namely, gliadins, secalins, and hordeins, respectively) 
are thought to be responsible for triggering CD. 
One of the known toxic α-gliadins, A-gliadin, has been sequenced and comprises 266 
aminoacids divided in five domains69. A number of in vitro studies have suggested that 
sequences derived both from the N-terminal and C-terminal region of this fraction may be 
coeliac activating. For A-gliadin 31-49, these data were also confirmed by in vivo challenge 
experiments80. Alanine substitution at position P38 of sequence 31-49 resulted in an 
increased DQ2-binding affinity but in a loss of toxicity81 which could be of great interest in 
terms of oral tolerance induction. Moreover, a peptide corresponding to residues 206-217 of 
A-gliadin and with a high grade of homology to the ElB protein of Adenovirus 12, an 
adenovirus usually isolated from the GT, was found to be toxic when directly instilled into 
the coeliac intestinal mucosa82. Although the adenovirus hypothesis was attractive and has 
analogies to theories of the pathogenesis of autoimmune disease, data about this topic 
have not been universally confirmed83. Finally, partially overlapping sequences in the region 
57-75 of α-gliadin seem to have all the characteristics to be considered possible candidate 
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epitopes. In fact, they are recognised by intestinal DQ2-restricted T-cells and act as strong 
antigens after tTG deamidation at position Q6584-86. This deamidation leads to the exposure 
of negatively charged aminoacids that are required for binding to the groove of HLA class II 
molecules. Preliminary studies have also demonstrated the toxicity of this sequence to the 
jejunal coeliac mucosa using an organ culture assay69. 
 
Figure 3. – Schematic presentation of wheat corn.  
 
 
A high content of glutamine and proline is a common feature of gliadins, secalins and 
hordeins, while prolamins of cereals considered to be non-toxic for persons with CD, such 
as rice and corn, have a lower content of these aminoacids87. This particular aminoacid 
composition confers resistance to complete degradation by gastrointestinal proteolytic 
enzymes, which results in accumulation of peptide fragments rich in glutamine and proline 
in the lumen of the small intestine88. An exceptionally immunoreactive 33-mer peptide 
LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF (residues 57–89) resistant to digestion 
by all gastric, pancreatic, and intestinal brush-border membrane proteases has been 
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identified from α-2 gliadin89, and an in silico analysis of the gluten proteome has led to the 
identification of as many as 60 putative peptides that have similar characteristics90. The 33-
mer peptide is of notable interest not only for its exceptional resistance to proteolytic 
degradation, but importantly, to the presence in it of three distinct T-cell epitopes that were 
identified previously in T-cell proliferation assays, namely, PFPQPQLPY, PQPQLPYPQ 
(three copies), and PYPQPQLPY (two copies), all recognized by DQ291. This peptide is 
considered a celiac “superantigen. 
Finally, more recently described is a 25-mer containing another well studied fragment of the 
a-gliadin molecule, p31–4392. 
In conclusion, at least five different epitopes have been identified to date93. Three of them 
are DQ2-restricted and deamidation of a single glutamine residue is essential for 
lymphocyte activation94. Two are DQ8-restricted epitopes95 one gliadin- and one glutenin-
derived, and tTG-mediated deamidation is relevant in one case only96. The existence of 
several gluten epitopes that are recognised by intestinal T cell clones is not contradictory, 
but it might be explained by the epitope spreading97. However, it is still unknown whether 
the peptides identified, so far, are also involved in the initiation of the gluten specific T cell 
response. In fact, identification of disease eliciting peptides is going to be important in terms 
of new strategies of prevention and treatment. 
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1.4.b. Epithelial barrier dysfunction 
For the toxic components of gluten to initiate the cascade of pathogenetic events leading to 
the histopathologic changes seen in CD (see paragraph 1.3), their translocation into the 
subepithelial compartment must take place either via the transcellular or by the paracellular 
routes (or both). Recently, evidence has been provided identifying potential pathways for 
the transcellular passage of gliadin fractions91. This evidence was suggested by in vitro 
transepithelial resistance measurements of epithelial cell monolayers without notable 
disruption or injury of the cells98 and by fluorescence-tagged a2-gliadin 33-mer not only in 
Caco-2 cell monolayers but also in human duodenal biopsy samples of active celiac 
patients99. In this latter system, epithelial translocation of the toxic 33-mer peptides occurs 
by transcytosis after partial degradation and is regulated by interferon (IFN)-γ. The uptake of 
this peptide is higher in untreated CD than in controls and in CD patients on a GFD. 
In course of CD, if on the one hand it reduces the absorption of nutrients through the 
intestinal mucosa, secondly, there was an increase in intercellular permeability. 
This is due to the opening of tight junctions (TJ), dynamic structures that normally regulate 
the flow of ions and soluble molecules through intercellular spaces, under the control of a 
variety of environmental stimuli, physiological and pathological conditions. 
In physiological conditions, intestinal epithelium with its intact TJ, acts as a barrier to the 
passage of foreign antigens, including gluten and bacterial toxins. When TJ are functionally 
intact, small but significant amount of antigen immunologically cross this barrier through two 
routes: 90% of the protein absorbed by the gut passes away "trans-cellular" and undergoes 
lysosomal degradation, which converts them into not immunogenic small peptides. The 
remainder is transported in the form of intact proteins by "para-cellular" route, i.e. through 
the TJ, involving a sophisticated regulatory mechanism that leads to antigen tolerance. 
When this balance is compromised, as observed during CD, a complex immune response 
with both an autoimmune and allergic component, can be triggered by various 
environmental stimuli. 
The para-cellular route for the passage of gliadin peptides has also been investigated in 
particular relation to a peptide, zonulin100. It is an intestinal peptide involved in the regulation 
of TJ, and it seems to be responsible of the increased intestinal permeability observed in 
CD and of the increased autoimmune disorders observed in untreated CD101. 
This protein is, in fact, known to induce disassembly of the tight junctions and, therefore, is 
hought to be involved in the early pathophysiological changes that lead to abnormal entry of 
gliadin peptides in celiac patients.  
A new study102 now finds that gliadin (via at least two a-gliadin 20-mer peptides) binds to the 
chemokine receptor CXCR3 and this binding results in a stimulation of the release of 
zonulin, previously demonstrated to be upregulated in celiac mucosa103. It is of interest to 
note that the stimulatory effect of gliadin on zonulin release and on intestinal permeability 
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can be observed in tissues not only from celiac patients but also, although to a lesser 
degree, from controls102,103. 
Zonulin by binding to a membrane receptor and in an "organ-specific" way triggers a chain 
reaction that leads to the rearrangement of the cytoskeleton leading to of signal of opening 
the TJ and so to the possible entry of allergens and great amounts of gliadin in the intestinal 
submucosa where, in the presence of genetically susceptible immune cells, it is activates an 
autoimmune response.  
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1.4.c. Genetic factors 
Genetic predisposition plays a key role in CD and considerable progress has been made 
recently in identifying genes that are responsible for CD predisposition. It is well known that 
CD is strongly associated with specific HLA class II genes known as HLA-DQ2 and HLA-
DQ8 located on chromosome 6p21. Most CD patients (around 95%) express HLA-DQ2 and 
the remaining patients are usually HLA-DQ8 positive. The HLA-DQ2 allele is common and 
is carried by approximately 30% of Caucasian individuals. Thus, HLA-DQ2 or HLA-DQ8 is 
necessary for disease development, but not sufficient, as its estimated risk effect is only 36–
53%104.  
Non-HLA genes contribute more than HLA to the CD genetic background; however, this 
predisposition depends on a multitude of genes, each of them adding only a modest 
contribution to disease development. Due to small effect size and genetic heterogeneity 
between populations, the search for non-HLA CD predisposing genes is like looking for a 
needle in a haystack. However, this process has been facilitated by the recent application of 
genome-wide association studies, a hypothesis-free approach that can test thousands of 
single nucleotide polymorphisms (SNPs) across the whole genome for association105. A 
provisional list of CD predisposing loci includes CELIAC1 on chromosome 6 (HLA-DQ2 and 
HLA-DQ8), CELIAC2 on chromosome 5q31-33, CELIAC3 on chromosome 2q33 (containing 
the T-lymphocyte regulatory genes CD28, CTLA4, and ICOS), and CELIAC4 (the myosin 
IXB gene, MYO9XB) on chromosome 19p13.1.  
MYO9B encodes an unconventional myosin molecule that may have a role in actin 
remodeling of epithelial enterocytes. It has been hypothesized that this genetic variant might 
lead to an impaired intestinal barrier, which might allow the passage of immunogenic gluten 
peptides106. Although the MYO9B association has not been replicated in some European 
populations, it was a puzzling finding that MYO9B genetic variants predispose also to 
inflammatory bowel disease. These data imply shared causal mechanisms underlying 
intestinal inflammatory diseases107. Genetic variation in MYO9B was found to be associated 
also with systemic lupus erythematosus and rheumatoid arthritis, suggesting that MYO9B is 
a general risk factor for autoimmunity108.  
Furthermore, associations with tight junction genes PARD3 and MAGI2 has been reported 
in Dutch patients affected with either CD or ulcerative colitis, again suggesting a common 
defect of the intestinal barrier in these two conditions109. The first genome-wide association 
studies in a large cohort of UK CD patients and controls identified risk variants in the 1q31, 
3q25, 3q28, 12q24 and 4q27 regions. In addition, new evidence for association in the region 
2q31 (ITGA4) was reported110. 
The 4q27 region contains IL2 and IL21 genes111. IL-2, secreted in an autocrine fashion by 
antigen-stimulated T cells, is a key cytokine for T-cell activation and proliferation. Another T-
cell-derived cytokine, IL-21, enhances B-cell, T-cell, and natural killer cell proliferation and 
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IFN-γ production. Both cytokines are implicated in the mechanism of other autoimmune 
conditions, namely type 1 diabetes and rheumatoid arthritis, suggesting that the 4q27 region 
might represent a general autoimmune disease risk locus.  
Furthermore, recent evidences in non-Europeans populations have suggested that 
rs6822844 at the IL2-IL21 region is strongly associated with multiple autoimmune diseases, 
such as CD, type 1 diabetes, rheumatoid arthritis, primary Sjögren's syndrome, systemic 
lupus erythematosus and Behçet's disease  in individuals of European descent, suggesting 
similar molecular mechanisms112. 
A further genome-wide association studies on follow-up samples from three independent 
European CD collections identified seven previously unknown regions contributing 
significantly toward disease risk113. These seven newly identified regions, together with IL2–
IL21, explained 3–4% of the heritability of CD. Six out of seven regions harbored genes 
controlling immune responses, for example leukocyte signaling in response to IL-18 and 
IFN-g production. Together with other recent genome-wide association studies reports114 
these findings suggested possible common mechanisms between CD and type 1 diabetes 
at the SH2B3 region, 3p21 CCR gene region, RGS1 (1q31), IL18RAP (2q12), TAGAP 
(6q25), PTPN2 (18p11), and CTLA4 (2q33)115,116 and between CD and Crohn’s disease at 
the IL18RAP region. 
 
Table IV. Non-HLA loci of CD susceptibility117. 
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Two novel CD risk regions were identified at chromosomes 6q23.3 (OLIG3-TNFAIP3) and 
2p16.1 (REL) by testing large case-control European cohorts, both genes are key mediators 
in the nuclear factor kappa B pathway, an innate immunity that has not been reported to be 
heritably altered in CD before118. To summarize, it appears that the genetic predisposition to 
celiac disease depends on one gene with a large effect (HLA-DQ2/DQ8) on the adaptive 
immune response to gluten peptides and many other genes influencing different aspects of 
innate and adaptive immune reactions, intestinal permeability, and general predisposition to 
autoimmunity118. 
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1.4.d. Environmental factors 
Environmental factors that have an important role in the development of CD have been 
suggested by epidemiologic studies119. These include a protective effect of breast-feeding120 
and the introduction of gluten in relation to weaning. The initial administration of gluten 
before 4 months of age is associated with an increased risk of disease development, and 
the introduction of gluten after 7 months is associated with a marginal risk (Norris et al., 
2005). However, the overlap of gluten introduction with breast-feeding may be a more 
important protective factor in minimizing the risk of CD. 
Recently, a high frequency of rotavirus infections has been shown to increase the risk of CD 
in genetically predisposed children121; in addition, a subset of serum anti-tTG IgA antibodies 
of persons with active CD has been found to recognize the rotavirus protein VP-7, 
suggesting a rotavirus driven mechanism of molecular mimicry in the pathogenesis of the 
disease122.  
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1.5. Pathogenesis 
 As seen in paragraph 1.4.a. prolamins of gluten are rich in proline and glutamine, and 
undergo partial but incomplete digestion in the small intestine. The result is an accumulation 
of relatively large peptide fragments, as many as 50 aminoacids in length (such as a 
recently described 33mer sequence in CD)89,90.  
Under normal physiologic conditions, the intestinal epithelium, with its intact intercellular TJ, 
serves as the main barrier to the passage of macromolecules, such as gluten proteins. 
Through the possible mechanisms seen in paragraph 1.4.b. large peptides are able to cross 
the epithelial barrier and reach antigen-presenting cells in the lamina propria stimulating an 
immune response.  
Data from Maiuri and colleagues clearly show that certain gluten peptides elicit an innate 
immune response, while others drive adaptive immunity123-126. 
The adaptive immune response involves CD4+ T cells in the lamina propria that recognize 
specific immunogenic gluten peptides processed and presented by antigen-presenting 
cells127. Gluten antigens are modified enzymatically by tTG2, a calcium dependent which is 
expressed by many cell types and associates with the extracellular matrix (endomysium or 
reticulin fibers). TG2 targets certain glutamine residues in some extracellular and 
intracellular proteins, usually tethering them to a lysine residue of a second protein that 
results in crosslinking of both proteins. Alternatively, in an acidic pH that occurs with 
inflammation, TG2 merely deamidates these glutamines to negatively charged glutamic acid 
residues128. Due to their high content in glutamine and neighboring proline and hydrophobic 
aminoacid residues, gluten proteins, especially prolamins but also the glutenins, are 
preferred substrates for TG2117. 
These deamidated peptides are more antigenic than native gluten peptides and usually 
adhere to the binding grooves of HLA-DQ2 and HLA-DQ8 molecules with a higher affinity 
than native peptides129. HLA-DQ peptide complexes trigger a more rigorous gluten-specific 
CD4+ Th1 T cell activation, which in turn stimulate production of autoantibodies in the form 
of anti-tTG and EMA130; the presence of these antibodies is a specific indication of CD. 
Subsequently, CD4+ T lymphocytes infiltrate the lamina propria, activated CD4+ T-cells 
release cytokines (such as IFN-γ) that promote immuno-inflammatory mechanisms (such as 
secretion and activation of matrix metalloproteinases by fibroblasts and and inflammatory 
cells) that ultimately lead to tissue damage131. Activated CD4+ T-cells also induce activation 
and clonal expansion of B-cells, which produce antibodies: AGA, EMA, and anti-tTG. 
Production of antibodies directed against tTG is probably due to the fact that tTG can form 
covalent complexes with gluten peptides132. The role of these antibodies in the 
pathomechanism of CD is unclear; nonetheless, they are important for diagnostics127,133. 
Figure 4 summarizes pathogenesis of CD. 
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Figure 4. Pathogenesis of CD. Gluten peptides that are highly resistant to intestinal proteases reach the lamina 
propria, via either epithelial transcytosis or an increased epithelial TJ permeability. Cross-linking and particularly 
deamidation of gluten peptides by TG2 creates potent immunostimulatory epitopes that are presented via HLA-
DQ2 or HLA-DQ8 on antigen-presenting cells. Subsequently, CD4+ T cells are activated, secreting mainly Th1 
cytokines such as IFN-γ, which induces the release and activation of metalloproteinases (MMPs) by 
myofibroblasts, finally resulting in mucosal remodeling and villus atrophy. Additionally, Th2 cytokines are 
produced driving the production of (auto-)antibodies to gluten and TG2. Other cytokines such as IL-18, IFN-γ, or 
IL-21 seem to play a role in polarizing and maintaining the Th1 response. Furthermore, IL-15 links the adaptive 
immune system to innate immune responses (see Figure 5). The scheme is simplified. It does not show that T 
cells circulate to mesenteric lymph nodes where they encounter and are primed by antigen-presenting cells 
(mainly dendritic cells) and from where they home back to the lamina propria, a process that is driven by the 
lymphocyte homing receptors CCR9 and integrin α4β7117.   
 
 
Although the importance of the adaptive immune response to gluten has been well-
established, observations now also point toward a central role for the gluten-induced innate 
stress response in the pathogenesis of CD and its malignant complications134. 
Proteins from wheat, rye, or barley (apparently in contrast to “non toxic” cereal proteins 
derived from, for example, corn or rice) can elicit an innate immune response in professional 
antigen-presenting cells (monocytes, macrophages, and dendritic cells) that activates 
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predominantly IELs, but also intestinal epithelial cells123,135-138. Figure 5 summarizes innate 
immune response. 
 
 
 
 
Figure 5. Innate immune responses CD. Upon stimulation with gliadin peptide p31-49 (and other 
peptides), epithelial cells, macrophages, and dendritic cells secrete IL-15, which in turn up-regulates 
both the NKG2D receptor on IELs and its epithelial ligand MICA. The thus stimulated cytotoxic 
lymphocytes induce increased epithelial apoptosis and permeability. Furthermore, the NKG2C 
receptor on a subset of natural killer–like IELs is stimulated by its epithelial ligand HLA-E on epithelial 
cells, resulting in their proliferation and cytotoxicity, whereas stimulation of γ/δ CD8+  IELs bearing 
the NKG2A receptor via HLA-E induces TGF-β secretion and therefore a regulatory phenotype. 
Gliadin (cereal) peptides can also directly elicit innate immune responses in macrophages and 
dendritic cells via pattern recognition receptors such as Toll-like receptor 4 or other MyD88-
dependent pathways. This drives maturation of these cells and secretion of inflammatory cytokines 
such as IL-1β, IL-8, tumor necrosis factor α and MCP-1, which can potentiate the adaptive immune 
response to gluten.  
APC, antigen presenting cell; pDC, plasmacytoid dendritic cell.117. 
 
 
 
This innate immune response is an immediate reaction and is usually directed against 
relatively uniform microbial antigens but also against yet ill-defined constituents of 
cereals139. In CD, the innate immune response appears to favor the development of 
adaptive immunity to gluten in patients that carry HLA-DQ2 or HLA-DQ8123. α2-gliadin 
peptide p31-43, which is distinct from peptides that elicit adaptive immunity, was shown to 
trigger innate immunity in intestinal epithelia and intestinal organ cultures123,140. Other 
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peptides reportedly stimulated rodent monocyte or macrophage cytokine release135,136,138. 
However, these peptides have not been generally confirmed and none of the studies 
identified a receptor on a responsive cellular subset. Two recent studies that rigorously 
ruled out contamination by lipopolysaccharide implicated MyD88, the major downstream 
signal transducer of Toll-like receptor 4 on monocytes, macrophages, and dendritic cells, 
and Toll-like receptor 4 itself as primary receptor for innate responses to cereal 
proteins137,141. 
The innate immune response is the initial activation step induced by α-gliadin peptides and 
is mediated primarily by CD8+ T cells, enterocytes, macrophages, and dendritic cells. These 
cells trigger production and proliferation of proinflammatory cytokines, interleukin-15, which 
induce expression of natural killer receptor NKG2D and its ligand MIC molecules on 
epithelial cells that arm the cytolytic NKG2D pathway to destroy stressed epithelial cells. 
Infiltration by CD4+ T lymphocytes into the lamina propria and CD8+ T lymphocytes into the 
intestinal epithelium are characteristic of active CD142. 
As regards IELs  many progress has been made in our understanding how these cells are 
activated by luminal cereal proteins. The perforin/granzyme and/or Fas/FasL pathways are 
central to the observed cytotoxicity and apoptosis-inducing activity of IELs on the intestinal 
epithelium in CD143-145. Innate immune activation of IELs by gluten induces expression of the 
non-classic class I molecule MICA on the intestinal epithelium, which serves as ligand for 
the heterodimeric NKG2D receptor on natural killer, γ/δ T cells and on subsets of CD4+ and 
CD8+ T cells146. Epithelial MICA and up-regulated epithelial production of interleukin (IL)-15 
leads to activation of NKG2D on IELs142. NKG2D also links innate and adaptive immunity, 
because it both triggers antigen-specific lymphocyte–mediated cytotoxicity and induces a 
direct cytolytic function independent of T-cell receptor specificity in effector CD8 T cells147. 
Similarly, the NKG2C receptor that is activated by its epithelial ligand HLA-E is implicated in 
the pathogenesis of CD, stimulating IEL proliferation and cytokine secretion in patients with 
CD148-150. IELs can also have an immunoregulatory capacity through the secretion of 
transforming growth factor (TGF)-β1, as reported for a subset of CD8+TCRαβ+ IELs that 
express the inhibitory NK receptor NKG2A. Interestingly, this subset of regulatory cells was 
reduced in duodenal biopsy specimens from patients with active CD as compared with 
controls or patients on a GFD151. 
The central role of IL-15 in the activation of innate and adaptive immunity in CD has been 
confirmed by several investigators144,152-155, coupled with an increased expression of IL-15 
receptor and a lower threshold for activation on IELs153. Both intestinal epithelia and 
dendritic cells/macrophages are major sources of IL-15156. 
Apart from being a potent growth factor for IELs, IL-15 blocks Smad3-dependent 
transcription via the activation of c-Jun-N-terminal kinase and phosphorylation of c-jun and 
thus counteracts the immunosuppressive TGF-β pathway. Recently, IL-21, which is 
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produced by CD4+ Th1 T cells, has emerged as an additional driving force of innate 
immunity that often acts in concert with IL-15157. 
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1.6. Clinical picture 
1.6.a. Clinical classification 
The clinical presentation of CD varies greatly, depending on a patient’s age, the duration 
and extent of the disease, and presence of extraintestinal manifestations.  
The recognition of the celiac iceberg demonstrates the clinical variability of CD and helps to 
understand its systemic nature (Figure 6).  
 
 
             Figure 6. The “coeliac iceberg”158. 
 
The highest stratum of the iceberg (above the waterline) describes patients with typical 
symptoms that are gastrointestinal.  Classic symptoms associated with CD in children are 
diarrhea, abdominal distension, and failure to thrive18. Similarly, adolescents and adults 
present with diarrhea, constipation, weight loss, weakness, short stature, flatus, abdominal 
pain, and vomiting159-161. Presence of obesity does not exclude the diagnosis of celiac 
disease158. 
The subsequent stratum (just under the water) contains those patients considered to have 
atypical presentations of CD (no gastrointestinal symptoms). Atypical clinical manifestations 
of celiac disease are characterized by few or no gastrointestinal symptoms, instead, 
extraintestinal symptoms such as iron-deficiency anemia, reduced bone mineral density, 
chronic fatigue, irritable bowel, dyspepsia, infertility, miscarriage, hypertransaminemia, 
coagulopathy, short stature, pubertal delay, arthralgia, folate/zinc deficiency, DEDs, SAR or 
better ALU (see paragraphs 2..1.a-2.2.a) and otherwise unexplained neurological disorders 
(primarily peripheral neuropathy and ataxia) predominate162,163.  
The third level of this iceberg include latent and silent forms. Latent form refers to patients 
who were previously diagnosed with CD but who are currently asymptomatic with normal 
histology despite continued ingestion of gluten. “Latent” may also apply to patients with 
normal histology on a GFD who will subsequently develop CD due to genetic predisposition 
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or underlying immunologic abnormalities; in this setting, the term “potential” may also be 
used. Patients with latent or potential CD may or may not have positive serology, and up to 
50% of these individuals may develop overt CD164. 
There is also a subset of patients who have asymptomatic or silent form, in which patients 
have histologic changes, probably limited to the proximal intestine, and positive serologic 
findings, but are are apparently asymptomatic without signs and symoptoms of 
malabsorption.   
Patients who have a subclinical form of CD are unaware of it because outwardly they have 
no physical symptoms, yet they have positive serological test results for CD and villous 
atrophy on intestinal biopsy. Subclinical CD is identified as a result of screening at-risk 
groups or by recognition on biopsies obtained for another indication (ie, dyspepsia or reflux).  
Table V shows the possible clinical manifestations of CD. 
 
Table V. Possible clinical manifestations of CD. 
 
Typical symptoms 
 
 
Atypical symptoms 
 
Associated 
conditions 
 
 
Complications 
Chronic diarrhea Sideropenic anaemia IgA deficiency Refractory sprue 
 Vitamin B12 deficiency   
 Folate deficiency   
Failure to thrive Short stature Dermatitis 
herpetiformis 
Enteropathy-
associated T-cell 
lymphoma 
Abdominal distension Osteopenia/osteoporosis Type 1 diabetes Carcinoma of the 
oropharynx, 
esophagus, and 
small bowel 
Steatorrhoea Alopecia Autoimmune thyroid 
diseases 
Ulcerative 
jejunoileitis 
Wheight loss Psoriasis Sjogren’s syndrome Collagenous sprue 
Irritability Recurrent abortions Microscopic colitis  
Anorexia Hepatic steatosis Rheumatoid arthritis  
 Recurrent abdominal pain Down’s syndrome  
 Gaseousness Turner syndrome  
 DEDs Williams syndrome  
 ALU Congenital heart 
defects 
 
 Atrophic glossitis Addison diseae  
 Ataxia Autoimmune hepatitis  
 Primary biliary cirrhosis Autoimmune atrophic 
gastritis 
 
 Hepatic steatosis Autoimmune 
emocytopenic 
diseases 
 
 Hypertransaminasemia Sarcoidosis  
 Myastenia gravis Cystic fibrosis  
 Recurrent pericarditis Fibrosing alveolitis  
 Polyneuropathy Lung cavities  
 Epilepsy (with or without 
intracranial calcifications) 
Pulmonay 
hemosiderosis 
 
 Vasculitis Inflammatory bowel 
disese 
 
 Dilatative cardiomiopathy Systemic  
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erythematous lupus 
 Hypo/hyperthyroidism Polymiositis  
 Follicular keratoses   
 Pre-term   
 Reproductive disorders   
 Thrombocytosis   
 Arthralgia or arthropathy   
 Anxiety and depression   
 Delayed puberty   
 Dysmenorrhea or 
amenorrhea 
  
 Vitamin K deficiency   
 Schizophrenia   
 Dyspepsia   
 Reflux   
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1.6.b. Clinical presentation 
CD primarily affects the proximal small intestine, but can involve the entire small intestine in 
some individuals. This proximal location of CD often results in overt malabsorption of 
vitamins and minerals. Diarrhea in CD presentation is due to progression of the disease 
into the distal small bowel. 
Currently, CD is thought to resemble a multisystem immunological disorder rather than a 
disease restricted to the GT160.  In fact, The wide range of the CD clinical manifestations 
must induce many different specialists - gastroenterologists, endocrinologists, 
rheumatologists, haematologists, cardiologists, neurologists, as well as paediatricians, 
dermatologists, and dentists18 - to consider this disorder when a patient presents some 
clinical signs and symptoms. 
Studies confirm18,161,165 that fewer patients present with severe gastrointestinal symptoms, 
and the clinical face of CD in the United States is diverse. Adult presentations are now more 
common than pediatric presentations18; and 25% of newly diagnosed CD occurs in patients 
older than 60 years of age159. Subclinical or atypical presentations are more frequently 
encountered165,166, and more cases are being diagnosed as a consequence of widespread 
serological testing and increased awareness. 
 
Infancy and childhood 
The onset of symptoms in the classic form generally occurs between 6 and 18 month of 
age. This form is typically characterised by chronich diarrhea, failure to thrive, anorexia, 
abdominal distension, apathy, pallor, and muscle wasting. Growth is usally normal during 
the first month of life. Symptoms begin within weeks to a few months after introduction of 
weaning foods containing prolamines, and soon there is a progressive decrease in weight 
gain with a decline in the child’s percentile for weight and weight for height. On examination, 
the children are often pale and noticeably thin with a protuberant abdomen, decreased 
subcutaneous fat, and reduction in muscle mass. The stools are characteristically pale, 
loose, bulky, and highly offensive because of fat malabsorpion. Very young infant may 
present with vomiting, which is often effortless, of large volume, and usually associated with 
abdominal distention and little or no diarrhea. Abdominal pain may be so severe that a 
laparotomy is undertaken because a mistaken diagnosis of intestinal obstruction. In some 
cases, this pain is caused by constipation. Retardation of motor activity has been observed. 
In the very young infant with early onset of symptoms there may be frank watery diarrhea 
with dehydratation and electrolyte imbalance. A small number of these infants also have 
severe hypoproteinemia and oedema and may present in shock-like state tha has been 
termed “celiac crisis”. 
Patients with severe, untreated CD may present with short stature, pubertal delay, iron and 
folate deficiency with anemia, and rickets. 
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Atypical CD is usually seen in older children and adolescents, who have no overt features of 
malabsorption. They tend to have more varied and extra-intestinal symptomatology 
presenting with anemia, failure to grow normally and neurologically symptoms. In fact, in 
addition to recurrent abdominal pain, hypertransaminasemia, ALU. DEDs, dental eruption 
delay, arthralgia, children may have behavioural disturbances such as depression, may be 
irritable, and may perform poorly in school167. 
Laboratory signs of the malabsorption include iron deficiency anemia, hypoalbuminemia, 
hypocalcemia and vitamin deficiencies. 
 
Adult life 
The diagnosis of CD is increasingly being in adults. About 20% of cases occur in patients 
who are older than 60 years of age167. Some patients are short or have symptoms dating 
back to childhood. However, many have no history of symptoms, suggesting that CD can 
develop in adulthood. CD may present during pregnancy, or post partum, and the diagnosis 
should be considered in pregnant women in whom severe anemia develops. In a group of 
patients diarrhea could be the main presenting feature; however, approximately 50% of 
adult CD patients does not have significant clinically diarrhea but unspecific signs and 
symptoms, such as lassitude, loss of weight, unspecific atrophic glossitis, and symptoms of 
anemia. In fact, iron-deficiency anemia is now the most common clinical presentation in 
adults with CD.  
A small group present because of abnormal psychological or psychiatric symptoms, 
including schizophrenia. There may be presentation with problems related to osteomalacia, 
including spontaneous fractures, and myopathy, skin complaints, bleedin diathesis, or 
infertility. 
Many individuals have long-standing ill health for many years and, never having had severe 
symptoms, accept this as normal. Abdominal pain occurs in 5% of cases. ALU may be the 
sole presenting symptom, and therefore CD should be excluded in cases of severe 
unexplained mouth ulceration. 
Presenting symptoms in many patients with CD are non-specific and therefore a high 
diagnostic suspicion should be aroused with minor abnormalities such as haematological or 
biochemical profiles, including persistent transaminitis.  
Because the proximal small intestine is the predominant site of inflammation and also the 
site of micronutrient absorption, deficiencies of iron, folate, and calcium are common. As the 
disease progresses along the intestine, malabsorption of carbohydrates, fat, and fat-soluble 
vitamins A, D, E, and K, and other micronutrients occurs17. The finding of a mild unexplained 
anemia with persistently low serum or red cell folate, iron and vitamin B12 levels should 
suggest further investigation and may lead to a diagnosis of CD. In fact, the association of 
CD to refractory iron deficiency anemia is well-established168-170. Frequency of iron-
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deficiency anemia in CD varies from 12% to 69%171, and is reportedly higher in patients with 
long-standing, untreated disease172. Incidence of vitamin B12 deficiency in untreated 
patients ranges from 8% to 41%172,173, though there is a relative sparing of villous atrophy in 
the ileum where vitamin B-12 is absorbed. While the mechanisms inducing deficiency are 
unclear, mucosal changes are considered the most likely cause of vitamin B12 deficiency. 
Folic acid is absorbed in the jejunum, the proximal segments of which can be inflamed and 
damaged in active CD. 
Atrophic glossitis, angular stomatitis and cheilosis may be present. Nause and vomiting are 
common, particularly during episodes of diarrhea in children. There may be anorexia, 
although appetite may be increased in some patients and polyphagia has been reported. 
Abdominal distention is common and often associated with flatulence.  
Symptom of cramp and tetany may occur, usually associated with low serum calcium or 
magnesium levels. 
Bowel disturbance is the most frequent problem, usually in the form of loos stools. The 
motion may be paler than normal, sometimes offensive, occacionally frothy, and difficult to 
flush away. Bowel frequency varies, but is commonly 3-4 times a day and rarely more than 
8 times a day. Normally formed and colored stools do not preclude the diagnosis. 
Steatorrhea may be present even though the patient has stools with normal appearance. 
Physicians should remember to enquire specifically about a subject’s stool because patients 
with long-standing bowel disturbance frequently make no complaint. In addition, clinicians 
should examine patients’ stools to avoid any problem any problem pertaining to the patients’ 
powers of observation. It has been reported that many adults present with episodic or 
nocturnal diarrhea, flatulence, and weith loss174.  
Secondary lactose intolerance resulting from decreased lactase production by the damaged 
villi is also common175. 
Abdominal discomfort and bloating are common and often lead to a mistaken diagnosis of 
irritable bowel disease. In fact, a study has shown that 10% of patients suffering from 
irritable bowel syndrome were subsequently found to suffering from CD176. Constipation has 
been reported to occur in 10% of cases, although this may be underestimate. 
Abdominal pain is uncommon and may be indicate the need for investigation to exclude 
intra-abdominal pathology complicating CD. In particular such conditions as volvulus, 
intussception, mesenteric adenitis, cholelithiasis, peptic ulceration, and pancreatitis. Scurvy 
and epistaxis have been reported, and occasionally there may be bleeding into skin and 
subcutaneous tissue. This may reflect vitamin K deficiency. 
Osteomalacia, rickets or bone pain lead to the diagnosis of CD in an appreciable number of 
subjects reflecting low calcium ond vitamin D absorption.  
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1.6.c. Associated diseases and complications of unrecognized CD 
 
A number of medical conditions are significantly associated with CD (Table V). 
 
Malignancy 
Untreated CD is associated with a number of complications. The best recognized is 
malignancy. The overall relative risk of all types of malignancy in coeliac patients has 
probably been historically overestimated. The relative risk is likely to be less than 2-fold 
when compared with the general population. Although small intestinal lymphoma may have 
a 50-fold increased relative risk (compared with the general population), this is still a rare 
condition. 
Enteropathy-associated T-cell lymphoma occurs in adults, with the incidence peaking in the 
sixth decade of life, and is usually at an advanced stage at diagnosis. Symptoms may 
include malaise, anorexia, weight loss, diarrhea, abdominal pain, and unexplained fever. 
The development of lymphoma is usually indicated by clinical relapse of symptoms of CD 
after a period of good response to gluten withdrawal119. Enteropathy-associated T-cell 
lymphoma usually develops in the jejunum but may also be found in the ileum or in 
extraintestinal sites (e.g., liver, brain, chest, and bone) and is often multifocal. The 
prognosis is poor; less than 20% of patients survive for 30 months177. The phenotype of 
enteropathy-associated T-cell lymphoma is consistent with a tumor that derives from a 
clonal proliferation of intraepithelial lymphocytes. Immunohistochemical phenotyping 
indicates that this lesion is most commonly CD3+, CD4–, CD8–, CD30+, and CD103+178. 
Thus, the overall number of cases and absolute risk remains low. Improvements in small 
intestinal imaging modalities such as wireless capsule endoscopy may help to target 
highrisk individuals such as those with refractory symptoms or ulcerative jejunitis.  
Other associated malignancies include oesophageal (proximal and distal), small intestinal 
adenocarcinoma and colonic cancer179-181. 
In patients with celiac disease, the risk of adenocarcinoma of the small intestine, generally a 
rare cancer, is increased many fold as compared with the risk in the general population182; 
still, the overall risk is very low given the rarity of this cancer. These carcinomas are most 
often located in the jejunum and are more likely to develop as an adenoma–carcinoma 
sequence than as dysplasia in flat mucosa. 
Intriguingly, patients with CD may have lower rates of breast and lung cancer179. Risk of 
cancer appears to reduce over time, particularly in patients who adhere strictly to the GFD. 
Prior studies demonstrated increased cancer incidence at all sites and found correlation 
with the lack of adherence to the gluten-free diet181. A confounding factor may be age at 
diagnosis of CD with older patients appearing to have a higher risk of neoplasia183. 
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Bone mineral density 
CD is known to be associated with reduced bone mineral density (both osteopaenia and 
osteoporosis)184. The prevalence of abnormal bone mineral density is reported to be around 
40% and leads to an increased fracture risk. This increased relative risk is small overall as 
bone mineral density usually improves (or remains stable) once gluten has been excluded 
from the diet. Additionally, the excess fracture risk is small overall even when considering 
elderly patients where the risk is highest and has been calculated to be two to three 
additional hip fractures per 10 years of follow-up185. Potential protective factors include a 
lower rate of smoking and a higher rate of hormone replacement therapy use in coeliac 
patients186. 
 
Autoimmunity 
CD is associated with a number of other conditions some of which are autoimmune in origin. 
In most cases, CD is identified subsequent to the original diagnosis often because 
symptoms may be misconstrued as due to the original diagnosis. A good example of this is 
persistent tiredness in patients with thyroid disease187. The effect of concurrent CD on other 
autoimmune diseases has not been well studied as can be seen by the paucity of outcome 
data in patients with both CD and type 1 diabetes188. 
There have been some studies suggesting that patients who are not compliant with the GFD 
are more likely to develop other autoimmune conditions. This may be related to the finding 
that patients with CD have a high prevalence of other organ-specific autoantibodies. 
Additionally, following a GFD, the level of these antibodies has been found to fall189. 
However, this is a controversial perspective with other studies suggesting that the 
development of further autoimmune conditions is independent of gluten exposure and may 
be related to specific HLA haplotypes. 
 
Reproductive problems 
Infertility, reduced fertility and an increased risk of an adverse outcome during pregnancy 
(miscarriage, low birth weight and intrauterine growth retardation) have all been attributed to 
undiagnosed CD. However, these risks may be less than historically described190,191. 
 
Sepsis  
Functional hyposplenism may occur in up to 30% of patients with CD — for this reason, 
vaccination with pneumovax and haemophilus influenza type b vaccines are advised. A 
recent population database study has described a hazards ratio of 2.6 for sepsis and 3.9 for 
pneumococcal sepsis192. 
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Neurological manifestations 
An unusual but more frequently recognized presentation of CD is with neurological 
symptoms. Studies in this area have historically described ataxia and peripheral neuropathy 
as presenting features for atypical CD193-195. However, more recently two groups have also 
demonstrated subclinical neuropathy being present in patients who were diagnosed with CD 
(and did not present with neurological symptoms)196. Work done in Sheffield has also 
described the phenomenon of neurological gluten sensitivity—these patients may have 
positive serology but either minimal or no changes on duodenal biopsy193. Treatment with a 
GFD can arrest or improve neurological symptoms194. The underlying pathophysiology is not 
fully determined but changes in the humoral response have been described194. In addition, 
excess tissue transglutaminase type 2 deposits have been found in duodenal samples in 
such patients (even when structurally normal at conventional histology)197. tTG is ubiquitous 
and therefore tTG antibodies may themselves be pathogenic in some patients198. 
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1.7. Diagnosis 
The diagnosis of CD is based on 3 key parameters: (1) case identification, (2) screening 
using serological tests, and (3) small intestinal biopsy. As demonstrated by the coeliac 
iceberg, the presence of relevant symptoms is not essential for a diagnosis of CD. 
No single test exists that can definitively diagnose or exclude CD in every individual199. 
Serological testing, used as an initial non-invasive screen, is the first step in pursuing a 
diagnosis of CD. Typical indications for serologic testing include unexplained bloating or 
abdominal distress; chronic diarrhea, with or without malabsorption or the irritable bowel 
syndrome; abnormalities on laboratory tests that might be caused by malabsorption (e.g., 
folate deficiency and iron-deficiency anemia); first-degree relatives with CD; and 
autoimmune diseases and other conditions known to be associated with GSE119. 
The most sensitive antibody tests for the diagnosis of CD are of the IgA class. The available 
tests include those for AGA, connective-tissue antibodies (antireticulin and EMA), and 
antibodies directed against tTG, the enzyme responsible for the deamidation of gliadin in 
the lamina propria119. 
EMA are autoandibodies directed against the endomysium, a connettive tissue protein 
found between myofibrils in the GT; whilst the demonstration that the antigen for EMA was 
tTG has allowed the development of an enzyme-linked immunosorbent assay for both IgA 
and IgG tTG to screen CD200.  
The AGA are no longer considered sensitive enough or specific enough to be used for the 
detection of CD, except in children younger than 18 months of age201, although, iven if in 
association with IgA tTG,  new-generation antibodies to deamidated gliadin peptides appear 
to be promising202,203. Antireticulin antibodies are also rarely measured, having been 
surpassed in use by EMA and anti-tTG antibodies.  
The most sensitive and specific tests are the EmA and anti-tTG204; The IgA anti-tTG has 
95% to 97% specificity and approximately 90% to 96% sensitivity. The serological gold 
standard is IgA EmA with its virtual 100% specificity, though a somewhat lower sensitivity 
than anti-tTG119, and reports exist of lower sensitivity and specificity in the clinical practice 
setting205-207. Table VI summarizes characteristic of the celiac serological tests. 
 
Table VI. Operating characteristics of serological markers to detect the CD in adults158. 
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Positive serological testing alone is not sufficient to confirm the diagnosis as there are a 
number of pitfalls to this assumption. First, falsely positive gliadin antibodies occur in a 
variety of other conditions such as inflammatory bowel disease208. Similarly, EMA is a 
qualitative test dependent upon the degree of immunoflourescence seen and positivity has 
been correlated with the degree of villous atrophy. In fact, CD207 patients with lesser 
degrees of villous atrophy are less likely to have positive celiac serologies207. In fact, now 
we have learned that CD can be present with subtle, sometimes almost negligible, 
histological findings, and that it may be there even in the presence of a complete normal 
serology for any autoantibodies. In fact, it has become clear that in CD patients with only 
Marsh I type lesion (i.e., increased infiltration of intraepithelial lymphocytes, a nonspecific 
finding), the serology can often be negative209,210, thus leading to underdiagnosis. Finally, 
also tTG has been found to be falsely positive in other autoimmune disease. 
Children younger than 2 years of age lack EMA and tTG antibodies211; for this reason, 
serological testing in children younger than 5 years of age may be less reliable and requires 
additional study199. For these reasons, the diagnosis of CD cannot purely be based upon 
serological results. An additional consideration is antibody negative disease. CD could be 
associated with IgA deficiency212 which may render both EMA and tTG negative as these 
antibodies are IgA-based. IgG-based tests are available but are still under investigation. 
Antibody negative CD can occur in individuals with a normal serum IgA level and may 
account for up to 9% of all cases of CD213. These individuals are often older and have more 
severe symptoms suggesting a diminished immunological response and therefore negative 
serology213-215. 
Although often positive test results can be supportive of a diagnosis, a small intestinal 
biopsy is the gold standard for the diagnosis of CD, and is used to confirm positive antibody 
test results119,206,216.  
The recognition of endoscopic signs of villous atrophy, such as scalloping of mucosal folds, 
absent or reduced duodenal folds, or a mosaic pattern of the mucosa (Appendix I, Figure 2), 
should prompt biopsy. As reported in paragraph 1.3 the spectrum of pathologic changes in 
CD ranges from near-normal villous architecture with a prominent intraepithelial 
lymphocytosis to total villous atrophy73. To avoid pitfalls in the pathological diagnosis, 
several parameters must be take into account. One of the commonest reasons for 
diagnostic uncertainty is that the individual has already commenced a GFD prior to the 
biopsy with subsequent histological improvement. It is essential that all individuals under the 
investigation CD remain on a gluten containing diet until a duodenal biopsy is performed. 
Furthermore, the number of biopsies taken is important as there appears to be histologically 
variable grades of villous atrophy within the same individual217. Current advice is that four or 
five biopsies should be taken from the second part of the duodenum (or more distally). In a 
recent work, the duodenal bulb frequently revealed villous atrophy (when placed in a 
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separate specimen container and marked for the attention of the gastrointestinal 
pathologist). There has been interest in adjuvant techniques for improving diagnostic yield 
such as the use of dye spraying with magnification endoscopy or confocal laser 
endomicroscopy218, however these techniques require further training and as yet have not 
obviated the need for biopsy. When diagnostic uncertainty exists one strategy is to repeat 
biopsies following a period of gluten challenge (at least four slices of bread per day for 4–6 
weeks) or consider jejunal biopsies via enteroscopy219. 
Recent evidence shows that the diagnostic accuracy of an intestinal biopsy can be greatly 
enhanced by measuring EMA and anti-tTG produced in loco by cultured duodenal 
mucosabipsies from patients with active CD or from patients in remission after in vitro 
stimulation with a peptic-tryptic digest of gliadin that usually contains the major immune 
stimulatory epitopes220-223.  
Other Authors210 observed in a risk group of patients with potential or latent CD that 1% of 
these patients were positive for anti-tTG in serum and 6% were positive for anti-tTG in the 
cultures of duodenal biopsies, suggesting that local production of autoantibodies may 
precede subsequent histological damage. It is reasonable to add, however, that individuals 
with normal serology who only have Marsh I type lesion but positive duodenal anti-tTG need 
to be followed up clinically for a definitive diagnosis.Hence, the measurement of 
autoantibodies in the supernatant of the intestinal biopsy culture system was considered as 
an helpful tool to improve the diagnosis of CD in seronegative patients or patients with 
boubtful or borderline histological features. However, quality and size of the intestinal biopsy 
samples, their shor life span and standardization problems prohibited their wide use224. 
Another pitfall includes overinterpretation of villous atrophy in poorly oriented biopsy 
specimens and inadequate biopsy sampling in patients with patchy villous atrophy 225,226.  
The histologic findings in CD are characteristic but not specific227; their presence permits a 
presumptive diagnosis of CD and initiation of a GFD. Indeed, CD is not the only cause of 
villous atrophy (Table VIII).  
 
 
Table VIII. Causes of villous atrophy other than CD119. 
Giardiasis 
Collagenous sprue 
Common-variable immunodeficiency 
Autoimmune enteropathy 
Radiation enteritis 
Whipple’s disease 
Tuberculosis 
Tropical sprue 
Eosinophilic gastroenteritis 
Human immunodeficiency virus enteropathy 
Intestinal lymphoma 
Zollinger-Ellison syndrome 
Crohn’s disease 
Intolerance of foods other than gluten (e.g., milk, soy, chicken, tuna)
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Diagnosis depends on the finding of characteristic changes of intraepithelial lymphocytosis, 
crypt hyperplasia, and various degrees of reduced villous height, identified by intestinal 
biopsies, together with symptomatic and histologic improvement when gluten is 
withdrawn119 (see paragraph 1.3). 
 
Figure 7. Diagnostic algorithm167. 
 
 
As regards genetic assessment, as reported in paragraph 1.4.c the HLA-DQ2 allele is 
identified in 90 to 95% of patients with CD, and HLA DQ8 is identified in most of the 
remaining patients228. Because these alleles occur in 30 to 40% of the general population 
(with HLA-DQ2 more common than HLA-DQ8), the absence of these alleles is important for 
its high negative predictive value229. Thus, the presence or absence of HLA-DQ2 and HLA-
DQ8 is important for determining which family members should be screened with serologic 
testing and is useful for ruling out the disease in patients already on a gluten-free diet or for 
patients in whom the diagnosis is unclear. 
Finallly, in the context of diagnostic approaches it is useful to underline that the detection of 
anti-tTG antibodies in human saliva is possible and may be useful to monitor adherence to 
GFD with a good correlation between saliva and serum titers (r=0.75, P=0.0001) 230. 
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Clinical-based evidence concludes that in certain high-risk symptomatic groups (eg, 
unexplained iron-deficiency anemia), individuals who initially have a negative serological 
test result may later develop a positive result (with repeat testing every few years) and 
subsequently have a biopsy compatible with CD18. Diagnosis of CD is often delayed for 
many years when disease progression in the small intestine is slow or mild. Investigators 
have noted a long duration of extraintestinal symptoms before diagnosis231,232. Studies 
report that symptoms are present for an average of 11 to 12 years 233 prior to diagnosis. The 
delay is thought to be due to physicians failing to diagnose the disease rather than patients 
not seeking medical care233,234. Absence of specific symptoms and the high variability in 
clinical presentation associated with CD have led to the misconception that it is a rare 
condition and physicians are not likely to suspect CD as a cause17,235,236. In national 
surveys17,159,233, patients reported having received one or more different diagnoses before a 
definitive diagnosis of CD was made. 
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1.8. Treatment 
Currently, the only scientifically proven treatment for CD is strict lifelong adherence to a 
GFD. All foods and medications containing gluten from wheat, rye, and barley, and their 
derivatives are eliminated, as even small quantities of gluten may be harmful. Complete 
removal of gluten from the diet in a patient with CD will result in symptomatic, serologic, and 
histologic remission in the majority of patients17,237,238. Growth and development in children 
returns to normal with adherence to the GFD and, in adults, many disease complications 
are avoided. 
Green and colleagues159 found that 70% of patients reported an improvement in symptoms 
within 2 weeks of initiating the GFD. With strict dietary control, antibody levels may revert to 
normal during 6 to 12 months of instituting the diet, complete histologic resolution may take 
up to 2 years239. In a small percentage of patients, it has been reported that small intestinal 
recovery and resolution of symptoms is incomplete240. 
Some patients have been found to suffer from refractory CD, a complicated form of CD in 
which patients may not respond entirely to the GFD241,242. Researchers have found that a 
non compliance rate of about 50% accounted for symptoms in patients with non-responsive 
CD243. 
Nutritional status of the newly diagnosed person with CD depends on the length of time that 
a person has lived with active but undiagnosed disease, extent of damage to the GT, and 
degree of malabsorption. At the time of diagnosis, some patients present with substantial 
weight loss, anemia, and evidence of overt vitamin/mineral deficiencies. A comprehensive 
nutritional assessment by a dietitian who is experienced in CD will determine the degree of 
malnutrition that exists168,169,244,245. Patients who present with nutrient deficiencies may 
require temporary or long-term nutrient supplementation with gluten-free vitamins, minerals 
and protein to correct deficiencies and replenish nutrient stores 168,169,244,245, although studies 
have not specifically looked at the efficacy of nutrient supplementation in the treatment of 
CD. Anemia may be treated with iron, folate, or vitamin B12, depending on the origin of the 
anemia. However, studies have shown that 78% and 94% of adults, respectively, recovered 
from anemia while being treated with a GFD alone246. Folate supplementation is 
recommended to ensure that the goal daily allowance is consumed until the damaged, 
functionally impaired villi heal in the absence of gluten in the diet168,169,244,245. 
Fat-soluble vitamin deficiencies (vitamins A, D, E, and K) are encountered in patients with 
classic malabsorption. 
Recommended repletion dosages of fat-soluble vitamins are individually based; however, 
newly diagnosed patients may benefit from a water miscible form168. Calcium, phosphorus, 
and vitamin D deficiencies may occur due to malabsorption or a decreased intake of milk 
and dairy products in an effort to avoid lactose. In many cases, lactose intolerance resolves 
naturally with time on the GFD167. Given the considerable risk for bone disease in CD, 
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measurement of bone density, serum calcium, alkaline phosphatase, and parathyroid 
hormone levels is recommended at the time of diagnosis, and adequate dietary intake of 
calcium and vitamin D is essential. Gluten-free sources of calcium and vitamin D include 
most milk and dairy products (eg, calcium-fortified soy milk, rice milk, and juices); tofu; 
beans; canned salmon and sardines with bones; and cooked spinach, kale and broccoli. 
Some patients may not be able to meet the Recommended Daily Intake for calcium and 
vitamin D by diet alone247, and supplements may be indicated162. 
Finally, since to conduct to a true GFD is increasingly challenging many laboratories are 
now working at different strategies to offer celiac patients more therapeutic options. 
 
 
Figure 8. Novel therapeutic approaches. Use of ancestral and/or modified wheat strains with lower 
immunogenicity. Intraluminal therapies that either bind or degrade ingested gluten peptides in the 
intestine (glutenases, gluten binders, neutralizing antibodies). Blocking the ZOT receptor with the 
octapeptide AT-1001 to decrease intestinal permeability is another option. Furthermore, because the 
deamidation of gluten peptides by TG2 and the subsequent presentation by HLA-DQ2/8 initiates the 
adaptive immune responses, TG2 inhibitors and DQ2 blocking peptides seem to be an attractive 
possibility to prevent inflammation. Another promising alternative, especially for patients with 
refractory celiac disease, is directly targeting the immune cells either by lymphocyte blocking (anti–IL-
15, anti-CCR9, anti-α4β7) or tolerance induction117. 
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The novel therapeutic strategies that have been tested in in vitro or in vivo models of CD 
and approaches that may be promising in the near future are showed in Table IX and Figure 
8. Therapies can be subdivided as to their intraluminal, epithelial, or subepithelial action117. 
 
 
Table IX. Novel therapies for CD117. 
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2. Celiac disease and oral cavity 
As reported in paragraph 1.5.a among the atypical or extra-intestinal aspects of CD, 
literature has reported some affections interesting the oral cavity248-250, mainly ALU251-253 and 
DEDs254-257, and secondarily unspecific forms of atrophic glossitis258, oral variants of 
dermatitis herpetiformis259. Furthermore, Sjögren’s syndrome (SS)189,260 and OLP261 
occasionally reported in CD patients, must be considered as immuno-mediated diseases, 
sharing an immuno-mediated pathogenesis similar to CD260,262. 
 
2.1. Oral hard tissue lesions 
2.1.a. Dental enamel defects  
 
DEDs may be defined as a disturbances in hard tissue matrices and in their mineralization 
during odontogenesis, resulting in quantitative and/or qualitative enamel defects clinically 
obvious. The defect may be localize, affecting single or multiple teeth, or systematic 
affecting groups of teeth developing at the period of disturbance263-265. 
The reason for the presence of DEDs in celiac patients still remains not clear257. 
Hypocalcaemia due to malabsorption could be a possible cause, in agreement with the 
unifying hypothesis on mechanism of enamel hypoplasia development266. However, no 
differences in mean serum calcium concentration were found between celiac children with 
and without dental lesions267, and celiac-type DEDs were also detected in healthy first-
degree relatives of celiac patients having normal small-bowel mucosal architecture268. So, a 
gluten-induced, immune-mediated enamel damage should seem a more likely cause of 
DEDs in celiac patients. Consistently with this hypothesis, CD-associated dental changes 
were found significantly related to HLA antigen DR3267-269. Furthermore, a strong association 
between the same HLA allele and celiac-type DEDs were also demonstrated in healthy first-
degree relatives of celiac patients268. Hypocalcaemia resulting from malabsorption could be 
nevertheless a contributing factor in inducing defective enamel formation270. 
Mineralization disturbances may be distinguished in hypoplasia and hypocalcification. 
Hypoplasia is defined as a quantitative defect of enamel involving the surface of the enamel 
with a reduced thickness of enamel. The defective enamel may occur as shallow or deep 
pits or small or large, wide or narrow grooves. Hypocalcification is defined as a qualitative 
defect of enamel identified visually as an abnormality in the translucency of enamel271. 
Furthermore, DEDs in CD, symmetrically and chronologically distributed, show specific and 
characteristic features as: 
- symmetry of the lesions with involvement of different teeth; 
- bilateral defects in both dental archs; 
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- chronological coherence: enamel defects follow chronology of dental amelogenesis, 
involving enamel surfaces that are forming when act pathogen agent264,265. 
The existence of an association between gastrointestinal disorders and dental enamel 
defects has been known since the turn of the century. In 1908 Black introduced the term 
“dental atrophy”, which he used in reference to a deformity caused by a disease that 
interferes with correct nutrition269.  
In 1955, pronounced DEDs were described in a 7-year-old girl with clinical features of 
CD272, and in 1956 seven patients with CD were examined, three of whom exhibited DEDs 
of the permanent dentition273. A case report of a 7.5-year-old girl with CD and hypoplastic 
permanent incisor teeth was presented by Pindborg274. In a Polish study of 18 children aged 
six to 17 years with a history of CD 20 hypoplastic teeth were found in eight children275. 
Thereafter, other cases of DEDs in subjects with CD were reported 273,276. 
In a Swiss study, realized in 1980, of  252 patients with CD only nine were described as 
having mild to severe enamel hypoplasia277. Besides, the first controlled study available in 
English literature which investigated the presence of DEDs in CD patients reported no 
significant difference between celiac patients and healthy controls251. However, in 1986 Aine 
provided the strongest evidence that DEDs may be an extraintestinal manifestation of CD, 
reporting a 95.94% prevalence of DEDs of permanent teeth in 74 children with CD278. In this 
study, the celiac-type DEDs were defined as “systematic” (i.e. symmetrically and 
chronologically distributed in all four sections of dentition), and classified in four grades 
(Table X). 
 
 
Table X. Grading of dental enamel defects according to Aine (1986254). 
 
Grade 
 
 
Dental enamel defect 
 
Grade I 
 
Defect in colour of enamel. 
Single or multiple cream, yellow or brown opacities with clearly 
definied or diffuse margins; a part or the entire surface of enamel 
is without glaze. 
Grade II Slight structural defects. 
Enamel surface rough, filled with horizontal grooves or shallow 
pits; light opacities and discoloration may be found; a part or the 
entire surface of enamel is without glaze. 
Grade III Evident structural defects. 
A part or the entire surface of enamel rough and filled with deep 
horizontal grooves which vary in width or have large vertical pits; 
large opacities of different colours or strong discolouration may be 
in combination. 
Grade IV Severe structural defects. 
The shape of the tooth changed: the tips of cusps are sharp-
pointed and/or the incisal edges are unevenly thinned and rough; 
the thinning of the enamel material is easily detectable and the 
margins of the lesions are well defined; the lesion may be strongly 
discoloured. 
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Almost all the subsequent controlled studies related significantly higher prevalence values 
of DEDs in CD patients compared with non-celiac subjects, and confirmed that the celiac-
type enamel defects are systematic, as differences for unspecific and unsystematic defects 
were not significant (Table XI). The different frequency likely depends on environmental, 
dietetic and, above all, genetic factors279. 
 
Table XI. Prevalence of dental enamel defects in patients with CD. 
 
Reference Dentition Type of DED Study group 
(patients with CD) 
 
   No. of 
patients 
Prevalence 
of DED (%) 
 
Malahias et al., 2009 M, P a systematic 67 51%  
Avşar  et al., 2008 D, P, M  systematic 64 42.2%  
Ortega Páez et al., 2008 D 
D 
D 
any 
unspecific 
systematic 
30 
30 
30 
83.3% 
10% 
73.3% 
 
Campisi et al., 2007* D, M, P  systematic 197 23%  
Procaccini et al., 2007 D, M, P systematic 50 26%  
Wierink et al., 2007 D, M, P 
D, M, P 
D, M, P 
any 
unspecific 
systematic 
53 
53 
53 
55% 
31% 
69% 
 
Bucci et al., 2006 D, M, P  systematic 70 20%  
 D systematic 17 5.88%  
 M, P systematic 53 24.53%  
Farmakis et al., 2005 D opac., 
hypopl.b 
13 92.30%  
 P opac., hypopl. 15 60%  
Ciacci et al., 2005 P NR 360 16.11%  
Priovolou et al., 2004 M, P any 18 83.33%  
 M, P systematic 18 44.44%  
Rasmusson.and Eriksson, 
2001  
M, P opac., hypopl. 40 50%  
Lähteenoja et al., 1998b D, M, P systematic 128 10.16%  
Aguirre et al., 1997 M, P any 137 52.55%  
 M, P unspecific 137 14.59%  
 M, P systematic 137 37.95%  
Rea et al., 1997 D, M, P systematic 45 24.44%  
 D systematic 15 13.33%  
 M, P systematic 30 30%  
Ventura and Martelossi, 1997 M, P systematic 603 32.33%  
Martelossi et al., 1996  M, P systematic 90 53.33%  
Bertoldi et al., 1995 D, M, P systematic 32 37.50%  
Mariani et al., 1994 D, M, P systematic 82 28.04%  
Ballinger et al., 1994 P systematic 42 9.52%  
Petrecca et al., 1994 M, P systematic 29 75.86%  
Aine et al., 1992 c P any 30 100%  
 P unspecific 30 46.66%  
 P systematic 30 53.33%  
Aine et al., 1990 P any 40 100%  
 P unspecific 40 17.50%  
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 P systematic 40 82.50%  
Balli et al., 1988 D, M NRd 49 34.69%  
Prati et al., 1987 D, M NR 10 33.33%  
Aine, 1986 P systematic 74 95.94%  
Andersson-Wenckert et al., 
1984 
M, P any 19 68.42%  
 M, P unspecific 19 15.78%  
 M, P systematic 19 52.63%  
Shmerling et al., 1980 NR NR 252 3.57%  
Romankiewicz-W. et al., 1973 M, P NR 18 44.44%  
Miller, 1956 g P NR 7 42.85%  
Hertz, 1955 D, M NR 27 3.70%  
a D=deciduous; M=mixed; P=permanent;; bopac.=opacities, hypopl.=hypoplasias;  
c This study was performed on patients with dermatitis herpetiformis;  dNR=not reported 
* Data from this PhD study. 
 
 
A few studies compared the prevalence of celiac-type DEDs in deciduous and 
mixed/permanent dentition. From all of these a higher prevalence of systematic enamel 
defects in mixed/permanent dentition emerges. In fact, a recent Italian study quoted 5.88% 
and 24.53% prevalence values of DEDs in celiac patients with respectively deciduous and 
mixed/permanent dentition256; in another paper279 two out of 15 (13.33%) celiac patients had 
deciduous teeth with systematic enamel hypoplasia, compared with nine out of 30 (30%) 
celiacs with mixed/permanent dentition. Consistently with these figures, DEDs were 
detected in 1.68% and 29.56% of respectively deciduous and permanent teeth examined in 
celiac patients267. In a recent work280, among CD patients, mixed dentition had significantly 
higher rate of DEDs than permanent dentition (90% vs. 34.0%, p<0.0001). 
Taking into account the studies which have considered the systematic defects, the overall 
prevalence of CD-related DEDs in patients with mixed/permanent dentition ranges from 
9.52% to 95.94% (with a mean value of 51.6%), whilst that for celiacs with deciduous teeth 
is 5.88% - 73.3%% (mean: 41,45%). The higher prevalence for permanent dentition is easily 
explainable considering that the development of crowns of permanent teeth occurs between 
the early months of life and the seventh year (i.e. after the introduction of gluten), while the 
formation of deciduous teeth mainly occurs in utero. But the presence of DEDs also in 
deciduous teeth supports the hypothesis that immuno-genetical factors are more likely 
involved in development of CD-related dental defects rather than nutritional deficiencies, or 
at least they represent the main cause.  
The distribution of different grades of DEDs (according to the classification of Aine) shows 
that grade I and II defects are on the whole most common (Table XII).  
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Table XII. Distribution of grades of CD-related dental enamel defects (Aine L, 1990)255. 
Reference Dentition No. of 
celiacs 
with 
DEDs 
No. of 
celiacs with 
grade I DEDs 
(%) 
No. of 
celiacs with 
grade II 
DEDs (%) 
No. of 
celiacs with 
grade III 
DEDs (%) 
No. of celiacs 
with grade IV 
DEDs (%) 
Ortega Páez 
et al., 2008 
D a 22 11 (50%) 4 (18.2%) 3 (13.6%)  4 (18.2%) 
Campisi et 
al., 2007* 
D, M, P 46 40 (87%) 5 (11%) 0 (0%) 1 (2%) 
Procaccini et 
al., 2007 
D, M, P 13 10 (76.9%) 3 (23.1%) 0 (0%) 0 (0%) 
Wierink et al. D, M, P 20 3 (15%) 14 (70%) 2 (10%) 1 (5%) 
Bucci et al., 
2006 
D, M, P  14 7 (50%) 4 (28.57%) 2 (14.28%) 1 (7.14%) 
Priovolou et 
al., 2004 
M, P 15 12 (80%) 1 (6.66%) 0 (0%) 2 (13.33%) 
Aguirre et 
al., 1997 
M, P 52 32 (61.54%) 16 (30.77%) 3 (5.77%) 1 (1.92%) 
Rea et al., 
1997 
D, M, P 11 5 (45.45%) 4 (36.36%) 2 (18.18%) 0 (0%) 
Martelossi et 
al.,1996 
M, P 48 8 (16.66%) 22 (45.83%) 14 (29.17%) 4 (8.33%) 
Petrecca et 
al., 1994 
M, P 22 10 (45.45%) 9 (40.90%) 2 (9.09%) 1 (4.54%) 
Aine et al., 
1992 b 
P 16 6 (37.50%) 10 (62.50%) 0 (0%) 0 (0%) 
Aine et al., 
1990 
P 33 15 (45.45%) 17 (51.51%) 1 (3.03%) 0 (0%) 
Aine, 1986 P 71 10 (14.08%) 39 (54.93%) 14 (19.72%) 8 (11.27%) 
a D = deciduous; M = mixed; P = permanent 
b This study was performed on patients with dermatitis herpetiformis  
* Data from this PhD study 
Which factors determine the severity of DEDs are unclear at all. In fact, conflicting data 
become from the literature. It was reported that DEDs in adults are much less severe than in 
children, despite a similar prevalence255. In fact, no grade IV and only 1 case of grade III 
defects were found out of 40 adult celiac patients (with a mean age at diagnosis of CD 
equal to 34), whilst nearly 30% of children with CD had grade III or IV DEDs. This 
considerable difference could indicate that the adult patients had had a clinically mild or 
silent disease at childhood (with a consequent late diagnosis) and this determined slight 
dental lesions 255. In support of this hypothesis, a correlation between the severity of CD 
clinical presentation and the grade of DEDs was also demonstrated in another study254.  
However, in another study a higher prevalence of enamel lesions in patients with atypical or 
asymptomatic CD was found256. 
Other studies considered the hypothesis of an association between late CD diagnosis and 
higher DEDs prevalence. Concordantly with the hypothesis that late diagnosis and 
prolonged gluten exposure relate to likelihood of DEDs, a few studies demonstrated that 
mean age at diagnosis of CD is significantly higher in patients with dental defects281,282, 
although others failed to do so256,267. However, one of the latter papers267, albeit found no 
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significant difference in age at diagnosis between celiac patients with and without DEDs, 
nevertheless noted in subjects with enamel lesions a correlation between age at diagnosis 
and the number of affected teeth. Furthermore, in a series of 360 adults with CD, no case of 
DEDs was described among patients with proved CD diagnosis in childhood and on a strict 
GFD since diagnosis, while DEDs were found in 18% of patients with early diagnosis but 
who were re-exposed to gluten, and in 26% of adults with newly diagnosed CD283. 
However, in a study on patients affected by dermatitis herpetiformis and without a history of 
symptoms suggestive of CD in childhood, no correlation between the degree of mucosal 
damage and the presence of DEDs was reported284. 
Concerning the location of CD-related DEDs, incisors are the teeth most frequently affected, 
followed by molars, canines and premolars256,269 280,285,286. This distribution should seem 
related to the chronology of development of the permanent dentition, as incisors and first 
molars are the first teeth that undergo calcification; the lesser involvement of teeth that 
calcify at a later stage could be explained considering that their calcification starts when CD 
has been possibly already diagnosed, and gluten removed from diet269. Instead, in non-
celiac subjects dental defects seem to be equally distributed for all the teeth256,269, with 
significant difference with respect to involvement of incisors as compared to CD patients269. 
In regard to the coronal distribution of DEDs, the incisal third resulted the most affected 
surface both in CD and control groups280,285,286; however, involvement of the incisal two 
thirds or of the complete crown were also observed in celiacs, while none of the control 
group showed this coronal involvement, and the difference resulted statistically 
significant269. 
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2.1.b.  Other hard oral tissue lesions 
Several studies investigated the prevalence of dental caries in celiac patients. Balli et al. 
reported an higher dental caries prevalence in CD children252. In another recent study287 the 
number of caries-free subjects in the control group was higher (38%) than in the CD group 
(17%).   
Instead, other studies reported no difference in caries prevalence between celiac patients 
and control healthy subjects251,257,264,277,288-291. Rather surprisingly, others found significantly 
lower caries indexes (DMFT, DMFS, dmft and dmfs) in CD subjects as compared to control 
groups 251,269,291,292.  A possible explanation for these findings is that the need for a carefully 
controlled diet should make celiac patients more diet-conscious, so that they maybe have a 
low cariogenic diet 251,269,291. 
Finally, dental age was studied in 49 children with CD{Ansaldi, 1989 #5930: delay in teeth 
eruption, estimated according to the dental standard of Schour and Massler293, was noticed 
in 28.57 % of patients, this datum was subsequently confirmed by Prati et al.288. Similarly, in 
one-third of 38 children with CD examined in a Polish study the dental age was delayed in 
relation to calendar age294. Recently, in a Mediterranean sample, delayed eruption was 
observed by our research group (data from this thesis){Campisi, 2007 #13366} in 27% of 
the paediatric CD patients vs 7% of the controls (p<0.0001; OR=5.9). 
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2.2. Oral soft tissue lesions 
2.2.a. Recurrent aphthous stomatitis 
RAS (aphthae or canker sores) is one of the most common mucosal diseases known 
among humans, and the first use of the term “aphthai” in relation to disorders of the mouth 
is credited to the Greek philosopher Hippocrates253. 
RAS is a common condition which is characterized by multiple recurrent painful, round or 
ovoid ulcers with circumscribed margins, erythematous haloes, and yellow or grey floors, 
appearing first in childhood or adolescence295. 
As reported by Scully296 the term “recurrent aphthous stomatitis” should be reserved to 
recurrent oral ulcer that present in patients without systemic diseases. Instead, ulcers that 
have a clinical appearance similar to RAS, but found in systemic disorders297-302, if not 
present the typical clinical features or an onset in childhood are often termed ALU; but, 
generally these two terms are wrongly used indistinctly.  
Depending upon the group examined, RAS may affect 5-60% of the general population, with 
a mean of 20%303.  According to Stanley 304 RAS has three main clinical presentations: 
minor, major or herpetiform ulcerations. Patients may sometimes present with a mixed 
pattern of RAS, but this is relatively uncommon301.   
An association between oral ulcerations, diarrhoea and weight loss has been described for 
more than three centuries305, but the first study about the association between CD and RAS 
date back to 1940306. Subsequently, many authors carried out several studies to confirm this 
association, but, the results are equivocal (Table XIII-XIV). 
 
 
Table XIII. Prevalence of CD in patients with RAS. 
Reference Study group 
(patients with RAS) 
 No. of 
patients 
Type of RAS Prevalence of CD 
(%) 
Shakeri et al., 2009 247  NR a 2.8% 
Olszewska et al., 2006 42 NR 4.7% 
Aydemir et al., 2004 41  NR  4.88% 
Robinson and Porter, 2004 87 minor 0% 
Nowak et al., 2002  20 NR 5% 
Jokinen et al., 1998 27 NR 11.1% 
Tavarela Veloso and Vaz Saleiro, 
1987 
24 NR 16% 
Merchant et al., 1986 100 minor 1% 
Tyldesley, 1981 97 min., maj., her.b 6.2% 
Ferguson et al., 1980 50 minor 4% 
Rose et al., 1978  26 NR 3.8% 
Ferguson et al., 1976 33 NR 24.24% 
Wray et al., 1975 130 minor 3.8% 
Ferguson et al., 1975 35 NR 20% 
a NR = not reported;  b min. = minor; maj. = major; her. = herpetiform. 
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Table XIV. Prevalence of ALU in patients with CD. 
Reference Study group 
(patients with CD) 
 
 No. of 
patient
s 
Prevalence 
of RAS (%) 
Type of 
RAS 
 
Malahias et al., 2009 67 42.4%   NR a  
Campisi et al., 2008* 269 22.7% Minor, major  
Campisi et al., 2007* 197 19% NR  
Procaccini et al., 2007 50 36% NR  
Bucci et al., 2006 72 33.33%  NR   
Sood et al., 2003 96 19.79% NR  
Sedghizadeh et al., 2002  61 40.98% NR  
Lähteenoja et al., 1998 128 3.12% NR  
Petrecca et al., 1994 29 17.24% NR  
Corazza et al., 1993  226 15.93% NR  
Meini et al., 1993; Majorana et al., 
1992 113 17.69% minor 
 
Balli et al., 1988 49 26.53% NR  
Biemond et al., 1987  414 9.66% NR  
Andersson-Wenckert et al., 1984 19 31.58% NR  
a NR = not reported 
* Data from this PhD study 
 
Oral ulceration akin to RAS can be a feature of GSE but only 5% of outpatients who initially 
present with RAS307,308 have GSE. 
The first study that investigated the prevalence of CD in patients affected by RAS reported 
very high values. Notably, Ferguson et al.305 quoted a 24% prevalence of CD in 33 patients 
with RAS, and asserted the importance of performing jejunal biopsy in subjects with 
recurrent aphthae309. Subsequent studies307,310,311 lessened this matter, albeit they reported 
CD prevalence values higher than those expected for the normal population, and thus 
supported the hypothesis of a correlation between CD and RAS. On the contrary, in 1986 
only one of 100 patients with RAS had histological evidence of CD312, and no CD-affected 
patient has been recently described among 87 subjects with RAS313. However, in the only 
controlled study that have searched for CD in patients with RAS, histological signs of CD 
have been demonstrated in two of 41 patients with RAS (4.8%), while none of the biopsies 
obtained from the 49 subjects of the control group revealed CD314. 
When papers examining the prevalence of RAS in CD patients are considered, the evidence 
of a correlation between the two conditions seems to be less robust. The prevalence of RAS 
in CD patients ranges from 3.12%258 to 42.4%280, a frequency similar to that reported in the 
general population (Table XIV). 
A support for the hypothetical correlation between CD and RAS is provided by the 
observation that GFD may be effective in the management of RAS. In fact, several authors 
reported significant improvement, if not complete remission, of oral aphthae in most CD 
patients which had been placed on GFD 256,305,307,315-317, and reappearance of recurrences 
with the reintroduction of gluten306,311,318,319. However, Pastore et al.250 referred that RAS 
does not always resolved after a strict GFD, this fact could be explained on the basis of the 
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multifactorial aetiopathogenesis of the RAS, although they reported a reduction of the RAS 
relapse. 
Furthermore, patients with RAS and no histological evidence of CD showed a favourable 
response to GFD and a positive gluten challenge, suggesting the existence of a form of 
gluten-sensitive RAS308. On the other hand, a double-blind controlled study examined the 
effect of GFD in patients with RAS and without CD; four of the 11 subjects on GFD reported 
benefit as regards the oral aphthae, but no significant statistical difference was observed as 
compared with control subjects which underwent GFD supplemented by gluten given 
blind320. 
As regards the severity of aphtae, most papers assert that celiac patients with RAS suffer 
from minor aphthae306,307,312,318,321. However, cases of celiac patients with major or 
herpetiform RAS were also reported311. 
A possible explanation for the hypothetical correlation between CD and RAS is that oral 
aphthae in CD patients could be related to haematinic deficiencies (iron, folic acid or vitamin 
B12). In fact, even if in our recent article303 we found haematological deficiencies in 56.2% 
of patients with recurrent aphthosis, it is generally accepted that  about 20% of subjects with 
RAS may have a haematinic deficiency322, and the serum levels of iron, folic acid and 
vitamin B12 are usually low in patients with untreated CD323. Consistently with this 
hypothesis, haemoglobin and serum folate levels were found significantly lower in patients 
affected by both RAS and CD compared to non-celiac patients with RAS305,324. Moreover, all 
the five cases of CD diagnosed in a series of 130 patients with RAS were deficient in iron, 
vitamin B12 or folic acid321. It has been suggested that the association between CD and 
RAS is related to the anemic status that frequently characterized an “atypical” celiac 
subjects319. In 1972, Lehner suggested that CD and RAS were the consequence of a similar 
immunological mechanisms306,325, 
Today, it is clear that the association between CD and RAS is not accidental, even if the 
causes of this link remains to be established.  
The above-mentioned hypothesis, supported by the association between RAS and other 
immune-mediated gastrointestinal diseases, such as Chron’s disease and ulcerative colitis, 
is confirmed by a detection of an association between RAS and DR7 and the presence of 
an lymphocytic infiltrate of CD8+, CD4+ and NK into aphthous ulcerations326,327 
Furthermore, Meini et al.318 demonstrated an higher prevalence of haplotypes HLA-DRW10 
and HLA-DQ1 in CD patients with RAS than CD patients without RAS, suggesting a genetic 
predisposition of CD patients to develop RAS. 
An ultimate consideration regard “atypical” CD: RAS may represent the sole evident clinical 
sign of a asymptomatic malabsorption and must be consider as a possible proof of 
oligosymptomatic CD.  
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2.2.b. Non specific atrophic glossitis 
A series of 128 patients with CD and 30 healthy controls was examined for oral mucosal 
lesions and symptoms in a Finnish study258. The tongue was most frequently affected, as 
29.68% of CD patients referred soreness or burning sensation of the tongue, and the 
difference with the control subjects was statistically significant. Procaccini et al.285 showed 
unspecific atrophic glossitis only in 4/50 patients with CD vs 1/50 control patients; whilst 
Campisi et al.317 (data from this PhD study) found atrophic glossitis in 31/197 (16%) CD 
patients vs 1/413 controls (0.2%), whit all patients showing a resolution of the clinical picture 
after a period of GFD.  
Pastore et al.328 report the case of a man with erythema and atrophy of the dorsal tongue 
and without gastrointestinal complaints, whose serological tests for CD were positive; the 
small-intestine biopsy confirmed the diagnosis of CD, and GFD resulted in resolution of 
tongue lesion. 
We found no more paper that supports a correlation between CD and glossitis. However, 
iron and vitamin B12 deficiencies are frequent in untreated CD patients323, and it is well 
known that such deficiencies may cause atrophic glossitis, often accompanied by soreness 
or burning sensation. Furthermore, several reports describe cases of CD associated with 
Plummer-Vinson syndrome329-335. Plummer-Vinson syndrome (also referred as Paterson-
Brown Kelly syndrome, or sideropenic dysphagia) is a rare condition that comprises the 
classical triad of dysphagia, iron-deficiency anaemia and esophageal webs; other clinical 
features may also be observed, among these atrophic glossitis336. 
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2.3. Oral manifestations of dermatitis herpetiformis 
Dermatitis herpetiformis (DH) is a pruritic bullous skin disease considered as a part of the 
spectrum of gluten-sensitive disorders. In fact, although patients with DH are unlikely to 
have gastrointestinal complaints, nearly all of them have some degree of small intestinal 
histopathologic changes identical to those of CD, and they share the same serologic 
antibody profile of celiacs337. Moreover, GFD is an effective therapy for DH, which confirms 
the role of an intestinal reaction to gluten in the pathogenesis of DH338. Typically, DH 
consists of symmetrical, erythematous, papulo-vesicular lesions that generally involve the 
extensor surfaces of the elbows, knees, buttocks and scalp. Owing to their intense itching, 
lesions often look as skin erosions secondary to scratching. 
In a study on 15 patients with DH, oral lesions were found in 12 cases339. Oral involvement 
consisted of erithematous, pseudo-vesicular, purpuric and erosive lesions, but only in two 
cases the direct immunofluorescence examination revealed the typical granular deposits of 
IgA along the basement membrane, that is a sine qua non for the diagnosis of DH. Similarly, 
57% of 27 patients with DH were found as having oral lesions, that included ulcerations, 
erythema and atrophies340; however, no direct immunofluorescence study was performed. 
At the opposite, no oral mucosal involvement was described in a large review of 926 cases 
of DH341, and only one case of small oral blisters was reported in a study on 149 DH 
patients 342. Rather, in an old paper343 the absence of oral lesions was referred as a 
diagnostic criterion for DH. 
Actually, oral involvement in DH is at present considered very rare, and generally consists 
of vesicles and bullae that result in ulcers344. Reports that describe DH lesions in the oral 
cavity are sparse259,345-348, and two of these259,348 relate cases of oral manifestations 
appeared before the onset of the skin lesions.  
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2.4. Other oral manifestations 
Other oral lesions described in celiac patients are oral T-cell lymphoma349, carcinoma of the 
tongue and of the oesophagus181,182,350,351 and oral mucosal melanosis352. Occurrence of T-
cell lymphoma in the oral cavity is uncommon for celiac individuals, as CD-related 
lymphomas usually develop in the upper small intestine. The case of oral melanosis 
concerns a 32-year-old celiac woman, also affected by neuropathies and unspecified 
“dental irregularities”; GFD resulted in improvement of neurological findings, but not of oral 
hyperpigmentation. However, the association between CD and oral melanosis is likely 
occasional. 
Interesting results have been recently obtained in a prospective, multivariate study on facial 
anthropometry of CD patients353. Face photographs of 120 celiac adults and 100 healthy 
controls were marked at predetermined reference points, and ratios of distances calculated 
by a computer program. CD patients diagnosed in adulthood and those diagnosed in 
childhood but who were not adherent to the GFD presented facial proportions significantly 
different as compared to both controls and celiac subjects with early diagnosis and on GFD 
since diagnosis. In particular, the former had a peculiar aspect of the face characterised by 
a larger forehead. Authors attributed this sign to an abnormal pattern of craniofacial growth 
due to nutritive and/or immunological factors, and proposed the “celiac face” as an extra-
intestinal manifestation of CD.   
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2.5. Immunomediated disorders  
SS189,260 and OLP261,354 have been reported in CD patients, but they should be considered 
expressively immuno-mediated diseases more than true oral manifestations of CD, since 
sharing pathogenesis and even the HLA DQ2 haplotype260 as shown in SS260. As follows, it 
is reported the majority of the literature on this topic. 
 
2.5.a. Sjögren’s syndrome  
Nutritional deficiencies in patients with SS were described since early 1950’s355, and in 1965 
it was first reported a case of association between CD and SS356. Since then, several 
reports of patients affected by both the diseases have been published189,357-362, as well as 
cases of SS occurring concomitantly with the gluten-related dermatitis herpetiformis363,364. 
In a study on 335 CD patients365, 11 SS cases were found, with a prevalence significantly 
higher than those of healthy controls (3.28% vs 0.29%). 
Five papers were identified that assessed the prevalence of CD in patients with SS (Table 
XV). One of these366 is a large study on 5600 patients with various rheumatic complaints, 23 
of whom were found affected by CD; SS resulted the most common rheumatic disease in 
celiacs, and CD prevalence in patients with SS was 9.52%. On the whole, the prevalence of 
CD in SS patients ranges from 2.53% to 14.70%260,366-369. Two out of these five studies were 
controlled260,367; both reported CD prevalence values in SS groups significantly higher than 
those of controls. 
No significant difference concerning gastrointestinal symptoms was found between celiac 
and non-celiac patients with SS, suggesting that atypical or latent CD is more frequent in SS 
patients368. On the other hand, the mean age of SS patients with CD resulted significant 
lower than that of non-celiac SS patients, suggesting that CD should affect mostly younger 
SS patients368. 
The hypothetical link between CD and SS could be explained at least in part by a similar 
immunogenetic profile, since both diseases are associated with HLA DR3-DQ2 
antigen260,362,367. Interestingly, GFD seems to be not effective on the sicca symptoms of 
patients with both SS and CD260,366. However, it has been suggested that the risk for 
autoimmune disorders in celiac patients is related to the age at diagnosis of CD and the 
duration of exposure to gluten 189, but this datum was not successively confirmed370,371. 
One study has recently examined oral mucosal and dental findings in patients with both CD 
and SS, and compared with those of patients with either CD or SS alone362. Prevalence of 
celiac-type DEDs was similar in CD and CD/SS groups, but significantly lower in subjects 
with SS alone. No difference was found as regards DMFT values in SS and CD/SS groups, 
whilst the caries index for the CD group resulted significantly lower; these findings suggest 
that the impaired salivary secretion should predispose to the development of dental caries 
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irrespective of the CD status. Oral mucosal lesions were found in 80% of SS, 65% of CD/SS 
and 40% of CD patients; the authors argued that the SS-related dryness of the mouth 
should affect oral mucosal health  more than the inflammation associated with CD only362. 
 
Table XV. Prevalence of CD in patients with SS248. 
Reference Study group 
(patients with SS) 
Control group 
(subjects without SS) 
CD diagnostic 
criteria 
p value 
 No. of 
patients 
Prevalence 
of CD (%) 
No. of 
subjects 
Prevalence 
of CD (%) 
  
Szodoray et al., 2004 111  4.50% - - biopsy - 
Luft et al., 2003 50 12% 50 4% IgA anti-tTG  0.05 
Calella et al., 2002 79 2.53% - - biopsy - 
Iltanen et al., 1999 34 14.70% 28 0% biopsy NR a 
Collin et al., 1992 63 9.52% - - biopsy - 
a NR = not reported 
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2.5.b.  Oral lichen planus 
In 1993, an unusual association of OLP and CD was reported261. This was the case of a 70-
year-old male with a biopsy-proven erosive OLP; iron, folate and vitamin B12 deficiencies 
led to perform jejunal biopsy, that demonstrated CD. Surprisingly, GFD resulted in relief of 
OLP within six month. But the hypothesis of an association between CD and OLP was 
promptly refuted by Scully et al.354, who one month later referred that they had investigated 
103 patients with OLP and none had CD. So, they replied that OLP would seem only 
occasionally associated with CD. 
In 1998, 39 consecutive patients with OLP were screened for CD; 12 were positive for IgA 
gliadin antibody test and two for endomysium antibody test, but only one had small intestinal 
signs of CD372. Furthermore, Ruiz Villaverde et al. described a case of a case of a 9-year-
old female with erosive mucosal lichen planus associated to hyper IgE syndrome and CD373. 
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2.6. Oral mucosa for initial diagnosis of CD or for gluten challenge 
Although the small intestinal mucosa represents the main site of the gut involved in CD, 
other mucosal surfaces belonging to the gastrointestinal tract (GT) and to the gut-
associated lymphoid tissue GALT can also be involved. In fact, modifications have also 
been found in the gastric374,375, terminal ileal376 and rectal mucosa377-383. Rectal mucosa, 
furthermore, has also been used for gluten challenges381,384-386. Finally, esophageal 
involvement has also been shown in patients with untreated CD374,387. All this demonstrates 
that gluten-driven T-cell activation is not restricted to the proximal part of the intestine but is 
present in the whole intestine, probably including the mouth. 
In fact, as the first part of GT the oral cavity is the route for all materials ingested, including 
products made from cereals. It might be suspected that oral cavity would react to ingested 
gluten in the same way as the mucosa of the gut, showing oral changes when the disease is 
untreated and improvement in these changes when CD is treated with GFD. 
In this context, differences in histological features of the oral mucosa of persons both with 
and without CD were demonstrated in a study that involved persons with GFD-treated CD, 
those with newly diagnosed CD, and healthy control individuals258. Moderate to severe 
lymphocytic inflammation was observed in 42.7% of the oral biopsy specimens from 
persons with treated CD, as compared with 10% of control individuals. Intra-epithelial T-
cells were significantly increased in persons on GFD vs both untreated persons and healthy 
control individuals. The lamina propria of the persons with untreated CD had a significantly 
lower amount of mast cells as compared with that of both treated persons and control 
individuals.  
These results were confirmed in another study by the same investigators388, in which the T-
cell count in the epithelium of treated persons was higher than that in untreated persons and 
control individuals, and the mastcell count in the lamina propria of treated persons was 
higher than that of untreated persons. Moreover, the mean amounts of CD3+, CD4+, and 
TCRgd+ cells were increased in the lamina propria of persons with CD and on GFD, 
compared with those in the other groups. The authors concluded that the oral mucosa 
cannot be used for the initial diagnosis of CD, since persons with untreated CD did not differ 
from healthy control individuals with regard to oral mucosal infiltration. In contrast, persons 
with treated CD showed significantly increased numbers of T-cell subsets in their oral 
mucosa, despite a strict adherence to a GFD; this finding was interpreted as a late immune 
response to minute amounts of gluten. Recently, another study389,390(data from this PhD 
study) confirmed that no differences exist in CD3+ count or B- and T-lymphocyte counts 
either in the epithelium or in the lamina propria of the oral mucosa in CD patients and in 
controls, although in the lamina propria of the CD patients there was a trend towards a 
higher number of CD3+ and CD45RO lymphocytes. 
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The observation that, in the oral mucosa of persons with GFD-treated CD, an immunological 
‘memory’ for gluten hypersensitivity is perpetuated prompted the authors to evaluate the 
reaction of the oral mucosa to a local gluten challenge391,392. A solution of an a-gliadin-
related synthetic peptide was injected into the buccal submucosa of persons with GFD-
treated CD and healthy control individuals391. The peptide significantly increased the T-cell 
counts in the lamina propria of persons with CD. The numbers of CD3+ and CD4+ cells 
were significantly higher after than before peptide challenge in persons with CD; the 
expression of the T-cell activation marker CD25 was also observed in the lamina propria of 
these persons after the challenge. The oral challenge induced no statistically significant 
difference in the cell counts of the control individuals. Importantly, neither the persons with 
CD nor the control individuals had any oral complaints or visible changes after the 
challenge; similarly, results of the serum EMA test remained negative after the challenge in 
all participants.  
In another study, the same group performed the oral gluten challenge both at supramucosal 
(gliadin powder applied with an oral adhesive bandage) and submucosal (injection of gliadin 
solution) sites392. After a supramucosal challenge on the oral mucosa of persons with CD 
and on GFD, the number of intra-epithelial CD4+ and CD8+ T-cells increased in 67.6% and 
73% of cases, respectively. Also, there was a significant increase in the number of CD4+ 
cells in the lamina propria of persons with CD. After a submucosal gliadin challenge, the 
mean numbers of total T-cells and CD4+ T-cells were significantly increased in the lamina 
propria of persons with CD. There were no differences in the mean cell counts of the 
healthy control individuals after submucosal challenge. 
Based on these results, the authors reported a 73% sensitivity of the submucosal gliadin 
challenge in persons with treated CD, and a specificity of 80%; the positive predictive value 
was 93%, and the negative predictive value was 44%. Specificity and sensitivity of 
supramucosal challenge were not counted, since, in this study, control individuals were not 
tested for this kind of challenge. Mild pain or a burning sensation at the site of gliadin 
provocation was reported by some persons with CD, while others experienced mild mucosal 
changes (erythema, small blisters, swelling). Two persons with CD reported gastrointestinal 
complaints after the supramucosal challenge. The challenge did not have any influence on 
the serum EMA levels.  
Recently, results from two groups of investigators have demonstrated that in vitro culture 
media of oral mucosa biopsies from persons with untreated CD can release IgA-class EMA 
and anti-tTG393,394. One of the groups (data from this PhD study)393 found IgA EMA and 
antitTG in 53.6% and 57.2% of cultured oral biopsies, respectively. IgA EMA and anti-tTG 
assayed on culture media of duodenal biopsies were positive in all persons with CD. 
Interestingly, the results were identical when a 31-43 gliadin peptide was added to the 
culture systems. The sensitivity of the EMA test on oral mucosa media was 53.6%, the 
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specificity was 100%, and the diagnostic accuracy was 79%. For the anti-tTG test, 
sensitivity, specificity, and accuracy were 57.2%, 100%, and 79%, respectively. The second 
study394 demonstrated IgA EMA and anti-tTG in all but one of the cultured oral mucosa 
biopsies from 16 persons with untreated CD. The single individual whose oral biopsy was 
negative for both IgA EMA and anti-tTG had a selective IgA deficiency. 
Alla these findings are not surprising since the oral cavity is closely bound to the 
immunogenic defence systems. In fact, although the structure of the halthy oral mucosa 
differs from that of the bowel from an immunological point of view the lymphoepithelial 
structures of Waldeyer’s pharyngeal ring in the posterior part of the oral cavity, including 
nasal-associated lymphoid tissues NALT constitute an important part of GALT. Although 
GALT is the largest and most important part of MALT 395, and after antigen-activation, 
proliferation and partial differentiation in GALT nad or MALT, memory B and T cells migrate 
to regional lymph nodes and secretory glands, including salivary glands where they can 
begin to produce sIgA396, there is now compelling evidence that supports the 
compartmentalization of the mucosal immune system397. Therefore, activated immune cells 
seem to home preferentially to the sites where they were originally primed398. In this view, 
NALT and bronchus-associated lymphoid tissue (BALT) may be more important than GALT 
in inducing an immune response in the upper aerodigestive tract (Figure 9), including the 
oral cavity. 
 
 
 
 
Figure 9. NALT and BALT could have a role, independent from that of GALT, in inducing a gluten-
related immune response in the oral cavity399. 
 
 
Further studies should also investigate whether the oral gluten-sensitized lymphocytes do 
originate exclusively from homing of cells primed in GALT, or, rather, whether they could 
also be primed directly in the oral cavity (Figure 9). The latter would have important 
implications not only for diagnostics, but also for the understanding of CD in general.  
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The hypothesis that gluten could stimulate an immunological response directly in the oral 
cavity would have important implications for the understanding pathogenesis, diagnosis, 
and management of CD. 
For example, the hypothesis of an induction of the gluten-related immune response even in 
the oral cavity should be taken into account in the development of new therapeutic 
strategies that aim to prevent the triggering of such immune reactions. Among these new 
non-dietary therapies under study, the most attractive seems to be the use of enzymes that 
digest immunogenic gluten peptides400,401; in the event that these peptides could already 
elicit an immune response in the oral cavity, enzymatic therapies could be ineffective or not 
fully effective, unless they are already active already in the mouth and not only in the 
stomach and/or in the small intestine. 
Moreover, the hypothesis that a gluten-related immune response could already be induced 
in the oral cavity should be taken into account in the development of new non-dietary 
therapies that aim to prevent the triggering of such immune reactions only at the 
gastrointestinal level. 
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CHAPTER II 
 
PhD Studies 
 
2.1. Aims 
 
The aims of the PhD study were:  
 
a) to examine the frequency of oral lesions in adults and children with CD and to assess 
their usefulness in making CD diagnosis;  
 
b) to perform a screening for CD in patients with oral lesions potentially associated with CD, 
and sharing a common immune-mediate pathogenesis with CD, such as OLP and RAS;  
 
c) to study the histomorphology of clinically healthy oral mucosa of untreated CD patients in 
order: (i) to assess the presence, quality (B⁄T lymphocytes) and intensity of lymphocytic 
infiltration and its relation to the severity of the intestinal histological damage; and (ii) to 
detect any other histological aspect which could be linked to CD;  
 
d) to evaluate the ability of the oral mucosa of patients with CD to produce antibodies in an 
in vitro culture system.  
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2.2. Examination of the frequency of oral lesions in adults and 
children with CD and to assess their usefulness in making CD 
diagnosis 
 
To achieve this objective two case-control studies were performed.  
 
The primary aim of the first study was to assess the frequency of oral diseases, including 
soft and hard tissue lesions and dental delayed eruption in CD patients, in comparison with 
otherwise healthy controls; the secondary objective was to consider what contribution an 
oral clinical examination could give to help suspect a CD diagnosis.  
 
The objectives of a second case-control study were to assess the prevalence of ALU in 
CD patients living in the Mediterranean area, and to evaluate the impact of a GFD. 
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2.2.a. Assessment of the frequency of oral diseases, including soft and hard 
tissue lesions and dental delayed eruption in CD patients and  to consider 
what contribution an oral clinical examination could give to help suspect a CD 
diagnosis 
 
Patients and Methods 
The total study population of this prospective study consisted of 610 subjects; of these, 197 
were CD patients, recruited at the time of diagnosis. They were consecutively enrolled, 
between January 2004 and June 2005: the adult patients (90 cases: 65 F, 25 M, age range 
18-75 years, median 31) in two centers – Gastroenterology and Internal Medicine - of the 
University Hospital of Palermo and the children (107 cases: 59 F, 48 M, age range 2-17 
years, median 9 years) in the Pediatric Gastroenterology Unit of the “Di Cristina Hospital” in 
Palermo.  
CD patients aged under 2 years were excluded.  
Four hundred and thirteen healthy subjects who were age/sex-matched (180 adults: 130 F, 
50 M age range 19-77 years, median 32; 233 children: 120 F, 113 M, age range 2-17 years, 
median 8.5) and living in the same geographic area as the CD group, were enrolled as 
controls. Pediatric controls were recruited (by simple randomization) at a day nursery, and 
at Primary and Secondary Schools during a health prevention program for oral diseases; 
these subjects did not refer any diseases, had no family history of CD and showed normal 
growth (weight/height ratio between 25th and 75th centiles). Adult controls were recruited 
among otherwise healthy patients consecutively referred to the Dental Unit of the University 
of Palermo for third molar surgery; they were tested for serum anti-tTG antibodies and were 
negative. 
CD diagnosis was based on the positivity of serum anti-tTG and/or anti-EMA antibodies, 
presence of clinical symptoms and evidence of intestinal histology damage on a gluten-
containing diet, and the disappearance of the symptoms and normalization of serum anti-
tTG and/or EMA on a GFD1. 
The clinical manifestations of CD were classified as “typical” when they included: chronic 
diarrhea, failure to thrive, anorexia, abdominal distension and muscle wasting; other clinical 
manifestations were considered “atypical”2. When CD diagnosis was made in subjects who 
were apparently asymptomatic, it was classified as “silent”. 
Immediately after CD diagnosis, the patients underwent  intra-oral examination of the soft 
and hard tissues. All evaluations were performed independently by two oral medicine 
practitioners, including Dr. Domenico Compilato, who were trained in oral health survey, and 
then tested for concordance.  
We focused on hard tissue lesions (i.e. DEDs), soft tissue lesions (e.g. presence of ALU, 
aspecific atrophic glossitis, geographic tongue) and clinical delay of dental eruption.  
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The enamel defects affecting deciduous and permanent teeth were graded 0 to IV 
according to Aine’s classification3 (see Chapter 1 paragraph 2.1.a). As regard ALU, we 
included recurrent ulcerative lesions clinically observed by the two dental practitioners 
during the intra-oral examination. However, as clinical evidence of the lesions is not always 
found because healing occurred before the oral investigation, but patients could have had a 
past history of aphthous ulcerations, we also considered ulcerative events, noted by parents 
or patients, or reported in hospital clinical records, with clinical features pathognomonic of 
RAS.   
To evaluate delayed eruption in the pediatric patients we used the conventional eruption 
tables for the Caucasian Population4 and we considered delayed eruption as when the teeth 
were not in arch after their normal age of eruption, with a range of ± 6 months.  
In all individuals, dental hygiene was categorized into nominal variables using three values: 
0 (poor), 1 (sufficient) and 2 (good)5. 
All CD patients with oral soft tissue lesions were re-evaluated one year after the beginning 
of GFD.  
Finally, all the paediatric controls positive for oral hard and/or soft tissue lesions potentially 
associated to CD were tested for anti-tTG antibodies to exclude the disorder. 
Informed consent was obtained for all participants in the study and the study was approved 
by the Ethics Committee of the University Hospital of Palermo. 
 
Statistical analysis 
Data were analyzed by means of SAS for Windows ver. 9.0, (SAS Institute Inc., Cary, NC, 
USA) and by means of Statistica 6.0 (Statsoft Inc, Tulsa, USA). To measure the association 
level, crude Odds Ratio (OR) and the 95% corresponding test-based Confidence Interval 
(CI) were calculated. Student’s t test was used to calculate significant differences between 
cases and controls at baseline for normally distributed variables. The Mann Whitney U-test 
was used to calculate differences between not-normally distributed variables (e.g. Aine’s 
scores). 
The concordance rate of the oral evaluation between the observers was evaluated using 
Cohen's kappa statistic, measuring agreement beyond that expected by chance (expressed 
as a coefficient ranging from 0 to 1.00)6.  
The relationship between CD and other variables was analyzed within conditional 
multivariate frameworks.  
A conditional logistic regression model was constructed stratified by age and dental 
hygiene, the same model permitted a stepwise selection procedure to obtain the most 
parsimonious model. The Maximum Likelihood Ratio (MLR) and Adjusted Odds Ratio (OR’) 
were obtained using the iterative weighted least squares procedure. In all of the evaluations 
p values ≤0.05 were considered statistically significant.  
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Furthermore, in a blind manner three Artificial Neural Networks (ANNs) models were applied 
to the same data, as previously described7. Fully-connected multilayer feedforward 
networks were used. The learning rule employed was the well-known Back-error 
Propagation (BP) which adjusts the internal parameters of the networks over the repeated 
training cycles to reduce the overall error8. The networks were validated with a new set of 
data, different from the training ones. The performance measured by Mean Squared Error 
(MSE), Accuracy, Sensitivity and Specificity values as well as the Receiver Operating 
Characteristic (ROC) area, which can ascertain the degree of meaningful prediction 9,10 
were calculated for the significant associations. In the present paper, all variables were 
selected as input ones, except for CD (the output variable) for ANNs system analysis.  
 
Results 
There was a substantial agreement (kappa = 0.85) between the observers for the main 
dental and oral lesions. 
Table XVI summarizes the main findings of the oral examination in CD patients and 
controls.  
 
Table XVI. Oral examination findings in CD patients and controls, grouped by adult and pediatric age. 
                                                        Adult  individuals                                                 Pediatric individuals 
 
 CD patients 
(n = 90) 
 
Controls 
(n = 180) 
p-value Unadjusted OR
OR (95% CI) 
CD 
patients
(n = 107)
 
Controls 
(n= 233) 
p-value Unadjusted OR 
OR (CI 95%) 
Dental enamel 
defects 
               no 
yes 
 
  
69 (77%) 
21 (23%) 
 
 
164 (92%)
16 (8%) 
 
 
0.001 
 
 
3.12 (1.53 - 6.33)
 
 
82 (77%)
25 (23%)
 
 
212 (91%) 
21 (9%) 
 
 
0.0003 
 
 
3.07 (1.63 -5.80) 
Soft tissue lesions 
no 
yes 
 
56 (62%) 
34 (38%) 
 
177(97%) 
5 (3%) 
 
<.0001
 
21.49  
(8.02-57.59) 
 
59 (55%)
48 (45%)
 
229 (98%) 
4 (2%) 
 
<0.0001 
 
46.57 (16.14–134)
ALU 
 
no 
yes 
 
 
71 (79%) 
   19 (21%) 
 
 
179 (99.5%)
1 (0.5%) 
 
 
<.0001
 
 
47.36  
(6.22-360.53) 
 
  
89 (83%)
18 (17%)
 
 
231 (99%) 
  2 (1%) 
 
 
<0.0001 
 
 
23.35 (5.31–102) 
 
Forty-six out of 197 CD patients (23%) were found to have systematic and symmetric 
enamel defects versus a lower rate of 9% (37/413) in controls [p<0.0001; OR=3.510 
(95%CI=2.135:5.770)]. The frequency of the enamel defects was very similar in the adult 
and pediatric CD patients. The severity of enamel defects in CD patients, evaluated 
according to Aine3, was: grade I in 87%, grade II in 11%, and grade IV in 2%. (Appendix I, 
Figures 3, a-b). 
Clinical delayed eruption was observed in 28 out of 107 pediatric CD patients (27%) versus 
16 out of 233 (7%) controls [p<0.0001; OR=5 .932 (95%CI=3.407:10.330)]. 
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The overall prevalence of oral soft tissue lesions was 42% (82/197) in CD patients and 
9/413 in controls (2%) [p<0.0001; OR=22.257 (95%CI=13.828:35.824)]; frequency was 
similar in adult and pediatric CD. ALU was found in 37/197 (19%) CD patients versus 3/413 
(1%) controls [p<0.0001; OR=18.9505 (95%CI=9.552:37.595)]. In CD patients ALU was 
directly observed during the medical visit in 34 cases and simply recalled by the parents in 
three cases. (Appendix I, Figures c-d). 
The other soft tissue lesions detected were aspecific atrophic glossitis and geographic 
tongue. The first was found in 31/197 (16%) CD patients versus 1/413 (0.2%) controls 
[p<0.0001; OR=22.464 (95%CI=10.500:48.063)], while geographic tongue was noted in 
14/197 (7%) CD patients versus 5 out of 413 (1%) controls [p<0.0001; OR=7.0326 
(95%CI=2.650:18.666)]. CD patients showed a better dental hygiene status than controls 
[p<0.0001; OR=4.848 (95%CI=2.7027:8.695)]. 
None of paediatric controls with oral hard and/or soft tissue lesions present positive 
serological markers for CD. 
As regards the clinical manifestations of CD, “typical” symptoms were more often observed 
in children (60/107 cases, 56%) than in adults (40/90 cases, 44%), whereas the frequency 
of silent cases was similar (6.6% in adults versus 7.4% in children). However, oral hard or 
soft tissue lesions were observed with an almost identical frequency in patients with “typical” 
and “atypical” CD symptoms. Furthermore, as among patients without any signs and 
symptoms potentially related to CD, as diagnosed during familial CD screening, there were 
also cases of oral soft tissue lesions, they should be considered as patients with “atypical” 
and not with “silent” CD. In CD patients, the frequency of the oral hard and/or soft tissue 
lesions did not differ according to the severity of intestinal mucosa damage or to the ideal 
body weight. 
After a one-year follow-up, 33 out of 37 CD patients (89%) with ALU at diagnosis, referred 
that they had no longer suffered from ALU since beginning the GFD. The other 4 patients 
(11%) did not strictly adhere to GFD, as confirmed by persistently elevated serum anti-tTG 
antibodies, and did not report any improvement in ALU recurrence and number of ulcers per 
episode. Also atrophic glossitis disappeared in all the patients who adhered to GFD. As 
regards geographic tongue, no cases were present in the sample followed longitudinally. 
Conditional multi-logistic analysis in the stepwise procedure selected Oral Mucosa Lesions 
and Dental Enamel Hypoplasia as the most meaningful variables in CD patients (Table 
XVII). 
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Table XVII. Conditional multi-logistic analysis in the stepwise procedure. Characteristics and risk 
factors were stratified by age and oral care. 
 Odds Ratio 95% CI 
Gender (Female vs Male) 1.980 1.253-3.130 
Dental Enamel Hypoplasia 2.652 1.427-4.926 
Oral soft tissue lesions 41.667 18.868-90.909 
 
ANN methodology consistently proved that CD was the most meaningful variable related to 
soft tissue lesions in the present dataset, with MSE equal to 0.321. Performance indexes 
showed the following values: Accuracy= 83%; Sensitivity= 42%, Specificity= 98%. The ROC 
area was equal to 0.839.  
On the basis of the 3% prevalence of CD recorded in our centers during the study period, 
and of the sensitivity and specificity showed by the ANN methodology, the positive and 
negative predictive values of the oral lesions were 39% and 99%, respectively. On the basis 
of the 1% CD prevalence in the general population, the positive and negative predictive 
values of the oral lesions in CD diagnosis were 17% and 99% respectively. 
 
Discussion  
Recent epidemiology data have shown a prevalence of CD approaching 1% in the general 
population11-13. However, there has been a noticeable change in the clinical presentation of 
CD, as almost 50% of the patients with newly diagnosed CD do not present with 
gastrointestinal symptoms14,15 thus making diagnosis difficult. This is a paramount aspect as 
a GFD in CD patients is known to prevent many of the extra-intestinal symptoms, such as 
osteoporosis16, recurrent abortions17, and above all protects against the development of 
cancer18. Thus, to identify the greatest number of “atypical” or “silent” CD patients and 
prevent complications, clinicians must investigate “at-risk subjects”, e.g. those with chronic 
anemia19,20, hyper-transaminasemia or hyperamylasemia of unknown origin21,22, 
osteoporosis16, autoimmune thyroid disorders23. Although the proximal part of the intestinal 
mucosa represents the main site of the gut involved in CD, it has been demostrates that 
gluten-driven T-cell activation is not restricted to the small intestine but is present in the 
whole GT. The mouth, the first part of the gastrointestinal system and a part of GALT, 
represents a site very easy to detect, in fact an oral examination could to give a useful 
diagnostic contribution since lesions of the hard24,25 and soft tissues26-31 have been reported 
in CD.  
Ours is the largest uni-center study to have investigated the risk for CD patients of suffering 
from dental or oral mucosa lesions and showed the sensitivity and specificity of oral soft 
tissue lesions in suggesting a CD diagnosis. 
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As regards the hard tissues, we found systematic and symmetric DEDs in 23.3% of CD 
patients, with an odds ratio >3 in comparison with the controls. The enamel defects resulted 
in a dental deformity which can be easily recognized (see Appendix I, Figure 3, a-b), 
although low-grade lesions must also be accurately investigated. Other studies have 
reported a wide range of frequencies of enamel defects in CD patients3,24,30-41 (see table XI 
on the paragraph 2.1.a) but our data are in agreement with other studies performed in Italy, 
and the differences in frequency probably depend on environmental, dietetic and, above all, 
genetic factors34,42. The same hypothesis could be made for the severity of enamel defects 
which appeared less severe in our study (87% of the patients had a grade I lesion) than in 
other studies24 (see table XII on paragraph 2.1.a).  
The etiopathogenesis of these defects in CD patients still remains unclear. Since the crowns 
of deciduous and permanent teeth develop from 4-5 months of intra-uterine life to the 7th 
year of life except for the third molar, nutritional, immunologic or genetic factors (association 
with the HLA DR3 allele) have been hypothesized as causing developmental defects in the 
enamel33,43. Hypocalcemia due to malabsorption during dental development has been 
considered to be implicated in enamel hypoplasia. Regarding nutritional dynamics, despite 
some doubts raised by Maki et al.43, it has been hypothesized that a gluten-induced 
immunological process could occur between 6 months and 7 years in the enamel-producing 
organ, resulting in defective enamel formation. Finally, these dental anomalies have been 
found to be significantly related to HLA antigen DR333,36,43. Furthermore, an Italian study33, 
reporting a frequency of 28.8% in celiac patients versus 14.8% in controls, did not report 
any statistically significant differences in calcium concentrations, but a coincidence in 77.2% 
of CD and DEDs in DR3-positive subjects. Another finding on dental hard tissues was the 
significantly higher frequency of delayed eruption, observed in 27% of CD children. Only few 
papers in the literature have dealt with this issue25,44-46 and they are in agreement with our 
data. The delayed dental eruption could be seen as a possible sign of malnutrition (such as 
is delayed puberty) and advises for serological CD screening. 
However, the most important finding of the present study is related to the oral soft tissue 
investigation: in fact, mucosa lesions were found in 42% of CD patients with an odds ratio of 
22 versus controls. Within this group of lesions, ALU was found in 37/197 (19%) CD 
patients with an odds ratio of 19 versus controls. ALU frequency in CD observed in our 
study is in agreement with those reported by other authors47,48 (see table XIV on paragraph 
2.2.a). It is also very interesting that almost all (89%) the CD patients with ALU no longer 
suffered after beginning GFD and the lack of healing in the remaining patients was probably 
linked to the lack of adherence to GFD. Consequently, ALU persistence in CD patients 
could cautiously be considered a marker of lack of GFD adherence. This hypothesis is 
supported by a study which reported that ALU and intestinal histological alterations relapsed 
after gluten challenge49. 
CHAPTER II – PhD STUDIES 
 109
Except for a recent study50 about the DEDs in CD children with deciduos dentition which 
showed that the presence in a child of systematic lesions had a sensitivity of 73.3% and 
specificity of 76.7% for the diagnosis of CD, and although several studies have reported the 
presence of oral mucosa lesions in CD, our study reports the first evaluation of the risk of 
such lesions in CD patients using univariate, multi-logistic regression, ANN sensitivity and 
specificity testing.  
However, despite a good test accuracy, the presence of oral lesions showed a low positive 
predictive value of 16%, giving in the general population a 1% prevalence of CD.  
In conclusion, our study showed a higher frequency of oral alterations in CD patients in 
comparison with healthy controls. However, the presence of these lesions had a low 
positive predictive value in CD diagnosis.  
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2.2.b. Assessment of the prevalence of ALU in CD patients living in the 
Mediterranean area, and to evaluate the impact of a GFD 
 
Patients and methods 
The study population consisted of 844 subjects living in the Mediterranean area. Local 
ethical committee approval was obtained. 
The test group consisted of 269 CD patients (163 females, 106 males; range 3-17 years) 
consecutively enrolled, between 2004 and 2006, in two Italian centres: the Universities of 
Palermo and Ancona. Diagnosis of CD was based both on positive serology (IgA and/or IgG 
antibodies to htTG, together with positive histological evidence of villous atrophy with crypt 
hyperplasia and increase in intraepithelial lymphocytes, and the disappearance of 
symptoms and normalization of serum Ab-htTG after GFD. 
The controls group were 575 otherwise healthy subjects age/gender-matched (343 females, 
232 males; range 3-17 years) and living in the same geographic area as the CD group. 
Controls were recruited (by simple randomization) at a day nursery, and at Primary and 
Secondary Schools during an health prevention programme for oral diseases. These 
subjects were healthy, with no disease or previous positive medical history, or family history 
of CD and showed normal growth (weight/height ratio between 25th and 75th centiles).  
Immediately after CD diagnosis, the patients in the test group underwent an intra-oral 
examination. Test and control patients were examined after obtaining informed consent in 
the presence of their parents who were questioned about a clinical history of ALU. In this 
study we included both ALU clinically observed and ulcers noted by parents or patients, or 
reported in hospital records. 
According to Stanley51 ALU has three main clinical presentations: minor, major or 
herpetiform ulcerations. The first are round ulcers less than 10 mm in diameter, while those 
major are clinically similar to the minor but they are larger than 10 mm in diameter52,53.   
All patients were examined in conventional dental chairs, using a dental operating light. All  
evaluations were performed independently by two dental practitiones, included Dr. 
Compilato, trained in an oral health survey and tested for concordance.  
CD patients with ulcers or a history of ALU at the first visit were advised a GFD and re-
evaluated one year after beginning this diet. At that second visit, adherence to GFD, serum 
anti-htTG  and the frequency and severity of ALU were recorded.  
Finally, all the controls positive for ALU were tested for serum coeliac antibodies to exclude 
CD.  
 
Statistical analysis 
Data were analyzed by means of StatView for Windows (SAS Inc v. 5.0.1, Cary, NC, USA). 
To measure the association level, OR and the 95% corresponding test-based CI were 
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calculated. Student’s t-test was used to calculate significant differences between test and 
controls at baseline for ordinal variables. Chi-square test was used to assess statistical 
differences among categorical variables. In all of evaluations, p-values < 0.05 were 
considered statistically significant.  The concordance rate of the oral evaluation between the 
observers was evaluated using Cohen's kappa statistic, as measuring agreement beyond 
that expected by chance (expressed as a coefficient ranging from 0 to 1.00)6.  
 
Results 
No significant differences for age and gender (p>0.2 by Student’s t-test and chi-square test, 
respectively) were detected between the test and control groups. 
There was a substantial agreement (k=0.87) between the observers for ALU assessment. 
ALU was found in 61/269 (22.7%) of CD patients versus 41/575 (7.1%) of the control group, 
showing a highly significant association of ALU with CD (p=<0.0001; chi-square=41.687; 
OR=4.3123; 95%CI =2.7664-6.722). The majority of ALU in both study groups were of the 
minor type (90.1% vs 87.8%; p>0.2). There were no differences in the number of episodes, 
rate of occurrence and duration (p>0.2). 
None of forty-one control patients had positive serological markers for CD. 
At the 1 year visit, there were  8 drop-outs (13.1%), meaning that 53 CD patients with ALU 
were interviewed and examined. Forty-six of these 53 patients adhering strictly to the GFD 
(87%): 33 (71.7%) had had no ALU, in 4 (8.7%) ulcers were reduced in frequency and 
severity, and in 9 (19.6%) there was no change in ALU history. In  the other 7/53 patients 
who failed to strictly adhere to the GFD, six did not report any improvement in ALU, and Ab-
htTG remained elevated. The difference in ALU history between test patients adhering 
verus those non adhering to the GFD was significant (p=0.0003; chi-square=13.101; 
OR=24.67; 95%CI =2.63:231.441). 
 
Discussion  
Atypical CD is characterized by non-specific intestinal complaints or by extra-intestinal 
manifestations including dental enamel defects, or mouth ulcers. 
The frequency of the “true RAS” is debated, in fact, the literature reported different 
frequencies of RAS in the general young population: in some Brazilian studies it has been 
found in 0.9-1.57%54,55; Crivelli et al. described it in 10.87% of Argentine children56, and 
Kleinman observed RAS only in 1.23% of 39206 United States schoolchildren57,58. ALU, also 
usually labelled RAS as well, have been reported in CD but with controversial 
frequencies42,59,60. In the present study, the prevalence of ALU was 22.7 % among 269 CD 
patients versus 7.1% in 575 individuals from general population living in the same area, with 
an odds ratio to suffer from ALU among the risk population of about 4.3; whilst other studies 
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shown a prevalence of 3.12-42.4% (Table XVIII). These differences may be explained by 
environmental, dietetic and, above all, genetic factors.  
 
Table XVIII. Prevalence of ALU in CD patients. 
Reference Study group 
(patients with CD) 
 
 No. of 
patient
s 
Prevalence 
of RAS (%) 
Type of 
RAS 
 
Malahias et al., 2009 67 42.4%   NR a  
Present study 269 22.7% Minor, major  
Campisi et a.l, 2007* 197 19% NR  
Procaccini et al, 2007 50 36% NR  
Bucci et al., 2006 72 33.33% NR   
Sood et al., 2003 96 19.79% NR  
Sedghizadeh et al., 2002  61 40.98% NR  
Lähteenoja et al., 1998b 128 3.12% NR  
Petrecca et al., 1994 29 17.24% NR  
Corazza et al., 1993  226 15.93% NR  
Meini et al., 1993; Majorana et al., 
1992 113 17.69% minor 
 
Balli et al., 1988 49 26.53% NR  
Biemond et al., 1987  414 9.66% NR  
Andersson-Wenckert et al., 1984 19 31.58% NR  
aNR= not reported 
 
Thus, our data would support the hypothesis of a link between ALU and CD, but others 
have reported that only 5% of outpatients who initially present recurrent ulcers have 
evidence of CD61,62; consequently, in the absence of other systemic signs, screening for 
GSE among individuals with RAS has been generally considered fruitless59. However, on 
the basis of our findings of a very high percentage ALU in CD patients in a large population, 
we suggest to consider ALU, as proposed by Sedghizadeh59, as a “risk indicator” for CD 
more than a “risk factor”; hence, the presence of oral aphthae should not be 
underestimated, but it should be considered a potential marker of underlying disease, above 
all if a patient has a positive personal and/or familiar clinical history. Consequently, serum 
CD markers (EMA and anti-tTG antibodies) should be suggested also for oligosymptomatic 
or asymptomatic subjects who showed ALU. However, it must be remembered the 
association of RAS with Behçet's disease and other inflammatory bowel diseases63 and, 
consequently the association between ALU and CD cannot be considered specific. A further 
study has determined the positive predictive value of ALU in CD diagnosis26. 
A final point worthy of note is that in the CD patients suffering from ALU reported in our 
study a significant improvement in their ALU history 1-year after starting GFD, and 
conversely no improvement was observed in the CD who did not adhere to GFD. 
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2.3. Screening for CD in patients with oral lesions potentially 
associated with CD, and sharing a common immune-mediate 
pathogenesis with CD, such as OLP and RAS 
 
The aims of a first study were: to assess the prevalence of CD in patients with OLP and 
the effects of GFD on this oral disease. 
 
While in a second study tha aim was to assess the prevalence of CD in patients with RAS 
was performed. 
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2.3.a. Assessment of the prevalence of CD in patients with OLP and the effects 
of GFD on this oral disease 
 
Patients and methods 
Twenty-three patients (21 F, 2 M; mean age: 58.7 years, range: 18-84 years) with OLP 
confirmed both clinically and histologically and under topical corticosteroid treatment were , 
were recruited during follow-up clinical examinations from the Oral Medicine Sector at the 
University of Palermo (Italy). Patients with lichenoid reactions to drug, amalgam fillings, 
topical allergens or any unknown reasons were excluded from this study. All patients were  
investigated for HCV-positivity and history of food intolerance and tested for serum coeliac 
autoantibodies. Serum samples were stored at  20 °C until analysis. They were analysed for 
EMA, tTGrh and tTGgp.  
 
EMA IgA assay 
Detection of EMA IgA was performed with indirect immunofluorescence using monkey 
oesophageal tissue as antigen (in-house assay). Tissue sections from marmoset monkey 
oesophagus were mounted on microscopic slides. Undiluted sera and sera diluted 1:25 with 
phosphate-buffered saline (PBS) was applied to slides, which were incubated for 30 min at 
room temperature. After washing with PBS the sections were covered with fluorescein 
conjugated rabbit-antihuman IgA (Dako, Copenhagen, Denmark) for 30 min, washed with 
PBS and examined by fluorescence microscopy. Positive sera were further diluted (1:5, 
1:10, 1:25, 1:100, 1:400 and 1:1600). Sera positive in dilution 1:10 or more were defined as 
positive.  
 
IgA tTG antibodies assay 
The tTG antibody (IgA) tests were performed with two commercial ELISA-tests: (i) Celikey®, 
tTGrh, IgA antibody assay (Pharmacia Diagnostics, Freiburg, Germany). It was defined by 
the producer as positive when >8 U mL  1, negative when <5 U mL  1, borderline between 5 
and 8 U mL  1, and (ii) ImmuLisa®, tTGgp with guinea-pig-derived tTG (IMMCO, Buffalo, 
NY, USA). The result was defined by the producer as positive when >25 U, negative when 
<20 U, borderline when 20 25 U. All sera were analysed using the same batch of tTGrh test. 
We used the upper borderline levels as a cut off for all the analyses as recommended by 
the producers. The intra-assay variation was measured as CV% (CV=coefficient of 
variation). The values for Celikey® were 6.0, 9.3 and 9.4 for low, medium and high values 
respectively. Corresponding values for ImmuLisa® were 3.9, 2.6 and 3.4 respectively. The 
inter-assay variation measured as CV% was 13.3 for Celikey® and 6.8 for ImmuLisa®, 
measured with a medium-high in-house control.   
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Finally, serum level of IgA, iron, folate and vitamin B12 were also assessed. All patients with 
positivity to EMA and/or anti-tTG autoantibodies underwent small intestinal biopsy to 
confirm CD, and in case of confirmed diagnosis were re-evaluated after 3 months of GFD. 
 
Results 
None of the patients showed HCV-positivity, history of foods intolerance and IgA deficiency. 
Only 2/23 (8.7%) female patients with atrophic/erosive OLP localized on buccal mucosa, 
associated to burning sensation, despite topical corticosteroid therapy, showed positive 
values of celiac antibodies associated to low serum levels of folate, vitamin B12 and iron. 
The small intestinal biopsy confirmed the diagnosis of CD. A GFD was started and the oral 
soreness and anaemia gradually improved over the next 3 month. 
 
Discussion 
OLP is a chronic inflammatory disorder affecting stratified squamous epithelia. The disease 
is relatively common, affecting approximately 1–2% of the population64. 
Histopathologically, OLP is characterized by the existence of an inflammatory infiltrate 
mainly composed of T cells in the papillary corion that acquired a characteristic band-like 
disposition and by a vacuolar degeneration of the epithelial basal stratum65.  
Although the aetiology of OLP is unknown, the histological features of the lesions suggest 
that the pathogenesis of this disease is immunomediate65. 
In fact, current data suggest that OLP is a T cell-mediated autoimmune disease in which 
auto-cytotoxic CD8+ T cells trigger apoptosis of oral epithelial cells66. 
Causative, associated or possibly worsening factors such as HCV and chronic liver 
diseases have also been involved. 
The possible association between cutaneous-mucous LP and HCV infection is still 
controversial. A great number of studies carried out in Japan and southern Europe have 
identified high prevalence of anti-HCV antibodies in patients with OLP67-70. 
The HCV related OLP association is supported by the fact that HCV viral sequences have 
been found in the serum of patients with OLP, and HCV was shown to occasionally replicate 
in oral lichen planus tissue, possibly contributing to the pathogenesis of mucosal 
damage69,71. Moreover, recent data has shown that HCV-specific T cells can be found in the 
oral mucosa of patients with chronic hepatitis C and OLP72. 
OLP clinical relevance is owing to its high prevalence (up to 2%), to its association to a 
number of disorders, generally of autoimmune origin (myasthenia gravis, SS, ulcerative 
colitis, psoriasis, thymoma, lupus erithematosus, CD), and also to its potential for malignant 
transformation (about 0.4%). 
About the association of OLP and other immuno-mediated diseases, although an high 
prevalence of OLP has been found in certain liver diseases such as primary biliary 
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cirrhosis73, chronic active hepatitis74 and cryptogenic liver diseases, it has been scarcely 
investigated with respect to gastrointestinal diseases (e.g. inflammatory bowel diseases and 
CD), although sharing immunomediate pathogenesis. 
About OLP and CD, in 1993, an unusual association between these two conditions was 
reported75. This was the case of a 70-year-old male with a biopsy-proven erosive OLP; iron, 
folate and vitamin B12 deficiencies led to perform jejunal biopsy, that demonstrated CD. 
Surprisingly, GFD resulted in relief of OLP within six month. But the hypothesis of an 
association between CD and OLP was promptly refuted by Scully et al.76, who one month 
later referred that they had investigated 103 patients with OLP and none had CD. So, they 
replied that OLP would seem only occasionally associated with CD. In 1998, 39 consecutive 
patients with OLP were screened for CD; 12 were positive for IgA AGA antibody test and 
two for EMA antibody test, but only one had small intestinal signs of CD77. Furthermore, 
Ruiz Villaverde et al. described a case of a case of a 9-year-old female with erosive 
mucosal lichen planus associated to hyper IgE syndrome and CD78. 
Data from our study, although obtained on a small sample size, allow to hypotize a potential 
association between CD and OLP; in fact in both cases the lesion is associated with a 
mucosal T-cell infiltrate. However, it is uncertain whether the oral lesions are a direct 
manifestation of GSE or due to the effect of malabsorption and of the consequently 
haematinic deficiencies on the rapidly dividing mucosal cells already predisposed to 
soreness by pre-existing OLP. In fact, a recent work79 showed that 11 out 25 OLP patients 
suffered of low red cell folate levels.  
Hence the resolution of the burning sensation after GFD, in our patients with OLP and 
refractory to local therapy could be justify the second hypothesis. Furthermore, a search for 
underlying nutritional deficiencies in patients with atrophic/erosive oral lesions should be 
important for the patients’ general wll-being and in relieving oral soreness by nutritional 
means as opposed to palliative medications, which is often less successful. 
Unlike its cutaneous form, OLP, and particularly the atrophic/erosive forms, is chronic with 
little likelihood of spontaneous resolution, so that the relief from eating a GFD in our cases 
was surprising. 
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2.3.b. Assessment of the prevalence of CD in patients with RAS 
 
Patients and methods 
Over a period of 24 months, all patients with RAS who attended the the Section of Oral 
Medicine of the University Hospitsal of Palermo were asked to participate in a screening 
program for GSE. 
Patients included in the study had at least three episodes of oral aphthae during the year; 
exclusion criteria were Behcet's disease, inflammatory bowel disease, systemic lupus 
erythematousis, tumors of oral cavity, Reiter syndrome and oral lesions due to drugs and 
radiation. Soft tissues examination was carried out with conventional dental chairs, artificial 
light, flat mirrors, monouse probe and sterile gauzes. We registered, lesions as RAS if they 
match one of these three conditions: clinically confirmed by physician, referred by patients 
themselves and reported by hospital clinical records. 
The objectives of the study, as well as the possible necessity for a small bowel biopsy, were 
explained to the patients. 
Of all patients with RAS only 25 (13 M, 12 F; mean age 42,4 ± 17,8 years; range: 7-77 
years) agreed to participate in our study. 
Written informed consent was obtained from each participant, and , after a gastrointestinal 
anamnesis, five-milliliter venous blood sample was obtained from each patient for 
serological investigation of GSE. 
Patients were screened by IgA EMA, IgA anti-tTG (for procedure see the previous 
paragraph) and serum IgA level. Those with a positive serology underwent endoscopic 
biopsies of the duodenal mucosa. 
 
Results 
None of the patients referred gastrointestinal symptoms. Only 2 out of 25 (8%) RAS patients 
had a positive CD serology and the histological findings were compatible with GSE. 
All of them showed a significant improvement of RAS episodes 1 months after beginning of 
GFD. 
 
Discussion 
RAS was found in 3.12%-42.4% of patients with CD27,30, representing at least the fifth 
commonest presentations of CD80-82 and often may be the sole presenting features of CD27.  
As RAS is frequently seen in CD patients, evaluation of individuals with this symptom may 
reveal the patients with undiagnosed CD. 
Although the first association between RAS and GSE was proposed in 1975 by Ferguson et 
al.83 when they found 20% of patients with RAS showed histological evidence of CD on 
jejunal biopsy, just recently the question has been raised by several Authors as to whether 
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RAS might be pathogenetically related to CD and whether GFD may induce improvement in 
RAS (Table XIX). 
 
 
Table XIX. Prevalence of CD in patients with RAS. 
Reference Study group 
(patients with RAS) 
 No. of 
patients 
Type of RAS Prevalence of CD 
(%) 
Present Study 25  NR a 8% 
Shakeri et al., 2009 247 NR 2.8% 
Olszewska et al., 2006 42 NR 4.7% 
Aydemir et al., 2004 41  NR  4.88% 
Robinson and Porter, 2004 87 minor 0% 
Nowak et al., 2002  20 NR 5% 
Jokinen et al., 1998 27 NR 11.1% 
Tavarela Veloso and Vaz Saleiro, 
1987 
24 NR 16% 
Merchant et al., 1986 100 minor 1% 
Tyldesley, 1981 97 min., maj., her.b 6.2% 
Ferguson et al., 1980 50 minor 4% 
Rose et al., 1978  26 NR 3.8% 
Ferguson et al., 1976 33 NR 24.24% 
Wray et al., 1975 130 minor 3.8% 
Ferguson et al., 1975 35 NR 20% 
a NR = not reported;  b min. = minor; maj. = major; her. = herpetiform. 
 
Nevertheless, there is still considerable dispute concerning the actual prevalence of CD 
among patients with RAS, as different studies have reported different prevalence of CD in 
RAS patients84-86. As showed in table the prevalence of RAS in CD patients ranges between 
0% to 24.24%. 
On the other hand in recent years, some articles are published which expressed little or no 
significant etiological link between RAS and CD, and added that screening RAS patients for 
key serological markers of CD is of little clinical value59,87. Currently, there is no approved 
recommendation which can be used by clinicians to approach patients with RAS regarding 
celiac disease. 
However, our findings although obtained from a limited sample population of patients with 
recurrent aphthosis, showed that a good percentage (8%) of patients with RAS had CD. If 
this results is compared with the 1% prevalence of CD in general population of Italy88 this 
study suggest that evaluation of CD could be appropriate in patients with RAS.   
The effect of GFD on remission of RAS is still uncertain, as dietary withdrawal of gluten 
occasionally results in significant benefit whereas some studies reported it ineffective 61,89. In 
our study the 2 patients who started GFD showed an amelioration after only one month 
period of diet. 
Many physicians may still consider the gastrointestinal signs and symptoms as a main 
manifestation of celiac patients whereas recent studies demonstrated that gastrointestinal 
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presentations may be absent in GSE patients especially in the beginning of the disease. In 
this study, none of our GSE patients had any gastrointestinal symptoms. 
Therefore, gastrointestinal symptoms are sometimes absent in the setting of the disease 
and RAS could be the first or the sole presentation of GSE. 
Our study has some limitations. We did not take duodenal biopsies from the patients who 
had negative serological tests. As reported in paragraph 1.6, It has been reported that the 
sensitivities of the serological tests are decreased in GSE patients with minor mucosal 
damages90,91. We cannot exclude the possibility of missing some GSE patients with 
negative serological tests and Marsh I/II mucosal lesions (e.g. seronegative GSE). 
However, a patient with negative serological test and duodenal mucosal lesion may suffer 
from other disorders like autoimmune enteropathy, giardiasis, common variable 
immunodeficiency, tropical sprue, peptic duodenitis, Crohn's disease etc. Including such 
patients (e.g. those with negative serological tests with duodenal mucosal damage) in the 
spectrum of GSE could increase the rate of false positive results; unless symptomatic and 
histological improvements are confirmed by GFD. Therefore, in the epidemiological studies, 
a positive result from a highly specific serological test (e.g. EMA, or tTG) together with any 
degree of duodenal mucosal lesion provide reasonable criteria for identifying patients with 
GSE. 
Although our study was conducted on a small sample size, we can conclude that a subset 
of RAS patients could suffer from GSE. GSE should be considered in RAS patients; 
unresponsiveness to conventional anti-aphthae treatment could be an additional risk 
indicator. Implementation of GFD may prevent the complications of GSE and effectively 
treat RAS. 
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2.4. Study of the histomorphology of clinically healthy oral mucosa 
of untreated CD patients  
 
The aims of this study were: (i) to assess the presence, quality (B⁄T lymphocytes) and 
intensity of lymphocytic infiltration and its relation to the severity of the intestinal histological 
damage; and (ii) to detect any other histological aspect which could be linked to CD. 
 
Patients and methods 
The test group consisted of 21 newly diagnosed, and untreated CD patients (15 females 
and 6 males, median age 36 ± 14 years; range 13–68 years) consecutively enrolled, 
between June 2004 and May 2005, in 3 centers: the adults in two centers: Gastroenterology 
and Internal Medicine of the University Hospital of Palermo; while the children in the 
Pediatric Gastroenterology Unit of the ‘Di Cristina Hospital’ in Palermo. 
During the same period, 14 subjects (10 females and 4 males, median age 39 ± 15 years; 
range 12–66 years), matched for age and gender, were consecutively recruited from 
patients with symptoms compatible with CD diagnosis (weight loss, failure to thrive, anemia, 
chronic diarrhea, abdominal pain, dyspepsia, gastro-esophageal reflux and abdominal 
meteorism), but with negative serum assays for CD diagnosis. All underwent esophago- 
gastro-duodenoscopy (EGDS) with duodenal histological examination. All showed normal 
histology of the intestinal mucosa and were considered control subjects.  
CD diagnosis was based on positive serology (IgA and⁄or IgG anti-tTG, IgA and⁄or IgG EMA) 
together with positive histological evidence of villous atrophy with crypt hyperplasia and 
increase in intraepithelial lymphocytes, and the disappearance of symptoms and 
normalization of serum anti-tTG and⁄or EMA after a GFD was imposed1.  
Test and control patients were recruited after a careful clinical examination of the entire oral 
cavity, performed at the Oral Medicine Unit of the University Hospital of Palermo, and 
subjects showing soft tissue lesions (e.g., ALU, non-specific atrophic glossitis, mucosal 
erythema) were excluded from this study.  
Informed consent was obtained from all of the patients involved in the study or from their 
parents in the case of pediatric patients.  
 
Intestinal and oral biopsies, histological and immunohistochemical evaluation.  
Following general anesthesia (in children) or conscious sedation with meperidine⁄pethidine 1 
mg⁄kg i.v. and midazolam 0.05–0.1 mg⁄kg i.v. (in adults), EGDS were performed with 
standard pediatric or adult videocolonoscopes (Olympus, Milan, Italy). At least four 
duodenal biopsy samples were obtained from each patient.  
Both 21 untreated CD patients and 14 controls underwent oral mucosal biopsy. Biopsy 
specimens were taken at the same time as the EGDS in the children and under local 
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anesthesia (Xylocaine® 2%, adrenaline 1:100.000) in adults. The specimens were always 
taken by Dott. Domenico Compilato from a clinically healthy buccal mucosa adjacent to the 
right second molar tooth region, beneath the occlusal line. The biopsies were performed by 
punching (6 mm in diameter punch biopsy) or by incision with cold knife. 
The intestinal and oral biopsy specimens were immediately fixed in 10% neutral-buffered 
formalin for 2 h, washed in water for 1 h, dehydrated in graded ethanol (60%, 80%, 90%, 
95% and, 100%) and after permeation in xylene, embedded in paraffin using the standard 
procedures. The formalin-fixed, paraffin-embedded samples were cut into 5-μm-thick 
sections on a microtome with a disposable blade. The sections of the intestinal mucosa 
were stained with hematoxylin and eosin (H&E) for standard evaluation. From each 
specimen of the oral mucosa, three sections were obtained: one conventionally stained with 
H&E and the other two treated with 4 KB5 monoclonal antibodies against- CD45RA and 
with UCHL1 monoclonal antibodies against-CD45RO (Dako, Milan, Italy) to evaluate 
lymphocyte infiltrates B and T, respectively. 
Intestinal histological specimens were defined compatible with the clinical diagnosis of CD 
when there was both intraepithelial lymphocytosis (at least 40 lymphocytes⁄100 
enterocytes)92 and a villous height to crypt depth ratio (V⁄C) <2.5. Furthermore, based on 
this ratio, a CD histological grading was defined: Grade 1 = V⁄C 2–2.5; Grade 2 = V⁄C 1–2; 
Grade 3 = V⁄C 1–0.5; and Grade 4 V⁄C < 0.593,94. 
All oral biopsy slides were examined blindly by Prof. Emiliano Maresi. CD3+ IELs were 
examined using mAb Leu-4 (Becton Dickinson, San Jose, CA). B lymphocytes were 
detected in paraffin-embedded sections using monoclonal antibodies to CD20 (Dako a⁄s, 
Glostrup, Denmark) and T lymphocytes with monoclonal antibodies to CD45RO (Dako a/s).  
The densities of CD3+, CD20+ and CD45RO+ cells were light microscopically counted in the 
epithelium and in the lamina propria using an ocular graticule of 0.10 x 0.10 mm at x400 
magnification. Ten fields were counted in the buccal epithelium and lamina propria 
immediately below the basement membrane. The results were given as cells⁄mm2. The 
intensity of the lamina propria lymphocytic infiltrate in the H&E stainings was arbitrarily 
graded as none (0), low (1), moderate (2) or severe (3).  
Furthermore, the presence of a spongiotic tissue reaction was assessed. Spongiotic 
reaction was defined as the presence of intraepidermal and intercellular oedema and 
labeled “spongiosis’”. 
 
Statistical analysis 
Data were analyzed by means of STATVIEW for Windows (SAS Inc v. 5.0.1, Cary, NC, 
USA). To measure the association level, OR and the 95% corresponding test-based CI 
were calculated. Chi-square test was used to assess statistical differences between 
categorical variables. The Mann–Whitney U-test and Spearman rank correlation coefficient 
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(Spearman’s rho) were used to calculate differences between non-parametric continuous 
variables. Student’s t test was used for parametric continuous variables. In all of the 
evaluations, P-values ≤0.05 were considered statistically significant. 
 
Results 
Table XX shows the lymphocyte (B and T) counts in the oral mucosa of the 21 CD patients 
and of the 14 controls. No differences were observed in CD3+ count or B- and T-lymphocyte 
counts either in the epithelium or in the lamina propria of the oral mucosa in CD patients 
and in controls, although in the lamina propria of the CD patients there was a trend towards 
a higher number of CD3+ and CD45RO lymphocytes.  
 
TABLE XX. Number of T- and B-lymphocytes in the oral epithelium and in the lamina propria of 21 
untreated CD patients and of 14 controls (IELs were counted as cells/mm2; lamina propria 
lymphocytes as cells x 100 / mm2). Data are given as mean + SD. 
 
 
Furthermore, there was no relationship between the intensity of lymphocytic infiltration in the 
oral mucosa and severity of intestinal mucosal damage, evaluated as villi⁄crypts ratio (r = 
1.03, p= 0.8) (Table XXI). 
 
TABLE XXI. Relationship between the intensity of lamina propria  lymphocyte infiltration in the oral 
mucosa and severity of intestinal mucosa damage. 
  
Intestinal CD histological grading 
 
 
Number of CD patients 
 Grade 1 Grade 2 Grade 3 Grade 4 
 
 
Grading of oral lymphocytic infiltrate      
none 0 0 1 5 6 
low 0 2 3 9 14 
moderate 0 0 0 0 0 
intense 0 0 0 1 1 
 CD Patients Controls 
IELs   
CD3+ 152 + 121 168 + 110 
B-Lymphocytes 43 + 42 38 + 45 
T-Lymphocytes 121 + 102 131 + 98 
Lamina Propria   
CD3+ 5.1 + 4.7 3.1 + 3.8 
B-Lymphocytes 0.8 + 0.9 0.6 + 0.7 
T-Lymphocytes 4.5 + 2.9 3.8 + 3.9 
CHAPTER II – PhD STUDIES 
 123
A very frequent histomorphological finding was spongiosis of the oral mucosal epithelium, 
observed in 19⁄21 (90%) of CD patients and only in 4⁄14 (29%) of controls [p= 0.0002; x2 = 
14.29; OR = 23.75 (95%CI = 3.69:152.9)]. This spongiotic reaction was characterized by the 
presence of intraepidermal and intercellular oedema; intercellular spaces were widened with 
an elongation of the intercellular bridges (Appendix I, Figures 4-5). The foci of spongiosis 
were also characterized by a mild lymphocytic infiltrate, but not by the presence of 
eosinophils or neutrophils. These lesions were exclusively microscopic without any 
corresponding identifiable vesicles on the oral mucosal surface. 
 
Discussion 
Although histological and clinical features of the small intestinal mucosa in CD are well 
known, the involvement of the other mucosal surfaces belonging to the GT and to the GALT 
has been neglected. As reported in Chapter I (paragraph 2.6), it has been demonstrated 
that in CD patients, gluten-driven T-cell activation is not restricted to the proximal part of the 
intestine, but is present in the whole intestine. In fact, the dissemination of the immune 
effector cells involves very distant sites of the GALT including the oral and rectal mucosa95, 
the two extremities of the GT. 
Histological changes have already been shown in the gastric96,97, terminal ileal98, rectal 
mucosa99-101, and esophageal mucosa96 of CD patients. 
Although it is widely reported that in CD patients, the mouth can also be affected by several 
clinical manifestations such as ALU42,49,59,102, DEDs24,29,103,104 and non-specific atrophic 
glossitis27, data about histological features of clinically healthy oral mucosa in patients with 
CD are few and often contrasting27,105-107.  
The healthy mucosa of the mouth is quite different from that of the rest of the GT tract; the 
oral mucosa of the lips, buccal, and floor areas are covered by a non-keratinized stratified 
epithelium, while the lining of the stomach and small and large intestine consists of a simple 
epithelium composed of only a single layer of cells108. Chapter I (paragraph 2.6), although 
the structure of the oral mucosa differs from that of the bowel from an immunological point 
of view, the mouth is situated at the beginning of the gastrointestinal system and, as part of 
it, is considered to belong to the GALT. Consequently, after antigen activation, proliferation 
and partial differentiation in the GALT, memory B cells and T cells migrate to other parts of 
the GALT, including the oral mucosa lymphoid tissues95. There, these cells, in sensitized CD 
patients, may easily react to gluten and its peptides; in fact, more recent findings have 
suggested that the oral mucosa of CD patients could be useful to evaluate response to a 
gluten-challenge106. 
Based on these considerations, we expected the healthy oral mucosa of untreated CD 
patients to behave in a similar way to the small bowel mucosa. However, our results did not 
confirm our initial hypothesis and we did not find any significant presence of B and T 
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lymphocytes infiltrate or any relationship with severity of CD in the oral mucosa of our study 
group.  
These data are in agreement with a study performed in Finland in which untreated CD 
patients did not differ from controls in terms of T cell number in the buccal mucosa27,105. The 
behavior of the oral mucosa of our patients with untreated CD did not mirror that of the small 
intestinal mucosa in which an increase of T cells generally occurs and the density of these 
cells decreases on a GFD. An explanation of this result might be that in patients with 
untreated CD, a gluten-containing diet induces a sequestration of lymphocytes to the 
intestinal mucosa and hence a “concentration” of the inflammatory cells with greater 
mucosal damage at this site108,109. This may result in a low intensity of lymphocytic infiltrate 
in other mucosal tissues belonging to the GALT, including the oral mucosa27,110. 
The novel finding of our research is the detection of ‘spongiosis’ in the biopsy samples of 
the clinically healthy oral mucosa of untreated CD patients. We found epithelial spongiosis 
in almost all the study group (90%) with a crude OR of about 23.  
In general, spongiotic tissue is characterized by the presence of intracellular and 
intercellular oedema. Indeed, spongiosis is considered only a histopathological concept and 
not as a clinical entity, although several diseases present such a tissue reaction111.  
Spongiotic reaction has been found in several skin lesions112-116 and in some oral diseases, 
such as oral melanoacanthosis (melanoacanthoma)117, oral psoriasis118, allergic contact 
stomatitis119, plasma cell gingivitis, intra-oral fixed drug eruption, leukoedema and white 
sponge nevus120. In most of these oral lesions, the pathogenetic mechanism involved in the 
collection of the intraepithelial fluid is not clear and remains to be elucidated: spongiosis 
could be caused by extravasations of fluids from blood vessels located in the lamina propria 
or by the presence of an osmotic gradient developed towards the epithelium, drawing fluid 
into it subsequent to various immunological reactions111. 
Spongiosis is also a histopathological feature found in the epithelium at the margin of an 
aphthous ulcer120; moreover, the pre-ulcerative stage in the pathogenesis of RAS is 
characterized by oedema of the epithelium and keratinocyte vacuolization121, and therefore 
by spongiosis.  
However, as several conditions, like the presence of mucopolysaccharidic materials may 
simulate spongiosis, we demonstrate that this histomorphologic feature is not associated 
with the accumulation of PAS-positive substances (e.g., acid mucopolysaccharides) within 
the cytoplasm of the keratinocytes with spongiotic aspect (Appendix I, Figure 6).  
We underline that our finding of massive spongiosis was found in the otherwise healthy oral 
epithelium of CD patients. Noteworthy, this finding may support the hypothesis that 
spongiosis represents histological evidence or a key of the well-known higher susceptibility 
of these patients to suffering from ALU. The continuous contact of the gluten-containing 
foods with the oral mucosa could provoke epithelial spongiotic changes, characterized first 
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by intracellular oedema and then by intercellular oedema with elongation of the intercellular 
bridges. The increase of intercellular oedema leads to the formation of intraepithelial micro-
vesicles and thereafter breaking off to form ulcer. According to this theory, patients not 
adhering to GFD would be more likely to suffer from RAS, as actually verified by our 
research group and reported in the previous paragraph102,103. 
The lack of lymphocytes infiltration of the oral mucosa cannot exclude that other 
inflammatory mechanisms, cells and mediators play a role in determining an inflammatory 
condition that determines the onset of spongiosis.  
A further datum comes from a recent study122 in which authors showed that the clinically 
healthy oral mucosa of patients who underwent allogeneic hematopoietic stem cell 
transplantation presents the same histological changes as those observed in biopsy 
specimens of patients with clinical evidence of oral chronic GVHD; in this case, a basal cell 
hydropic degeneration resembling the spongiosis reported by us was observed.  
This latter study, as well as ours, proposes that oral biopsy could represent an important 
and useful diagnostic method for predicting the clinical onset of oral lesions in patients with 
some systemic diseases, such as CD or c-GVHD, especially if we consider that the oral 
cavity represents a site with less invasiveness and with an easy access.  
In conclusion, our findings confirm that the oral mucosa of untreated CD cannot be 
considered a counterpart of the jejunal mucosa, at least in terms of B and T lymphocyte 
infiltrate. 
The finding of oral mucosal spongiosis, to the best of our knowledge, is the first reported for 
CD; its meaning is not definitively explained, but it could provide the wellknown susceptibility 
of CD patients to RAS onset. In these patients with untreated CD, oral mucosal spongiosis 
may be related to histological phenomena induced by gliadin ingestion. Hence, future aims 
could be to demonstrate whether oral spongiosis is a reliable sign of naÏve CD, and whether 
it should be used as a marker of untreated CD, an indicator of non-adherence to GFD or a 
condition present despite strict adherence to GFD. 
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2.5. Evaluation of the ability of the oral mucosa of patients with CD 
to produce antibodies in an in vitro culture system  
 
Patients and methods 
Patients with new CD diagnosis observed in three centers (one for pediatric -  Pediatric 
Gastroenterology Unit of the ‘Di Cristina Hospital’ in Palermo - and two for adult patients 
Gastroenterology and Internal Medicine of the University Hospital of Palermo), between 
June 2004 and May 2005, were randomly invited to enter the study. Out of a total of 105 
new diagnoses, 51 patients were asked to participate and 28 subjects accepted and were 
recruited. Of these, 15 were adults (10 F, 5 M, median age 39 years, range 19-73 yrs) and 
13 children (10 F, 3 M, median age 7 years, range 1-16 years). The CD clinical presentation 
was typical (malabsorption syndrome) in 14 patients, atypical (absence of intestinal 
symptoms) in 12 and silent in 2 (patients identified through screening programs) (Fasano A, 
2001).  
In all patients, CD diagnosis was based on serum EMA and anti-tTG positivity associated 
with evidence of intestinal villi damage (villous height/crypt depth ratio < 3), and in all cases 
on a subsequent GFD clinical symptoms disappeared and EMA and anti-tTG became 
negative.     
Furthermore, 14 adult patients (8 F, 6 M, median age 36.5 years, range 21-70 years) with 
symptoms compatible with CD diagnosis but negative for serum EMA and anti-tTG assays 
were enrolled. They were being investigated for the presence of one or more of the 
following symptoms: weight loss or failure to thrive, anemia, chronic diarrhea, or abdominal 
pain. All underwent EGDS with duodenal histology examination, oral mucosa biopsy and 
EMA and anti-tTG assays in both the duodenal and oral mucosa culture medium. All 
showed normal histology of the intestinal mucosa and were considered control subjects. In 
these cases, the complete diagnostic work-up may also have included routine hemato-
chemical assays, a thyroid study, serum autoantibodies assay, abdominal ultrasonography 
and/or computed tomography, colonoscopy, small-intestine barium examination, H2 breath 
test, duodenal fluid microbiological evaluation and bone marrow biopsy. 
All the adult patients included in the study were followed as outpatients, whereas the 
children were hospitalized. 
The protocol was approved by the Ethics Committee of the University Hospital of Palermo 
and informed consent was obtained from the patients involved in the study or from the 
parents in the case of the pediatric patients. 
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Serology for CD diagnosis 
Serum IgA was measured by ELISA to exclude IgA deficiency. IgA EMA and anti-tTGs  
were assayed  with commercial kits as previously described123. 
. 
Intestinal and oral biopsies and histology study 
Following general anesthesia (in children) or conscious sedation with meperidine/pethidine 
1 mg/kg i.v. and midazolam 0.05-0.1 mg/kg i.v. (in adults), EGDS were performed with 
standard pediatric or adult video-colonoscopes (Olympus or Fujinon or Pentax, Japan). Six 
duodenal biopsy samples were obtained from each patient. Four samples underwent routine 
histology evaluation, and 2 specimens were cultured for 72 h at 37 °C with a commercial 
reagent set (anti Endomysium-biopsy, Eurospital), as described previously124,125. One 
sample was cultured in the presence of the 31–43 gliadin peptide (0.1 g/L) and the other 
without its addition. Culture supernatants were collected and stored at -80 °C until used. IgA 
EmA antibodies in undiluted supernatants were determined by the same commercial 
reagent set used for serum EMA.  
IgA anti-tTG antibodies were determined with a commercial ELISA as recently described124. 
In brief, recombinant h-tTG antigen diluted in PBS was used to coat the wells. The culture 
medium was diluted 1:5. The conjugate was diluted to obtain reliable OD. Absorbance was 
read in a microplate reader at 450 nm. Anti-tTG values in the supernatants were expressed 
as optical density (OD). Normal values were taken as < 300,  representing a value > 2 SD 
above the mean of 200 healthy individuals. The intra-assay CV (coefficient of variation) for 
the IgA h-tTG autoantibody ELISA on culture medium was 4.2% (n = 20), and the inter-
assay CV was 5.9% (n = 20).  
Oral mucosa biopsy specimens were taken at the same time as the EGDS in children and 
under local anesthesia (xylocain adrenalin) in adults. The specimens were taken in the 
mouth, at the second molar tooth region, beneath the occlusal line. Each sample was 
divided into four parts: two were fixed to be processed for histology evaluation and two were 
cultured with the procedure described above for the EMA assay in the duodenal mucosa 
culture medium. Before culture, biopsy samples were weighted (minimal weight required 5 
mg/fragment) and washed.  
Previous studies in which IgA EMA and anti-tTG antibodies were first assayed on fresh 
medium and then six months later after storage at -80 °C, had shown that storage did not 
alter the results obtained, as EMA and anti-tTG results were identical124,125. IgA EMA and 
anti-tTG assays on the culture media were performed by personnel unaware of the clinical 
and laboratory data of the patients.    
Biopsy specimens of the intestinal mucosa adequate in size were immediately oriented with 
a stereomicroscope and subsequently embedded in paraffin124,125. The slides were stained 
with H&E and graded by conventional histology according to Oberhuber et al.126. 
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Biopsy specimens of the oral mucosa were embedded in paraffin and the slides stained with 
H&E; lamina propria lymphocytes infiltration was arbitrarily graded as mild when < 10 
lymphocytes x 5 HPF (magnification 40X) were counted, and severe when there were > 10 
lymphocytes x 5 HPF.   
 
Statistical analysis 
We followed the STARD checklist for studies on the diagnostic accuracy of tests127. The 
sensitivity, specificity and diagnostic accuracy values of the diagnostic procedures 
examined were calculated by standard statistical methods128. The Fisher exact test was 
used to compare the different sensitivity, specificity and diagnostic accuracy values of the 
assays. The chi-squared test for trend was calculated to compare the frequency of CD 
cases showing mild, moderate or severe intestinal villous atrophy with or without EMA or 
anti-tTG positive assays in the culture medium. 
  
Results 
None of the patients enrolled showed IgA deficiency. The final diagnoses of the patients 
with negative serum EmA and normal intestinal histology were: multiple food intolerance (3 
cases), Crohn’s disease (2 cases), sideropenic anemia (3 cases), major RAS (3 cases), 
liver cirrhosis (2 cases), duodenal ulcer (1 case).  
The results of the IgA EMA and anti-tTG assayed on the duodenal and oral mucosa culture 
were identical and remained unchanged when the 31-43 peptide was added to the culture 
medium. A cross-tabulation of the EMA assay results on the culture medium of the oral and 
duodenal biopsies obtained in pediatric and adult patients, according to the final diagnoses, 
is shown in Table XXII.   
 
Table XXII. Cross-tabulation of the EMA assay results on the culture medium of the duodenal and 
oral biopsies, in adult and pediatric subjects, according to the final diagnoses. 
 
EmA ASSAY ON DUODENAL MUCOSA CULTURE MEDIUM 
 
 CD diagnosis (n) Non CD diagnosis (n) Total number 
ADULTS    
Positive test 15 0 15 
Negative test 0 14 14 
Total 15 14 29 
CHILDREN    
Positive test 13 0 13 
Negative test 0 0 0 
Total 13 0 13 
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EmA ASSAY ON ORAL MUCOSA CULTURE MEDIUM 
 
  
CD diagnosis (n) 
 
Non CD diagnosis (n) 
 
Total number 
ADULTS    
Positive test 9 0 9 
Negative test 6 14 20 
Total 15 14 29 
CHILDREN    
Positive test 6 0 6 
Negative test 7 0 7 
Total 13 0 13 
 
EMA assayed on the duodenal mucosa culture medium gave results completely concordant 
with the final diagnoses, as they were positive in all CD patients and negative in all patients 
not suffering from CD. EMA assayed on the oral mucosa culture medium was positive in 15 
of the 28 CD patients (53.6%). 
Also anti-tTG antibodies assayed on the duodenal mucosa culture medium were positive in 
all CD patients and negative in all patients not suffering from CD. Anti-tTG antibodies 
assayed on the oral mucosa culture medium were positive in 16 of the 28 CD patients 
(57%) (Figure 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Individual values of anti-tTG antibodies assayed in the oral mucosa culture medium, in 28 
celiac patients and in 14 patients not suffering from CD. Values are expressed as optical density 
(OD). Dotted line indicates the upper normal limit. 
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Table XXIII shows  the sensitivity, specificity and diagnostic accuracy of the EmA and anti-
tTG assays on the duodenal or oral mucosa culture medium in CD diagnosis.  
 
Table XXIII. Sensitivity, specificity and diagnostic accuracy in CD diagnosis of the antibodies assays 
on the culture medium of the duodenal and oral mucosa biopsies. The study groups included 15 adult 
CD patients, 13 pediatric CD patients and 14 adult controls. 
 
EMA ASSAY IN DUODENAL MUCOSA CULTURE MEDIUM 
 
 SENSITIVITY SPECIFICITY DIAGNOSTIC 
ACCURACY 
Adults  100% 100% 100% 
Children  100% Not evaluated Not evaluated 
Total 100% ---- ---- 
 
EMA ASSAY IN ORAL MUCOSA CULTURE MEDIUM 
 
 SENSITIVITY SPECIFICITY DIAGNOSTIC 
ACCURACY 
Adults 60% 100% 79% 
Children 46% Not evaluated Not evaluated 
Total 53.6% ---- ---- 
 
Anti-tTG ASSAY IN DUODENAL MUCOSA CULTURE MEDIUM 
 
 SENSITIVITY SPECIFICITY DIAGNOSTIC 
ACCURACY 
Adults  100% 100% 100% 
Children  100% Not evaluated Not evaluated 
Total 100% ---- ---- 
 
Anti-tTG ASSAY IN ORAL MUCOSA CULTURE MEDIUM 
 
 SENSITIVITY SPECIFICITY DIAGNOSTIC 
ACCURACY 
Adults 60 % 100 % 79 % 
Children 54 % Not evaluated Not evaluated 
Total 57 % ---- ---- 
 
As shown in Table XXIV, CD clinical presentation did not influence the behavior of the EMA 
and anti-tTG assays in the oral mucosa culture medium. The presence of oral mucosa 
lesions did not influence the EMA and anti-tTG assays on the oral biopsy culture medium 
either. In fact, we observed ALU in four CD patients and in four adult controls (three with 
final diagnosis of major ALU and one with Crohn’s disease); only one of the four CD 
patients and none of these four controls were positive for EMA and anti-tTG antibodies. 
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TableXXIV. Results of EmA and anti-tTG assays in the oral mucosa culture medium according to the 
different clinical presentations in 28 CD patients. 
 Number of EmA positive assays Number of EmA negative assays 
Typical CD presentation 7 cases 7 cases 
Atypical CD presentation 7 cases 5 cases 
Silent CD                          1 case 1 case 
 Number of anti-tTG positive assays Number of anti-tTG negative assays 
Typical CD presentation 8 cases 6 cases 
Atypical CD presentation 7 cases 5 cases 
Silent CD                          1 case 1 case 
Note: The CD clinical presentation was considered typical when there was malabsorption syndrome, 
atypical in the absence of intestinal symptoms, and silent in the absence of symptoms.  
 
 
Figure 11 shows the number of lamina propria lymphocytes in the oral mucosa of CD 
patients and controls. A greater severity of  inflammation of the oral mucosa was observed 
in the CD patients with positive EmA or anti-tTG in the oral mucosa culture medium (Table 
XXV). In fact, the frequency of positive assays was significantly higher in the patients with 
severe inflammation: p<.01 (Fisher’s test).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Number of the lamina propria lymphocytes in the oral mucosa in fifteen CD patients with 
positive EMA assay in the oral mucosa culture medium (GROUP 1), in thirteen CD patients with 
negative EMA assay in the oral mucosa culture medium (GROUP 2) and in fourteen patients without 
celiac disease (GROUP 3). Lines indicate the mean values. 
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Table XXV. Results of EmA and anti-tTG assays in the oral mucosa culture medium according to the 
severity of the lymphocytes infiltration in the lamina propria of the oral mucosa. 
 Number of EmA positive assays Number of EmA negative assays 
Mild inflammation 7 cases 10 cases 
Severe inflammation 8 cases 3 cases 
 Number of anti-tTG positive assays Number of anti-tTG negative assays 
Mild inflammation 7 cases 10 cases 
Severe inflammation 9 cases 2 cases 
Notes: 1) Lamina propria lymphocytes infiltration was graded as mild when < 10 lymphocytes x 5 
HPF (magnification 40X) were counted, and severe when there were > 10 lymphocytes x 5 HPF.2) 
The frequency of EmA positive assays was significantly higher in the patients with severe 
inflammation: P<.01 (Fisher’s test). 
 
Discussion 
Although nowadays there is general agreement that CD must be considered a systemic 
disease and may affect several extra-intestinal organs, the intestinal mucosa examination is 
still considered the corner stone of a definitive CD diagnosis2,129. However, the small bowel 
biopsy is an invasive procedure which many patients – especially if asymptomatic or 
suffering from only mild symptoms – find hard to accept. In this respect, a study of the 
potential diagnostic use of the oral mucosa could be of great interest. In fact, as reported in 
several sections of this thesis, the oral mucosa is very often damaged in CD130 and previous 
studies in patients with CD on GFD showed that both the oral supramucosal application and 
submucosal injection of gliadin powder or gliadin peptides induced significant immunological 
changes106. 
As previous studies have demonstrated that EMA and anti-tTG assays on duodenal mucosa 
culture medium have an excellent diagnostic accuracy in CD diagnosis124,125,131,132 we aimed 
to evaluate the ability of the oral mucosa in patients with CD to produce EMA and anti-tTG 
in a culture system, comparing results with those obtained on duodenal mucosa culture.  
Our results showed that the oral mucosa of patients with a new CD diagnosis, still on a 
gluten-containing diet, was able to produce EMA and anti-tTG in the culture medium, with or 
without in vitro gliadin stimulation. In fact, EMA and anti-tTG assays were positive in 15 and 
16 out of 28 patients with CD respectively. This result is in keeping with the theory that the 
mouth is part of the GALT system95 and, although its epithelium is very different from that of 
the gut, the dissemination of the immune effector cells involves the oral mucosa and can 
determine a gliadin-induced response in patients with CD. 
However, in general, the sensitivity of CD-specific antibodies assay in the oral mucosa 
culture medium was low, with EMA assay more sensitive in adults (60%) than in children 
(46%). One child negative for EMA assay on oral culture medium resulted to be positive for 
anti-tTG assay. The sensitivity of the assays was not influenced by clinical presentation as it 
did not differ between patients with typical, atypical or silent disease. Furthermore, the 
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presence of “macroscopic” oral manifestations was not relevant as four CD patients were 
suffering from ALU at the moment of the study but only one of these was positive for both 
EMA and anti-tTG assays on oral mucosa culture medium. There was a positive correlation 
between severity of the lymphocites infiltration in the lamina propria of the oral mucosa and 
EmA or anti-tTG positivity in the culture medium. This aspect is similar to the well-known 
observation that there is a positive correlation between the severity of intestinal histology 
and the presence of serum EMA in CD133,134.  
EMA and anti-tTG assays on the oral mucosa culture medium showed a specificity of 100%, 
as we did not observe false positive results. It must be underlined that even the presence of 
ALU – present in four controls – did not determine false positive EMA/anti-tTG results. 
Obviously, as we included few control patients, further studies are needed to confirm the 
absolute specificity of the EmA or anti-tTG assays on the oral mucosa culture medium. 
Subsequently to the publication of our results135, Vetrano et al.136 showed that EMA and 
anti-tTG autoantibodies were positive in 15/16 and in 15/16, respectively, cultured oral 
mucosa samples. However, the sensitivity in our oral biopsies was low with 54% for EMA 
and 57% for anti-tTG, in contrast to 100% sensitivity for anti-tTG described by Vetrano et 
al.136 These discrepancies could be related to the size of the biopsy samples; in fact, 
whereas we used biopsy pieces with an approximate weigh of 5mg, Vetrano et al..136 
pointed out that smaller biopsies (< 10 mg) yelded some false negative results, indicating 
that biopsy size is a limiting factor in the reability of the antibody determination.  
As long as this discrepancy cannot completely clarified, caution is advised to suggest the 
oral mucosa as an area for diagnostic purpose. 
However, all the results abovementioned open a new scenario to consider oral mucosa as a 
new immunological site to detect CD autoantibodies. 
A previous study of the oral mucosa histology of untreated CD patients did not show any 
significant histological alterations which could help diagnosis and the oral gluten challenge 
performed on CD patients on gluten-free diet showed a sensitivity of 73% and specificity of 
80%137. However, the immuno-histochemical methods used in previous studies106,107 were 
more cumbersome and time-consuming than the simple antibodies assay in the culture 
medium. Furthermore, the evidence that anti-tTG antibodies can be effectively assayed in 
the oral mucosa culture medium opens the way to an easy ELISA.  
As regards antibodies assay on duodenal mucosa culture medium, our results are in 
keeping with all the previous reports which have underlined the excellent diagnostic value of 
this assay106,107. The intestine is the main site of EMA production and both EMA or anti-tTG 
can also be assayed in the whole gut lavage fluid138 or in the duodenal mucosa by immuno-
histochemistry139,140, giving  relevant diagnostic help in cases of seronegative CD patients.   
In conclusion, this study demonstrated for the first time that the oral mucosa contributes to 
EMA and anti-tTG production in untreated CD patients. As the search for easier diagnostic 
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methods than the small intestine biopsy procedure is important, the antibodies assay on oral 
mucosa culture medium merits to be further evaluated. 
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IMPLICATIONS FOR FURTHER RESEARCHES 
 
The researches conducted in the context of this project, have yielded important results not 
only in terms of prevalence of oral lesions potentially associated with CD, but above all, 
thanks to the highly innovative research lines has led to consider the oral cavity, for the 
possibility to perform easily oral biopsies to be processed with appropriate methods of 
immunofluorescence and conventional histological examination, as a potential diagnostic 
gate minimally invasive and easily accessible in comparison with the endoscopic approach. 
However, clinical trials conducted on largest sample size and on CD patients before and 
after the GFD, will need to see if the mouth can really be helpful to duodenal endoscopy for 
the first diagnosis of CD, but also in the follow-up of the disease.  
Furthermore, the demonstration that the oral mucosa is a new site involved in the release of 
pathognomonic autoantibodies of CD and which may show some histological peculiarities 
offers us a site to obtaine bioptic samples to be underwent cDNA microarrays studies (for 
genomic studies) and cell and tissue cultures, in order to depth the pathogenesis of CD and 
to test less toxic compounds, such as different oats species, in the treatment of this 
condition. 
In particular, the potentiality of the oral mucosa to directely react immunologically against  
the gluten ingested should be taken into account in the development of new therapeutic 
strategies that aim to prevent the triggering of such immune reactions. Among these new 
non-dietary therapies under study, the most attractive seems to be the use of enzymes that 
digest immunogenic gluten peptides; in the event that these peptides could already elicit an 
immune response in the oral cavity, enzymatic therapies could be ineffective or not fully 
effective, unless they are already active already in the mouth and not only in the stomach 
and/or in the small intestine. 
Our prelimary results showing that a gluten-related immune response could already be 
induced in the oral cavity should be taken into account in the development of new non-
dietary therapies that aim to prevent the triggering of such immune reactions only at the 
gastrointestinal level. 
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Figure 1. Histological features of small intestinal mucosa in patients with 
untreated CD. (A) Normal mucosa. (B) Partial villous atrophy. (C) subtotal 
villous atrophy.  (D) Total villous atrophy. 
 
 
Figure 2. Endoscopic signs of villous atrophy. Please note the scalloping and 
reduction of the duodenal mucosal folds, associated to a mosaic pattern of 
the mucosa. 
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Figure 3. (a) Enamel defects of upper incisors (arrows indicate the color 
changes); (b) Enamel defects of upper incisors (structural changes); (d) major 
type of ALU and (c) numerous minor-type lesions of ALU. 
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Figure 4. Histological features of healthy oral mucosa in different celiac 
patients. Diffuse distension and vacuolation (spongiosis) of the intermediate 
and superficial acanthocytes and their overlapping. 
 
 
 
Figure 5. Marked overlapping of the acanthocytes 
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Figure 6. Absence of PAS-positive substances (e.g., acid 
mucopolysaccharides) within the cytoplasm of the keratinocytes with 
spongiotic aspect. 
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